thiophenes has been researched along with rivaroxaban in 1119 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 122 (10.90) | 29.6817 |
| 2010's | 993 (88.74) | 24.3611 |
| 2020's | 4 (0.36) | 2.80 |
| Authors | Studies |
|---|---|
| Perzborn, E; Pohlmann, J; Roehrig, S; Schlemmer, KH; Strassburger, J; Straub, A; Wilmen, A | 1 |
| Lampe, T; Pernerstorfer, J; Perzborn, E; Pohlmann, J; Reinemer, P; Roehrig, S; Schlemmer, KH; Straub, A | 1 |
| Becka, M; Kubitza, D; Voith, B; Wensing, G; Zuehlsdorf, M | 2 |
| Bauer, KA; Fisher, WD; Gent, M; Irwin, MW; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG | 1 |
| Buetehorn, U; Daehler, HP; Kohlsdorfer, C; Pleiss, U; Sandmann, S; Schlemmer, KH; Schwarz, T; Steinke, W; Weinz, C | 1 |
| Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F | 1 |
| Hampton, T | 1 |
| Becka, M; Kubitza, D; Mueck, W; Zuehlsdorf, M | 4 |
| Haas, S; Kubitza, D | 1 |
| Borris, LC; Dahl, OE; Dierig, C; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F; Muehlhofer, E | 1 |
| Becker, RC; Mahaffey, KW | 1 |
| Borris, LC; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F; Muehlhofer, E | 1 |
| Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E | 1 |
| Turpie, AG | 4 |
| Kakar, P; Lip, GY; Watson, T | 2 |
| Depasse, F; Elalamy, I; Gerotziafas, GT; Perzborn, E; Samama, MM | 1 |
| Beyer, J; Eriksson, BI; Halbritter, K; Kakkar, AK; Kälebo, P; Misselwitz, F; Schellong, SM; Turpie, AG | 1 |
| Ma, Q | 1 |
| Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG | 1 |
| Eikelboom, JW; Weitz, JI | 4 |
| Agnelli, G; Gallus, A; Goldhaber, SZ; Haas, S; Huisman, MV; Hull, RD; Kakkar, AK; Misselwitz, F; Schellong, S | 1 |
| Becka, M; Kubitza, D; Mueck, W; Voith, B; Zuehlsdorf, M | 1 |
| Kubitza, D; Laux, V; Misselwitz, F; Perzborn, E | 1 |
| Eikelboom, JW; Hirsh, J; O'Donnell, M | 1 |
| Becka, M; Breddin, HK; Graff, J; Harder, S; Kubitza, D; Misselwitz, F; von Hentig, N | 1 |
| Kubitza, D; Misselwitz, F; Perzborn, E | 1 |
| Becka, M; Kubitza, D; Mueck, W | 2 |
| Go, G; Gonzalez Della Valle, A; Lyman, S; Salvati, EA; Sharrock, NE | 1 |
| Bauersachs, RM | 1 |
| Gross, PL; Weitz, JI | 2 |
| Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Mueck, W; Turpie, AG | 1 |
| Harenberg, J; Wehling, M | 1 |
| Califf, RM; Fox, KA; Mahaffey, KW; Patel, MR; Piccini, JP | 1 |
| Borchmann, P; Eichhorst, B; Hallek, M; Hellmann, M; Hübel, K; Kochanek, M; Kreuzer, K; Kreuzer, KA; Reiser, M | 1 |
| Cushner, FD; Eriksson, BI; Friedman, RJ; Lassen, MR | 1 |
| Bandel, TJ; Beckmann, H; Borris, LC; Eriksson, BI; Friedman, RJ; Geerts, W; Haas, S; Huisman, MV; Kakkar, AK; Misselwitz, F; Muehlhofer, E | 1 |
| Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG | 1 |
| Becker, RC; Lohrmann, J | 1 |
| Brenner, B; Dahl, OE; Eriksson, BI; Haas, S; Kakkar, AK; Misselwitz, F; Mouret, P; Muntz, J; Pap, AF; Soglian, AG | 1 |
| Agnelli, G; Buller, HR; Cohen, A; Gallus, AS; Lensing, AW; Misselwitz, F; Prins, MH; Raskob, G; Schellong, S; Segers, A | 1 |
| Bakhos, M; Hoppensteadt, D; Iqbal, O; Jeske, WP; Maddineni, J; Messmore, HL; Prechel, M; Walenga, JM | 1 |
| Rohde, G | 1 |
| Gulseth, MP; Michaud, J; Nutescu, EA | 1 |
| Becka, M; Kubitza, D; Mueck, W; Roth, A | 3 |
| Borris, LC; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F; Mueck, W; Muelhofer, E | 1 |
| Spyropoulos, AC | 1 |
| Beyer, J; Hochauf, S | 1 |
| Paramanathan, V | 1 |
| Hess, C | 1 |
| Connolly, ES; Komotar, RJ; Starke, RM | 1 |
| Schuman, EP | 1 |
| Franchini, M; Lippi, G; Targher, G | 1 |
| Lotke, PA | 1 |
| Hamulyak, K; ten Cate, H | 1 |
| Oberpichler-Schwenk, H | 1 |
| Borris, LC | 3 |
| Eriksson, BI; Quinlan, DJ; Weitz, JI | 1 |
| Francis, CW | 1 |
| Garcia Nuño, L; Granero Xiberta, J; Soler Minoves, JM | 1 |
| Ferrandis, R; Llau, JV; López Forte, C; Sapena, ML | 1 |
| Abrams, PJ; Emerson, CR | 1 |
| Mantz, J | 1 |
| Laporte, S; Mismetti, P | 1 |
| Samama, CM | 2 |
| Arnaout, L; Bellamy, L; Chabbouh, T; Rosencher, N | 1 |
| Albaladejo, P | 1 |
| Drouet, L | 1 |
| Haas, S | 2 |
| Kubitza, D; Lang, D; Mueck, W; Schwarz, T; Weinz, C | 1 |
| Freudenberger, C; Lang, D; Weinz, C | 1 |
| Bounameaux, H | 1 |
| Farley, TM; Lewis, D; Macaulay, TE | 1 |
| Tripodi, A; van den Besselaar, A | 1 |
| Lassen, MR; Laux, V | 1 |
| Brighton, TA; Verma, AK | 1 |
| Darius, H | 1 |
| Bátorová, A | 1 |
| Harenberg, J; Nitschmann, S | 1 |
| Bandel, TJ; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG | 1 |
| Bandel, TJ; Bauer, KA; Benson, A; Berkowitz, SD; Cushner, FD; Davidson, BL; Fisher, WD; Gent, M; Kwong, LM; Lassen, MR; Lotke, PA; Misselwitz, F; Turpie, AG | 1 |
| Becker, RC | 1 |
| Arnaout, L; Bellamy, L; Rosencher, N | 1 |
| Kamphuisen, PW; Leebeek, FW | 1 |
| Arya, R; Roberts, LN | 1 |
| Boyle, AJ; Yong, CM | 1 |
| Crain, EJ; Watson, CA; Wong, PC; Xin, B | 1 |
| Ageno, W | 1 |
| Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A | 1 |
| Eagle, K; Gurm, HS | 1 |
| Crowther, MA; Lepic, K | 1 |
| Ferrandis, R; Llau, JV | 1 |
| Perzborn, E | 1 |
| Koscielny, J; von Heymann, C; Ziemer, S | 1 |
| Bauer, RJ; Cui, Y; Kubitza, D; Liu, Y; Mueck, W; Sun, P; Zhang, H; Zhao, X; Zhou, Y | 1 |
| Schulman, S | 5 |
| Stief, T | 1 |
| Denaro, V; Longo, UG; Maffulli, N | 1 |
| Dimmitt, S; Eikelboom, JW; Raju, NC | 1 |
| Blázquez-Pérez, A; Gómez-Outes, A; Pozo-Hernández, C; Suárez-Gea, ML; Vargas-Castrillón, E | 2 |
| Duggan, ST; Plosker, GL; Scott, LJ | 1 |
| Levine, MN | 1 |
| Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M | 1 |
| Stewart, RA | 1 |
| Apostolakis, S; Lip, GY; Shantsila, E | 1 |
| Barry, M; McCullagh, L; Tilson, L; Walsh, C | 1 |
| Heindl, B; Spannagl, M | 1 |
| Holmes, M; Kaltenthaler, E; Rees, A; Scope, A; Stevenson, M | 1 |
| Wittkowsky, AK | 1 |
| Roberts, C; Yenna, ZC | 1 |
| Scheen, AJ | 1 |
| Fassiadis, N | 2 |
| Conard, J; Horellou, MH; Samama, MM | 1 |
| Bauer, RJ; Hu, P; Hu, Y; Jiang, J; Kubitza, D; Meng, L; Mueck, W; Yang, J; Zhang, J | 1 |
| Verma, AK | 1 |
| Khalabuda, M; McBride, BF; Morell, J; Sullivan, B | 1 |
| Depasse, F; Guinet, C; LeFlem, L; Martinoli, JL; Perzborn, E; Plu-Bureau, G; Samama, MM | 1 |
| Ufer, M | 1 |
| Dick, W; Saxer, F | 1 |
| Gogarten, W; Pauschert, R; Quante, M | 1 |
| Becker, RC; Mackman, N | 1 |
| Kubitza, D; Laux, V; Mueck, W; Perzborn, E; Roehrig, S; Straub, A | 1 |
| Hillisch, A; Roehrig, S; Straub, A | 1 |
| Godier, A; Samama, CM | 1 |
| Clayton, RA; Gaston, P; Howie, CR | 1 |
| Banda, ZK; Benmira, S; Bhattacharya, V | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Fujimoto, T; Hiroe, K; Imaeda, Y; Kawamura, M; Konishi, N; Kubo, K; Shofuda, K | 1 |
| Bauer, KA | 2 |
| Exter, BP; Jarvis, CI; Melillo, SN; Scanlon, JV; Steinberg, M | 1 |
| Cohen, AT; Nandini, B; Ota, S; Wills, JO | 1 |
| Weitz, JI | 2 |
| Brummel-Ziedins, KE; Butenas, S; Gissel, M; Mann, KG; Orfeo, T | 1 |
| Lopes, RD; Mahaffey, KW; Piccini, JP | 1 |
| Lowenthal, DT; Sattari, M | 1 |
| Ahrens, I; Lip, GY; Peter, K | 2 |
| Fiessinger, JN | 1 |
| Harber, CR; Nathanson, MH | 1 |
| Adiguzel, C; Walenga, JM | 1 |
| Jiang, X; Wong, PC | 1 |
| Drabu, KJ; Foote, J; Phillips, S; Rogers, BA | 1 |
| Mousa, SA | 2 |
| Shakib, S; Tadros, R | 1 |
| Panchenko, EP | 1 |
| Hiroe, K; Kawamura, M; Konishi, N | 1 |
| Ananthapavan, J; Diamantopoulos, A; Forster, F; Lees, M; McDonald, H; Wells, PS | 1 |
| Amiral, J; Depasse, F; Guinet, C; Perzborn, E; Samama, MM | 1 |
| Alban, S; Völler, H; Westermann, D | 1 |
| Cao, YB; Jiang, YY; Shen, H; Zhang, JD | 1 |
| Clemens, A; Monz, BU; Plumb, JM | 1 |
| Lindhoff-Last, E; Ortel, TL; Samama, MM; Spiro, TE; Weitz, JI | 1 |
| Crowther, M; Lepic, K | 1 |
| Douketis, JD | 1 |
| Ageno, W; Rancan, E; Romualdi, E; Siragusa, S | 1 |
| Samama, MM | 3 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Chantarangkul, V; Guinet, C; Samama, MM; Tripodi, A | 1 |
| Baghaei, F; Fagerberg Blixter, I; Gustafsson, KM; Hillarp, A; Lindahl, TL; Sten-Linder, M; Stigendal, L; Strandberg, K | 1 |
| Burton, P; Gheorghiade, M; Greenberg, BH; Mehra, M; Nadar, VK; Plotnikov, AN; Sun, X; Thyssen, A; Tian, H; Zolynas, R | 1 |
| Chitolie, A; Green, L; Haddad, FS; Hossain, F; Lawrie, AS; Machin, SJ; Mackie, IJ; Patel, S | 1 |
| Barrett, YC; Frost, C; Shenker, A; Wang, Z | 1 |
| Caglayan, E; Er, F; Erdmann, E; Gassanov, N | 1 |
| Becka, M; Bruck, H; Halabi, A; Klause, N; Kubitza, D; Lufft, V; Maatouk, H; Mueck, W; Philipp, T; Wand, DD | 1 |
| Giannoudis, PV; Harwood, PJ; Karadimas, EJ; Nikolaou, VS; Tan, HB | 1 |
| Morris, TA | 1 |
| Baumhäkel, M; Böhm, M; Schirmer, SH | 1 |
| Conard, J; Depasse, F; Guinet, C; Horellou, MH; Le Flem, L; Samama, M | 1 |
| Butler, J; Gan, E; Kaplan, Z; Malan, E; Merriman, E; Tran, H | 1 |
| Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Bandel, TJ; Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Misselwitz, F; Turpie, AG; Westermeier, T | 1 |
| Penka, M | 1 |
| Kubitza, D; Misselwitz, F; Perzborn, E; Roehrig, S; Straub, A | 1 |
| Stiefelhagen, P | 4 |
| Erdmann, J | 1 |
| Hylek, EM | 1 |
| Farhan, S; Höchtl, T; Huber, K; Wojta, J | 1 |
| Jensen, CD; Muller, SD; Partington, PF; Reed, MR; Steval, A | 1 |
| Foote, J; Phillips, SN; Rogers, BA | 1 |
| Kwok, CS; Loke, YK | 1 |
| Mitka, M | 2 |
| Aumiller, J | 1 |
| Tripodi, A | 5 |
| Eikelboom, JW; Eriksson, BI; Quinlan, DJ | 1 |
| Doggrell, SA | 1 |
| Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD | 1 |
| Freyburger, G; Labrouche, S; Macouillard, G; Sztark, F | 1 |
| Arora, R; Chandrasekar, S; Loomba, R; Shah, P | 1 |
| Berkowitz, SD; Desai, M; Horsmans, Y; Larrey, D; Maddrey, W; Peters, G; Watkins, PB | 1 |
| Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, A; Tapson, V | 1 |
| Ageno, W; Romualdi, E | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Banghua, L; Jin, C; Turun, S; Ying, N; Yuan, Y; Zhenhui, L | 1 |
| Ageno, W; Streif, W | 1 |
| Giannoudis, PV; Goff, T; Kontakis, G | 1 |
| Braunwald, E; Steffel, J | 1 |
| Gans, RO; Landman, GW | 1 |
| Berkowitz, SD; Misselwitz, F; Perzborn, E | 1 |
| Antony, R; Buga, L; Clark, AL; Cleland, JG; Coletta, AP; Freemantle, N; Pellicori, P | 1 |
| Cerbone, AM; Coppola, A; Franchini, M; Ruosi, C; Tufano, A | 1 |
| Buetehorn, U; Gnoth, MJ; Muenster, U; Sandmann, S; Schwarz, T | 1 |
| Fisher, WD | 1 |
| Kwong, LM | 3 |
| Nutescu, E | 1 |
| Burghaus, R; Coboeken, K; Gaub, T; Kuepfer, L; Lippert, J; Mueck, W; Sensse, A; Siegmund, HU; Weiss, W | 1 |
| Merli, G | 2 |
| Friedman, RJ | 2 |
| Alexander, D; Jeremias, A | 1 |
| Nunnelee, JD | 1 |
| Bode, C; Braunwald, E; Burton, P; Cook-Bruns, N; Gibson, CM; Goto, S; Mega, JL; Plotnikov, A; Sun, X; Verheugt, F | 1 |
| Huisman, MV; Kooiman, J; van de Peppel, WR; van der Meer, FJ | 1 |
| Ajzenberg, N; Dumont, B; Faille, D | 1 |
| Fareed, J; Hull, R; Welzel, D | 1 |
| Keltai, K; Keltai, M | 1 |
| Hesse, C; Lindhoff-Last, E; Mani, H; Stratmann, G | 2 |
| Gawaz, M; Geisler, T | 1 |
| de Groot, PG; de Laat, B; Kamphuisen, PW; Meijers, JC; van Os, GM | 1 |
| Friedman, RJ; Lees, M; Sengupta, N | 1 |
| Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Kazmi, RS; Lwaleed, BA | 1 |
| Bea, F; Blessing, E; Isermann, B; Katus, HA; Preusch, M; Shahzad, K; Wang, H; Zhou, Q | 1 |
| Buerke, M; Hauroeder, B; Kaeberich, A; Linde, T; Maegdefessel, L; Perzborn, E; Raaz, U; Reindl, I; Schlitt, A; Steinseifer, U; Vogt, A; Werdan, K | 1 |
| Bernhard, H; Leschnik, B; Muntean, W; Novak, M; Schlagenhauf, A; Schweintzger, S | 1 |
| Rauch, BH; Rosenkranz, AC; Schrör, K | 1 |
| Ageno, W; Donadini, MP; Romualdi, E | 1 |
| Giese, C; Harenberg, J; Krämer, R; Marx, S; Wehling, M; Weiss, C | 1 |
| Thompson, CA | 1 |
| Ariyawansa, J; Burton, PB; Moore, KT; Plotnikov, AN; Thyssen, A; Vaccaro, N | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Pan, G; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE | 1 |
| del Zoppo, GJ; Eliasziw, M | 1 |
| Asmis, LM | 2 |
| Alberio, L; Angelillo-Scherrer, A; Asmis, LM; Korte, W; Mendez, A; Reber, G; Seifert, B; Stricker, H; Tsakiris, DA; Wuillemin, WA | 1 |
| Arya, R; Patel, JP; Roberts, LN | 1 |
| Kreutz, R | 3 |
| Fauchier, L; Le Heuzey, JY; Marijon, E | 1 |
| Büller, HR; Eerenberg, ES; Kamphuisen, PW; Sijpkens, MK; van Es, J | 1 |
| Mega, JL | 1 |
| Becker, RC; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, D | 1 |
| Jaeger, M; Jeanneret, B; Schaeren, S | 1 |
| Di Pasquale, G; Riva, L | 1 |
| Agnelli, G; Decousus, H; Lensing, AW; Misselwitz, F; Mueck, W; Prandoni, P | 1 |
| Buller, HR; Eerenberg, ES; Kamphuisen, PW; Levi, M; Meijers, JC; Sijpkens, MK | 1 |
| de Jong, H; Kluin-Nelemans, H; Meijer, K; Mulder, A; Nijland, H; Tichelaar, V | 1 |
| Beer, JH | 1 |
| Galanis, T; Kraft, WK; Merli, GJ | 1 |
| Björholt, I; Diamantopoulos, A; Forster, F; Fraschke, A; Lees, M; Ryttberg, L | 1 |
| Battinelli, EM | 1 |
| Bode, C; Diener, HC; Kaeufer, T | 1 |
| Giese, C; Harenberg, J; Krämer, R; Marx, S; Weiss, C | 1 |
| Andrade-Gordon, P; Chen, C; Connelly, MA; Damiano, BP; Huang, Z; Parry, TJ; Perzborn, E | 1 |
| Emerson, SS; Fleming, TR | 1 |
| Korte, W; Spahn, DR | 1 |
| Baccouche, H; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Hatmi, M; Samama, MM; Sassi, M | 1 |
| Heidinger, K; Kemkes-Matthes, B | 1 |
| Diamantopoulos, A; Duran, A; Forster, F; Kwong, L; Lees, M; Sengupta, N | 2 |
| Breen, KA; Hunt, BJ | 1 |
| Mulhall, KJ; Solayar, GN; Walsh, PM | 1 |
| Durand, M; Emmerich, J; Fischer, AM; Godier, A; Le Bonniec, B; Lecompte, T; Marchand-Leroux, C; Miclot, A; Samama, CM | 1 |
| Fürll, B; Greinacher, A; Hackbarth, C; Krauel, K | 1 |
| Jolobe, OM | 1 |
| Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Cohen, M; Cook-Bruns, N; Fox, KA; Gibson, CM; Goto, S; Mega, JL; Murphy, SA; Plotnikov, AN; Schneider, D; Sun, X; Verheugt, FW; Wiviott, SD | 1 |
| Ohman, EM; Roe, MT | 1 |
| Gehrie, E; Laposata, M | 1 |
| Finsterer, J; Stöllberger, C | 5 |
| Bode, C; Moser, M | 1 |
| Alves, C; Batel-Marques, F; Macedo, AF | 1 |
| Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM | 1 |
| Büller, HR; Combe, S | 1 |
| Banerjee, A; Lane, DA; Lip, GY; Torp-Pedersen, C | 1 |
| Contant, G; Gourmelin, Y; Guinet, C; Le Flem, L; Martinoli, JL; Perzborn, E; Rohde, G; Samama, MM; Spiro, TE | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Homering, M; Rosencher, N | 1 |
| Li, J; Li, Y; Shi, Z; Wang, J | 1 |
| Burton, P; Gibson, M; Moore, K; Mueck, W; Plotnikov, A; Rossenu, S; Stuyckens, K; Vermeulen, A; Xu, XS | 1 |
| Cid, A; Godoy Monzon, D; Iserson, KV; Vazquez, JA | 1 |
| Abu-Fadel, MS; Dib, C; Golwala, H; Tafur, A | 1 |
| Berglund, EG; Booth, BP; Bullock, J; Grillo, JA; Huang, SM; Lesko, LJ; Lu, M; Pang, KS; Rahman, A; Robie-Suh, K; Zhang, L; Zhao, P | 1 |
| Erdle, S; Harenberg, J; Krämer, R; Marx, S | 2 |
| Duggan, ST | 1 |
| Nagao, T | 1 |
| Dressel, T; Konstantinides, S; Schäfer, K; Wagner, NM | 1 |
| Biller, J; Flaster, M; Morales-Vidal, S; Schneck, MJ | 1 |
| Parma, Z; Syzdół, M; Tendera, M | 1 |
| Einecke, D | 3 |
| Godier, A; Lakhdari, M; Martin, AC; Samama, CM | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Ageno, W; Crowther, M; Gallus, AS; Hylek, EM; Palareti, G; Wittkowsky, A | 1 |
| Goldhaber, SZ | 1 |
| Funatsu, T; Iwatsuki, Y; Kaku, S | 1 |
| Alpert, JS | 1 |
| Soff, GA | 1 |
| Lip, GY; Riva, N | 1 |
| Cohen, AT; Dobromirski, M | 1 |
| Lee, S; White, CM | 1 |
| Mahan, C; Spyropoulos, AC | 1 |
| Cohen, A; Drost, P; Marchant, N; Mitchell, S; Orme, M; Rublee, D; Simon, TA; Sutton, A | 1 |
| Khemasuwan, D; Suramaethakul, N | 1 |
| Lip, GY; Shantsila, A | 1 |
| Gorelick, PB | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Carolei, A; Diener, HC; Donnan, GA; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Mas, JL; Massaro, A; Nessel, CC; Norrving, B; Paolini, JF; Patel, MR; Roine, RO; Singer, DE; Stevens, SR; Wong, L | 1 |
| Favaloro, EJ; Lippi, G | 2 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Ansell, J | 1 |
| Palareti, G; Tripodi, A | 1 |
| Golembiewski, J | 1 |
| Bryer, A | 1 |
| Amin, A; Deitelzweig, S; Graham, J; Jing, Y; Lin, J; Makenbaeva, D; Wiederkehr, D | 2 |
| Agnelli, G; Berkowitz, SD; Bounameaux, H; Büller, HR; Chlumsky, J; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Jacobson, BF; Lensin, AW; Minar, E; Misselwitz, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P | 1 |
| Cios, D; Fanikos, J | 1 |
| Ananthapavan, J; Diamantopoulos, A; Folkerts, K; Forster, F; Lees, M; McDonald, H; Wells, P | 1 |
| Dibattiste, PM; Ringwala, SM; Schneider, DJ | 1 |
| Cohen, AT | 1 |
| Herth, N; Hesse, C; Lindhoff-Last, E; Mani, H; Perzborn, E; Rohde, G; Schwers, S; Stratmann, G | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Miller, CS; Shimony, A | 1 |
| Morais, J | 1 |
| Clavé, A; Dumser, D; Fazilleau, F; Lacroix, J | 1 |
| Belavic, JM | 1 |
| Warwick, D | 1 |
| Bouras, G; Deftereos, S; Giannopoulos, G; Kossyvakis, C; Panagopoulou, V; Pyrgakis, V; Stefanadis, C | 1 |
| Haas, S; Schellong, SM; Spannagl, M | 1 |
| Kline, JA; Yealy, DM | 1 |
| Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 2 |
| Gibson, CM; Gopalakrishnan, L; Kohli, P; Kumar, V; Rastogi, U; Singh, P | 1 |
| Bommer, WJ | 1 |
| Augoustides, JG | 1 |
| Mustonen, P; Puurunen, M | 1 |
| Halperin, JL; Varughese, CJ | 1 |
| Lewalter, T | 1 |
| Albaladejo, P; Crackowski, JL; Cracowski, JL; Hodaj, E; Marlu, R; Paris, A; Pernod, G | 1 |
| Anglade, MW; Coleman, CI; Kluger, J; Lee, S; Pham, D; Pisacane, R | 1 |
| Goto, S; Hori, M; Iwamoto, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H | 3 |
| Barry, M; McCullagh, L; Walsh, C | 1 |
| Firriolo, FJ; Hupp, WS | 1 |
| Little, JW | 1 |
| Ismael, AG; Ribowsky, JH | 1 |
| Vivancos Mora, J; Ximénez-Carrillo Rico, A; Zapata Wainberg, G | 1 |
| Licina, MM; Lip, GY; Polovina, MM; Potpara, TS; Prostran, MS; Stojanovic, RM | 1 |
| Hussar, DA | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Haas, S; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, L; Schmidt, AC; Turpie, AG | 1 |
| Goel, R; Srivathsan, K | 1 |
| Bhatt, DL; Kar, S | 1 |
| Callahan, S; Goldsberry, A; Kim, G; Yoo, S | 1 |
| Levi, M | 1 |
| Ansell, J; Mantha, S | 1 |
| Ball, DG; Day, AG; Gibbens, SL; LaHaye, SA; Olesen, JB; Skanes, AC | 1 |
| Shafir, V; Spinler, SA | 1 |
| Agnifili, M; Bedogni, F; Brambilla, N; De Marco, F; Lanotte, S; Latib, A; Latini, RA; Laudisa, ML; Mattioli, R; Oreglia, J; Pizzocri, S; Testa, L | 1 |
| Müller, D; Stock, S; Stollenwerk, B; Zindel, S | 1 |
| Bode, C; Helbing, T; Moser, M | 1 |
| Larsen, TB; Rasmussen, LH; Skjøth, F | 1 |
| Avorn, J; Choudhry, NK; Gagne, JJ; Patrick, AR; Schneeweiss, S | 1 |
| Pollack, CV | 2 |
| Chechik, O; Dolkart, O; Gigi, R; Katzburg, S; Salai, M; Somjen, D; Stern, N | 1 |
| Fareed, J; Kalodiki, E; Lewis, B | 1 |
| Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C | 1 |
| Hashizume, K; Kajikawa, M; Kaneko, M; Mueck, W; Paolini, JF; Tajiri, M; Tanigawa, T; Ueda, H | 1 |
| Stief, TW | 1 |
| Capucci, A; Prisco, D | 1 |
| Crippa, L; Falanga, A; Finazzi, G; Manotti, C; Marongiu, F; Moia, M; Palareti, G; Pengo, V; Poli, D; Siragusa, S; Testa, S; Tiraferri, E; Tosetto, A; Tripodi, A | 1 |
| Berthold, HK | 1 |
| Mangiafico, M; Mangiafico, RA | 1 |
| Hui, AC; James, P; Jameson, SS; Muller, SD; Rymaszewska, M; Serrano-Pedraza, I | 1 |
| Harenberg, J; Marx, S; Wehling, M | 1 |
| Zhang, S | 1 |
| Yasaka, M | 1 |
| Berkowitz, RD; Damaraju, CV; Jennings, LK; Mills, RM; Wildgoose, P | 1 |
| Destephan, C; Dhruvakumar, S; Gerula, C; Kaluski, E; Maher, J; Mazza, V; Patel, RJ; Waller, AH | 1 |
| Carter, KL; Kraus, PS; Ross, PA; Shermock, KM; Streiff, MB; Thomas, ML; Wellman, JC | 1 |
| Ahrens, I; Bode, C | 2 |
| Griffiths, M; Scully, C | 1 |
| Beyer-Westendorf, J; Donath, L; Hartmann, A; Kuhlisch, E; Lützner, J; Radke, OC; Weiss, N; Werth, S | 1 |
| Attard, C; Ignjatovic, V; Kubitza, D; Monagle, P | 2 |
| Jin, M; Kamrul, R; Kosar, L; Schuster, B | 1 |
| DeDea, L | 1 |
| Cannon, CP; Kohli, P | 1 |
| Bradley-Kennedy, C; Clemens, A; Kansal, AR; Monz, BU; Peng, S; Roskell, N; Sharma, M; Sorensen, SV | 1 |
| Crockett, MT; Kavanagh, EC; Moynagh, MR | 1 |
| Ahmad, Y; Lip, GY | 2 |
| Lyrer, P; Nedeltchev, K; Seiffge, D | 1 |
| Kwong, LM; Tong, LM | 1 |
| Douketis, JD; Gerotziafas, G; Kaatz, S; Ortel, TL; Schulman, S; Spyropoulos, AC | 1 |
| Bauman, ME; Bruce, A; Massicotte, MP | 1 |
| Kopecky, S | 1 |
| Harenberg, J; Krämer, R; Marx, S; Samama, M; Schulman, S; Weiss, C | 1 |
| Gong, IY; Kim, RB; Mansell, SE | 1 |
| Brenner, B; Hoffman, R | 1 |
| Baglin, T; Keeling, D; Kitchen, S | 1 |
| Giorgi, MA; Miguel, LS | 1 |
| Costopoulos, C; Gorog, DA; Kukreja, N; Niespialowska-Steuden, M | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Loosen, C; Mullier, F | 1 |
| Brouwers, PJ; Kappelle, LJ; Koudstaal, PJ; Roos, YB; van Dijk, EJ | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Haas, S; Kreutz, R; Llau, J; Norrving, B; Turpie, AG | 1 |
| Ardissino, D; Casella, G; Magnani, G; Pavesi, PC | 1 |
| Haynes, LM; Mann, KG; Orfeo, T | 1 |
| Rajappan, K | 1 |
| Esmon, CT | 1 |
| Le Heuzey, JY | 1 |
| Eikelboom, JW; Manolakos, JJ; Paikin, JS | 1 |
| Graf, L; Tsakiris, DA | 1 |
| Ali, M; Nawal, CL | 1 |
| Asada, Y; Funatsu, T; Iwatsuki, Y; Kaku, S; Yamashita, A | 1 |
| Becker, RC; Chan, MY; Cyr, D; Kajikawa, M; Lin, M; Lucas, J; Moseley, A; Ortel, TL; Thompson, JW; Ueda, H | 1 |
| Casutt, M; Konrad, C; Schuepfer, G | 1 |
| Gonzalez, MD; Naccarelli, GV | 1 |
| Aalbers, J | 2 |
| Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K | 1 |
| Badimon, JJ; Becker, EM; Bütehorn, U; Kast, R; Klipp, A; Laux, V; Lücker, C; Perzborn, E | 1 |
| McBane, RD; Tafur, A; Wysokinski, WE | 1 |
| Merli, GJ | 1 |
| Dinkelaar, J; Leyte, A; Molenaar, PJ | 1 |
| Davies, R | 1 |
| Brasselet, C; Duval, S | 1 |
| Drabik, A; Goerge, T; Kerk, N; Luger, TA; Schneider, SW | 1 |
| Berkowitz, SD; Eriksson, BI; Gent, M; Homering, M; Kakkar, AK; Lassen, MR; Turpie, AG | 1 |
| Beyer-Westendorf, J; Braun, J; Klamroth, R; Koscielny, J; Lindhoff-Last, E; Spannagl, M; Tiede, A; von Heymann, C | 1 |
| Valle Bernad, R | 1 |
| Blanco-Molina, A | 1 |
| Nagler, M; Wuillemin, W | 1 |
| Haschke, M | 1 |
| Elias, A; Gaillard, C; Gouin, I; Nguyen, P; Ouvry, P; Pernod, G; Sié, P | 1 |
| Kaatz, S; Mahan, CE | 1 |
| Lipták, J | 1 |
| Graungaard, T; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F | 1 |
| Lazo-Langner, A; Sun, D | 1 |
| Burggraaf, J; Kluft, C; Kret, R; Meijer, P | 1 |
| Koracevic, GP | 2 |
| Hannan, T; Khalafallah, AA; Renu, S; Sharp, C | 1 |
| Choudhry, M; Keys, G; Yates, J | 1 |
| Dabitz, R; Ochs, G | 1 |
| Boehlen, F; de Moerloose, P | 1 |
| Albuquerque, LG; Dini, GM; Ferreira, LM; Ferreira, MCC | 1 |
| Hardy, G | 1 |
| Okada, Y; Yasaka, M | 1 |
| Beyer-Westendorf, J; Donath, L; Günther, KP; Hartmann, A; Knoth, H; Kuhlisch, E; Lützner, J; Radke, OC; Stange, T; Tittl, L; Weiss, N; Werth, S | 1 |
| Fitchett, DH | 1 |
| Wooten, JM | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Chang, Y; Fox, KA; Go, AS; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Martin, EN; Money, SR; Shamoun, FE | 1 |
| Crowther, MA; Siegal, DM | 1 |
| Kong, Y; Wang, G; Wang, L; Zhang, Y; Zhao, X | 1 |
| Ortel, TL | 1 |
| Pawlikowska, Z; Szponar, J | 1 |
| Coccheri, S; Orlando, D | 1 |
| Du, S; Giese, C; Harenberg, J; Krämer, R; Krämer, S; Schulze, A; Weiss, C | 1 |
| Mazur-Bialy, AI; Undas, A; Wypasek, E; Zdebska, K | 1 |
| Kitchen, S; Makris, M; Smith, J; van Veen, JJ | 1 |
| Medvegy, M; Simonyi, G | 1 |
| Guo, W; Tang, BQ; Tang, S; Tang, XD; Yan, TQ; Yang, RL | 1 |
| Gulseth, M; Hellwig, T | 2 |
| Alatrach, A; Becka, M; Halabi, A; Hinrichsen, H; Kubitza, D; Mueck, W; Roth, A | 1 |
| Deitelzweig, SB | 1 |
| Eraso, LH; Merli, GJ; Perez, A | 1 |
| Chidiac, J; Jamshedov, J; Klein, C; Mirshahi, M; Mirshahi, P; Mirshahi, S; Perzborn, E; Soria, C; Soria, J; Varin, R | 1 |
| Camm, AJ; Savelieva, I | 1 |
| Greenspon, AJ | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Ganetsky, V; Spinler, SA; Thomas, TF | 1 |
| Dolkart, O; Gigi, R; Katzburg, S; Salai, M; Sharon, O; Somjen, D; Stern, N | 1 |
| Debue, JM; Guinet, C; Le Flem, L; Ninin, E; Samama, MM | 1 |
| Berkowitz, SD; Homering, M; Llau, JV; Loewe, A; Mueck, W; Rosencher, N | 1 |
| Hashizume, K; Kajikawa, M; Kaneko, M; Mueck, W; Tajiri, M; Tanigawa, T | 1 |
| Bütehorn, U; Heitmeier, S; Nawroth, P; Perzborn, E; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Hammerstingl, C; Nickenig, G; Pötzsch, B | 1 |
| Shiga, T | 1 |
| Brem, E; Foran, M; Koyfman, A | 1 |
| Helin, TA; Joutsi-Korhonen, L; Lassila, R; Pakkanen, A | 1 |
| Büller, HR; Cohen, AT; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, V | 1 |
| Graff, J; Harder, S | 2 |
| Garcia, DA; Rojas-Hernandez, CM | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Mohanty, S; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Zhang, Z | 1 |
| Reynolds, MR | 1 |
| Contractor, T; Levin, V; Marchlinski, FE; Martinez, MW | 1 |
| Barrios, V; Escobar, C | 1 |
| Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H | 1 |
| Ageno, W; Ferrari, A; Filippi, A; Imberti, D; Palareti, G; Pengo, V; Rubboli, A; Toni, D | 1 |
| Douketis, JD; Faraoni, D; Levy, JH; Samama, CM; Spring, JL | 1 |
| Beyer-Westendorf, J; Gehrisch, S; Mahlmann, A | 1 |
| Dyrkorn, R; Roland, PD | 1 |
| Ageno, W; Bozzato, S; Donadini, MP; Riva, N | 1 |
| Abe, K; Conley, PB; DeGuzman, FR; Hollenbach, SJ; Hutchaleelaha, A; Inagaki, M; Karbarz, MJ; Lee, G; Lu, G; Luan, P; Phillips, DR; Sinha, U | 1 |
| Becka, M; Kubitza, D; Mueck, W; Stampfuss, J | 2 |
| Bock, F; Hartung, K; Isermann, B; Meyer, F | 1 |
| Akwaa, F; Spyropoulos, AC | 2 |
| Luettgen, J; White, A; Wong, PC | 1 |
| Galanis, T; Merli, GJ | 1 |
| Berman, JP; Halperin, JL | 1 |
| Lenchus, JD | 1 |
| Apostolakis, S; Kasmeridis, C; Lip, GY | 1 |
| Eby, CS | 1 |
| Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Huang, JH; Lin, YK | 1 |
| Roldán Schilling, V; Vicente García, V | 1 |
| Guijarro Merino, R; Villalobos Sánchez, A | 1 |
| Nieto Rodríguez, JA | 1 |
| Marchena Yglesias, PJ | 1 |
| Hernández, M; Suárez, C | 1 |
| Fernández, D; Heras, M; Penela, D | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Torres, LM | 1 |
| Masjuan, J | 1 |
| Dalmau, FG | 1 |
| Braunwald, E; Burton, P; Gibson, CM; Kiss, RG; Mega, JL; Murphy, SA; Parkhomenko, A; Plotnikov, AN; Tendera, M; Widimsky, P | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 2 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Pan, G; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Huo, MH; Russell, RD | 1 |
| Calvo Romero, JM; Lima Rodríguez, EM | 1 |
| White, HD; Wong, CK | 1 |
| Holley, AB; King, CS; Moores, LK | 1 |
| Adler, D; Beeton, A; Büller, H; de Jong, PR; Haas, S; Hsu, HC; Jacobson, BF; Louw, S; Mer, M; Rowji, P; Schapkaitz, E; Wessels, P | 1 |
| Kamphuisen, PW; Lisman, T; Northup, PG; Porte, RJ | 1 |
| Armstrong, EP; Harrington, AR; Malone, DC; Nolan, PE | 1 |
| Forster, MC; Goodson, MW; Rath, NK; White, SP | 1 |
| Reitsma, PH; Rosendaal, FR | 1 |
| Brinkman, HJ; de Laat, B; Dinkelaar, J; Leyte, A; Molenaar, PJ; Ninivaggi, M | 1 |
| Eby, C | 1 |
| Aung, TH; Foo, D; Francis, PJ; Ho, HH; Huang, W; Ong, PJ; Wong, CP; Yeo, D | 1 |
| Jeffery, SM; Ogbonna, KC | 1 |
| Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C | 1 |
| Bassand, JP; Bhatt, DL; Bode, C; Braunwald, E; Burton, P; Chakrabarti, AK; Cohen, M; Gibson, CM; Goto, S; Mega, J; Mohanavelu, S; Stone, G; Verheugt, FW | 1 |
| Limdi, NA; Thigpen, JL | 1 |
| Ageno, W; Buller, H; Glazer, S; Gunn, S; Peerlinck, K; Prins, M; Sonesson, E; Tangelder, M; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Harris, K; Mant, J | 1 |
| Atarashi, H | 1 |
| Darius, H; Sommer, S | 1 |
| Bonar, R; Butler, J; Favaloro, EJ; Marsden, K | 1 |
| Buchmueller, A; Buetehorn, U; Gruber, A; Heitmeier, S; Laux, V; Marzec, UM; Perzborn, E; Tinel, H | 1 |
| Beauloye, C; Dogné, JM; Douxfils, J; Goethals, M; Hainaut, P; Heidbuchel, H; Hermans, C; Ickx, B; Jochmans, K; Michel, S; Mottes, S; Mullier, F; Peeters, A; Scavée, C; Sinnaeve, P; Sprynger, M; Thijs, V; Vandenbroeck, C; Vandermeulen, E; Verhamme, P | 1 |
| Peeters, S; Warnez, M | 1 |
| Gonsalves, WI; Patnaik, MM; Pruthi, RK | 1 |
| Nutescu, EA | 1 |
| Kalus, JS | 1 |
| Eisenberg, MJ; Filion, KB; Grandi, SM; Wasserlauf, G | 1 |
| Arachchillage, DJ; Cohen, H | 1 |
| Bastovansky, A; Finsterer, J; Stöllberger, C; Zuntner, G | 1 |
| Spyropoulos, AC; Turpie, AG | 1 |
| Kerr, R; Ogden, G; Sime, G | 1 |
| Bonnabry, P; Daali, Y; Dayer, P; Desmeules, JA; Gschwind, L; Rollason, V | 1 |
| Böhm, M; Dichgans, M; Diener, HC; Ell, C; Endres, M; Epple, C; Grond, M; Laufs, U; Nickenig, G; Riess, H; Röther, J; Schellinger, PD; Spannagl, M; Steiner, T; Veltkamp, R | 1 |
| Gallego, P; Lip, GY; Roldan, V | 1 |
| Dentali, F; Riva, N | 1 |
| Carter, NJ; Plosker, GL | 1 |
| Berkowitz, SD; Burton, P; Cook-Bruns, N; DiBattiste, PM; Haskell, L; Jalota, S; Kubitza, D; Lensing, AW; Misselwitz, F; Moore, KT; Nadel, A; Nessel, CC; Oppenheimer, L; Pan, G; Perzborn, E; Peters, G; Sarich, TC; Sun, X; Weber, J; Westermeier, T | 1 |
| Aisenberg, J; Desai, J; Kolb, JM; Weitz, JI | 1 |
| Brardjanian, S; Coton, T; Diallo, I; Guisset, M; Jourdan, S; Mallaret, C | 1 |
| Braunwald, E; Gibson, CM; Gotcheva, N; Mega, JL; Murphy, SA; Plotnikov, A; Ruda, M; Wiviott, SD | 1 |
| Dager, WE; Fanikos, J; Gulseth, MP; Nutescu, EA; Smythe, MA; Spinler, SA; Wittkowsky, AK | 1 |
| Bauersachs, J; Flierl, U; Fraccarollo, D; Micka, J; Schäfer, A | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Singer, DE; van Diepen, S | 1 |
| Aisenberg, J; Desai, J; Granger, CB; Weitz, JI | 1 |
| Klein, HH | 1 |
| Ansell, J; Lindhoff-Last, E; Samama, MM; Spiro, T | 1 |
| Kaul, S; Krantz, MJ | 1 |
| Toth, PP | 1 |
| Jing, J; Li, J; Zhan, J; Zhou, Y | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hannan, KL; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Schwabe, K; Singer, DE | 1 |
| Hagen, G; Hamidi, V; Klemp, M; Reikvam, Å; Ringerike, T | 1 |
| Ambrus, R; Horváth, P; Szabó-Révész, P; Szőke, V; Takács-Novák, K; Völgyi, G | 1 |
| Cutler, NR; Goldenberg, NA; Halperin, JL; Hiatt, WR; Kessler, CM; Kittelson, JM; Schulman, S; Spyropoulos, AC; Steg, G; Turpie, AG | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; White, HD; Wojdyla, D | 1 |
| Becka, M; Gouya, G; Kapiotis, S; Kubitza, D; Mueck, W; Wolzt, M | 1 |
| Gong, IY; Kim, RB | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Boos, CJ; Camm, AJ; Nam, M | 1 |
| Diener, HC | 1 |
| Douketis, J; Lang, ES; Lazo-Langner, A | 1 |
| Douketis, J; Liew, A | 1 |
| Vanassche, T; Verhamme, P | 1 |
| Bates, P; Culpan, P; El-Daly, I; Reidy, J | 1 |
| Baruch, L | 1 |
| Lopes, RD; Newby, LK; Truffa, AA | 1 |
| Crowther, MA; Daw, HA; Fawole, A | 1 |
| Páramo, JA | 1 |
| Gericke, C; Heymann, Cv; Körber, MK; Langer, E; Perzborn, E; Ziemer, S | 1 |
| Bamber, L; Bauersachs, R; Cano, SJ; Ciniglio, C; Lensing, AW; Prins, MH; Wang, MY | 1 |
| Rider, EB; Rider, OJ | 1 |
| Chatelain, B; Chatelain, C; Dogné, JM; Douxfils, J; Mullier, F; Tamigniau, A; Wallemacq, P | 1 |
| Babatz, J; Beyer-Westendorf, J; Pannach, S | 1 |
| Castillo, J; de Andrés, J; Ferrandis, R; Gomar, C; Gómez-Luque, A; Hidalgo, F; Llau, JV; Sierra, P; Torres, LM | 1 |
| Giugliano, RP; Shimada, YJ | 1 |
| Díaz de Rada, P; González, AB; Muñoa, L; Valentí, A; Valentí, JR | 1 |
| Bhimani, AA; Hong, M | 1 |
| Geller, BJ; Gibson, CM; Guo, J; Hoffman, EB; Mega, JL; Morrow, DA; Ruff, CT | 1 |
| Opolonskaia, NA; Tseluĭko, VI; Vashakidze, ZS | 1 |
| Kamal, AK; Kamran, SH; Muzammil, SM | 1 |
| Chana, F; Llau, JV; Marco, P; Zamorano, JL | 1 |
| Al-Majzoub, O; Assiri, A; Donovan, JL; Kanaan, AO; Silva, M | 1 |
| Bertoletti, L; Buchmuller, A; Decousus, H; Lega, JC; Mismetti, P; Moulin, N | 1 |
| Alabalik, U; Azboy, I; Bulut, M; Demirtas, A; Necmioglu, NS; Ucar, BY | 1 |
| Accassat, S; Bertoletti, L; Décousus, H; Lega, JC; Merah, A; Mismetti, P | 1 |
| Ambrosi, P; Cohen, W; Habib, G; Kreitmann, B; Morange, P | 1 |
| Schellong, S | 1 |
| Aguilar, MI; Freeman, WD; Kuo, RS | 1 |
| Becker, C; Burghaus, R; Coboeken, K; Edginton, A; Lippert, J; Mück, W; Siegmund, HU; Thelen, K; Willmann, S | 1 |
| Baumann Kreuziger, LM; Reding, MT | 1 |
| Dalen, JE | 1 |
| Fanikos, J | 1 |
| Li, C; Li, T; Mao, L; Yuan, K | 1 |
| Wanat, MA | 1 |
| Baglin, T | 1 |
| Avorn, J | 1 |
| Barry, M | 1 |
| Pruthi, RK | 1 |
| Ansell, J; Shameem, R | 1 |
| Lip, GY; Potpara, TS | 1 |
| Diener, HC; Easton, JD; Hankey, GJ; Hart, RG | 1 |
| Bennaghmouch, N; Ten Berg, JM | 1 |
| Agnelli, G; Becattini, C; Franco, L | 1 |
| den Exter, PL; Huisman, MV; Kooiman, J; van der Hulle, T | 1 |
| Eriksson, BI; Quinlan, DJ | 1 |
| Cohen, AA; Rider, T | 1 |
| Majeed, A; Schulman, S | 1 |
| Barco, S; Cheung, YW; Coppens, M; Eikelboom, JW | 1 |
| Kansal, AR; Pokora, T; Sorensen, SV; Zheng, Y | 1 |
| Goto, S; Hori, M; Iekushi, K; Izumi, T; Kajikawa, M; Kato, M; Koretsune, Y; Matsumoto, M; Momomura, S; Tajiri, M; Tanahashi, N; Uchiyama, S; Ueda, H; Yamanaka, S | 3 |
| Hollis, S | 1 |
| Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M | 1 |
| Albaladejo, P; Blais, N; Cohen, A; de Maistre, E; Fontana, P; Godier, A; Gruel, Y; Llau, JV; Mismetti, P; Pernod, G; Rosencher, N; Samama, CM; Samama, MM; Schved, JF; Sié, P; Susen, S | 1 |
| Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS | 1 |
| Brunkhorst, R; Foerch, C; Lindhoff-Last, E; Luger, S; Pfeilschifter, W | 1 |
| Balletshofer, BM; Haering, HU; Jaschonek, K; Kanz, L; Kopp, HG; Randrianarisoa, E; Rittig, K | 1 |
| Asukai, Y; De Ruyck, M; Evers, T; Faes, P; Goethals, M; Kleintjens, J; Li, X; Rietzschel, ER; Saka, Ö; Simoens, S; Thijs, V; Vansieleghem, S | 1 |
| Lu, WX; Qin, L | 1 |
| He, B; Kun, L; Liu, X; Wu, B | 1 |
| Azuma, S; Lum, CJ | 1 |
| Blais, MC; Carioto, L; Conversy, B; del Castillo, JR; Dunn, M; Gara-Boivin, C | 1 |
| Hughes, DA; Lane, S; Pink, J; Pirmohamed, M | 1 |
| Gunalingam, B; Markus, R; Spina, R; Subbiah, R | 1 |
| Brown, TS; Huo, MH | 1 |
| Ando, M; Hirayama, H; Kihara, Y; Nakano, Y; Sairaku, A; Yoshida, Y | 1 |
| Atar, D; Ghanima, W; Sandset, PM | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Delepaul, B; Gras, S; Olivier, J; Van Agt, G; Yakoubi, R | 1 |
| Kornej, J; Lip, GY; Potpara, T | 1 |
| Sarode, R; Yates, S | 1 |
| Anisimova, AV; Borisov, SN; Gendlin, GE | 1 |
| Barbar, S; Milan, M; Pesavento, R; Prandoni, P; Vedovetto, V | 1 |
| Bay, C; Schwartz, F; Sharifi, M; Skrocki, L | 1 |
| Chandler, WL | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; White, HD | 1 |
| Diogène, E; Troncoso, A | 1 |
| Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C | 1 |
| Ragni, MV; Seaman, CD; Smith, KJ | 1 |
| Artoni, A; Bucciarelli, P; Fossali, EF; Martinelli, I; Passamonti, SM; Peyvandi, F; Tripodi, A | 1 |
| Biondi-Zoccai, G; Chatterjee, S; Lichstein, E; Mukherjee, D; Sharma, A; Uchino, K | 1 |
| Eikelboom, JW; Kapral, MK; McGrath, ER; O'Donnell, MJ | 1 |
| Braun, G; Messmann, H | 1 |
| Roldán, V; Suárez-Fernández, C; Vivancos, J | 1 |
| Haas, S; Holberg, G; Jamal, W; Kreutz, R; Lassen, MR; Mantovani, LG; Pattanayak, CW; Schmidt, A; Turpie, AG; van Eickels, M | 1 |
| Beyer-Westendorf, J; Gehrisch, S | 1 |
| Bookhart, BK; Coleman, CI; Huynh, L; Lefebvre, P; Mody, SH; Nutescu, EA; Tran, KN; Wang, ST; Zhuo, DY | 1 |
| Degirmenci, SE; Steib, A | 1 |
| Aramendi, JI; Mestres, CA | 1 |
| Nagatsuka, K; Okata, T; Takasugi, J; Toyoda, K; Yamagami, H | 1 |
| Alonso-Canovas, A; Alvarez-Velasco, R; de Felipe Mimbrera, A; Kawiorski, MM; Masjuan, J; Sainz de la Maza, S; Zarza, B | 1 |
| Peerlinck, K; Peetermans, M; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Bagot, CN; Hickman, G; Lawrence, C; McGurk, M; Rodgers, R; Tait, RC | 1 |
| Aldin, ES; Greenberg, C; Rachidi, S; Sachs, B; Streiff, M; Zeidan, AM | 1 |
| Frölich, L; Harenberg, J; Krejczy, M; Marx, S; Obermann, K; Wehling, M | 1 |
| Avorn, J; Brennan, TA; Canestaro, WJ; Choudhry, NK; Ito, K; Matlin, OS; Patrick, AR; Shrank, WH | 1 |
| Wood, P | 1 |
| Dütsch, M; Klauser, W | 1 |
| Germain, G; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Raut, MK; Schein, JR | 3 |
| Caliskan, A; Demirtas, S; Guclu, O; Karahan, O; Mavitas, B; Yavuz, C; Yazici, S | 1 |
| Baruch, L; Sherman, O | 1 |
| Manning, JA | 1 |
| Giugliano, RP; Murphy, SA | 1 |
| Kitazono, T | 1 |
| Uchiyama, S | 1 |
| Bruder, N; Graillon, T; Maurice-Szamburski, A | 1 |
| Baran, J; Kułakowski, P; Sikora-Frąc, M; Stec, S; Zaborska, B | 1 |
| Laffan, M; Shapiro, S | 1 |
| Breithardt, G; Califf, RM; Fox, KA; Halperin, J; Hankey, GJ; Hellkamp, AS; Jones, WS; Mahaffey, KW; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Greiten, LE; McKellar, SH; Rysavy, J; Schaff, HV | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; White, HD; Wojdyla, DM | 1 |
| Ragni, MV | 1 |
| Dekkers, OM; den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hulle, T | 1 |
| Avram, MJ; Benzon, HT; Bonow, RO; Green, D | 1 |
| Aumann, V; Boxberger, N; Hartung, KJ; Heim, MU; Siegemund, A | 1 |
| Heitmeier, S; Jenetzky, E; Ploen, R; Sun, L; Veltkamp, R; Zhou, W; Zorn, M | 1 |
| Aihara, K; Iba, T; Nagayama, M; Ohsaka, A; Tabe, Y; Yamada, A | 1 |
| Baker, R; Herrmann, R; Muhammad, S; Phillips, M; Thom, J; Wood, A | 1 |
| Du, S; Giese, C; Harenberg, J; Kraemer, R; Kraemer, S; Schulze, A; Weiss, C | 1 |
| Risselada, AJ; van Roon, E; Visser, MJ | 1 |
| Barillari, G; Cheng, JW | 1 |
| Crowther, MA; Garcia, DA; Siegal, DM | 1 |
| Martinez, M; Tandra, A; Vuppalanchi, R | 1 |
| Adcock, DM; Deal, AM; Francart, SJ; Friedman, KD; Gosselin, R; Hawes, EM; Jeanneret, C; Moll, S | 1 |
| Jiang, B; Li, H; Long, A; Mao, Z; Tang, P; Xie, Z; Zhang, L; Zhang, S; Zhang, Y | 1 |
| Alban, S; Birschmann, I; Busse, J; Dittrich, M; Eller, T; Flieder, T; Knabbe, C | 1 |
| Atkins, D; Baheiry, S; Barrett, CD; Bommana, S; Burkhardt, JD; Chalhoub, F; Di Biase, L; Gangireddy, S; Lakkireddy, D; Mansour, MC; Natale, A; Reddy, V; Reddy, YM; Ruskin, J; Sanchez, JE; Santangeli, P; Swarup, V; Vallakati, A; Verma, A | 1 |
| Archeval-Lao, JM; Bowry, R; Cai, C; Fraser, S; Grotta, JC; Parker, SA; Rahbar, MH | 1 |
| Burness, CB; Perry, CM | 1 |
| Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M | 1 |
| Diener, HC; Weber, R | 1 |
| Chantrathammachart, P; Hebbel, RP; Key, NS; Mackman, N; Mickelson, J; Monroe, DM; Pawlinski, R; Sparkenbaugh, EM; van Ryn, J | 1 |
| Aizawa, T; Kano, H; Kato, Y; Kirigaya, H; Matsuno, S; Nagashima, K; Oikawa, Y; Otsuka, T; Sagara, K; Sawada, H; Suzuki, S; Takai, H; Uejima, T; Yajima, J; Yamashita, T | 1 |
| Battegay, M; Elzi, L; Lakatos, B; Marzolini, C; Stoeckle, M | 1 |
| Bajorek, B; Wang, Y | 1 |
| Goto, S; Tomita, A | 1 |
| Büller, HR; Burton, P; Cohen, AT; Desanctis, YH; Haskell, L; Homering, M; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, S; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Berrut, G; Chevalet, P; De Decker, L; Gegu, M; Piloquet, FX | 1 |
| Hanon, O | 1 |
| Rondina, MT; Vazquez, S; Vo, T | 1 |
| Darvish-Kazem, S; Douketis, JD; Liew, A | 1 |
| Bollmann, A; Breithardt, OA; Dinov, B; Doering, M; Hindricks, G; Kosiuk, J; Koutalas, E; Nedios, S; Richter, S; Rolf, S; Sommer, P | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Altena, R; de Wit, H; Folkeringa, R; Hoogendoorn, M; van Roon, E | 1 |
| Hosokawa, K; Koide, T; Maruyama, I; Miura, N; Ohnishi, T; Sameshima, H; Tanaka, KA | 1 |
| Du, EX; Li, N; Liu, Y; Tan, R; Wu, C; Wu, EQ; Xie, J | 1 |
| Giugliano, RP; Gonzalez-Quesada, CJ | 1 |
| Adelmeijer, J; Arshad, F; Blokzijl, H; Lisman, T; Meijers, JC; Porte, RJ; Potze, W; van den Berg, AP | 1 |
| Alhenc-Gelas, M; Potaczek, DP; Undas, A; Wypasek, E | 1 |
| Dorian, P; Hernandez, L; Iloeje, U; Kongnakorn, T; Kuznik, A; Lanitis, T; Lip, GY; Liu, LZ; Phatak, H | 1 |
| Bounameaux, H; Fontana, P; Goldhaber, SZ | 1 |
| Miller, MP; Nordenholz, KE; Trujillo, TC | 1 |
| Becka, M; Krätzschmar, J; Kubitza, D; Mück, W | 1 |
| Gnall, EM; Ice, DS; Kowey, PR; Shapiro, TA | 1 |
| Buchmüller, A; Heitmeier, S; Laux, V; Perzborn, E | 1 |
| Plosker, GL | 1 |
| Crowther, MA; Linkins, LA; Manji, RA; Pai, M; Shivakumar, S; Warkentin, TE; Wells, PS | 1 |
| Albenque, JP; Boveda, S; Combes, N; Combes, S; Hireche, H; Jourda, F; Marijon, E; Morais, J; Providência, R | 1 |
| Angiolillo, DJ; Capodanno, D | 1 |
| Becker, RC; Califf, RM; Douketis, JD; Fox, KA; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Sherwood, MW; Singer, DE; Spyropoulos, AC | 1 |
| Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS | 1 |
| Crowther, M; Pasierski, T; Undas, A; Windyga, J | 1 |
| Heit, JA; Rooke, TW; Rosenbaum, AN; Yu, RC | 1 |
| Groh, C; Passman, R; Yadlapati, A | 1 |
| Herrmann, E; Herth, N; Kasper, A; Lindhoff-Last, E; Linnemann, B; Mani, H; Pfeilschifter, W; Schuettfort, G; Weil, Y; Wendt, T | 1 |
| Bookhart, BK; Coleman, CI; Limone, BL; Mody, SH; Nutescu, EA | 1 |
| Ong, A; Orozco, F; Parvizi, J; Post, Z; Radcliff, KE | 1 |
| Behrens, L; Capper, D; Purrucker, JC; Veltkamp, R | 1 |
| Gonzva, J; Lignac, D; Patricelli, R | 1 |
| Iavelov, IS | 1 |
| García de Frutos, P; Tàssies, D | 1 |
| Badhwar, N; Gerstenfeld, EP; Lee, BK; Lee, RJ; Marcus, GM; Olgin, J; Scheinman, M; Stepanyan, G; Tseng, ZH; Vedantham, V | 1 |
| Bode, C; Haas, S; Norrving, B; Turpie, AG | 1 |
| Cloutier, M; Coleman, CI; Damaraju, CV; Laliberté, F; Lefebvre, P; Nelson, WW; Olson, WH; Pilon, D; Schein, JR | 1 |
| Meddahi, S; Samama, MM | 1 |
| Bassand, JP | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Garg, J; Goodman, SG; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Giugliano, RP; Reddy, P | 1 |
| Becker, RC; Califf, RM; Fox, KA; Girgis, IG; Halperin, JL; Mahaffey, KW; Moore, KT; Nessel, CC; Patel, MR; Peters, GR | 1 |
| Cheng, W; Kan, W; Ren, Y; Xiao, Z; Xu, H; Zheng, Q | 1 |
| Arachchillage, DR; Cohen, H; Efthymiou, M; Lawrie, AS; Machin, SJ; Mackie, IJ | 2 |
| Budmiger, M; Hürlimann, S; Kullak-Ublick, GA; Niedrig, DF; Russmann, S; Schmidt, C; Stieger, B | 1 |
| Jing, J; Li, J; Yao, Y; Zhan, J; Zhou, Y | 1 |
| Sun, K; Tian, S; Wang, Y; Zou, Y | 1 |
| Arya, R; Couchman, L; Flanagan, RJ; Gous, T; Paradzai, C; Patel, JP | 1 |
| Bolbrinker, J; Douros, A; Ebinger, M; Kreutz, R; Schlemm, L | 1 |
| Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Kuhlisch, E; Röder, I; Röllig, D; Schreier, T; Stange, T; Thieme, C; Tittl, L; Weiss, N; Werth, S | 1 |
| Berkowitz, SD; Berlin, JA; DiBattiste, PM; Friedman, RJ; Homering, M; Levitan, B; Turpie, AG; Weinstein, RB; Yuan, Z | 1 |
| Thachil, J | 1 |
| Hagen, G; Klemp, M; Wisløff, T | 1 |
| Fenger-Eriksen, C; Grove, EL; Münster, AM | 1 |
| Hagii, J; Hitomi, H; Kamada, T; Kimura, Y; Metoki, N; Okumura, K; Osanai, T; Saito, S; Shiroto, H; Tomita, H; Yasujima, M | 1 |
| Brighton, TA; Davidson, BL; Gebel, M; Lensing, AW; Lyons, RM; Prins, MH; Rehm, J; Verheijen, S | 1 |
| Piccini, JP; Steinberg, BA | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Asrar ul Haq, M; van Gaal, WJ | 1 |
| Alabalik, U; Alemdar, C; Azboy, I; Bulut, M; Demirtaş, A; Uçar, Y | 1 |
| Jing, JH; Li, J; Shi, ZJ; Zhou, Y | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Harrell, FE; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, R; Fox, KA; Hacke, W; Hankey, GJ; Hu, DY; Mahaffey, KW; Oomman, A; Patel, MR; Singer, DE; Tan, RS; Wong, KS | 1 |
| Lip, GY; Yasaka, M | 1 |
| Buetehorn, U; Heitmeier, S; Laux, V; Perzborn, E | 1 |
| Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, MI; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P | 1 |
| Douketis, J; Ing, E | 1 |
| Guan, Z; Kou, B; Li, H; Lin, J; Wei, W; Zhang, H; Zhou, D | 1 |
| Carrothers, AD; Gollish, JD; Murnaghan, JJ; Razmjou, H; Rodriguez-Elizalde, SR; Rogers, BA | 1 |
| Bookhart, B; Huynh, L; Lefebvre, P; Mody, SH; Tran, KN; Zhuo, DY | 1 |
| Gislason, G; Sørensen, R | 1 |
| Davidson, N; Galloway, SW; Lai, A; Thachil, J | 1 |
| Barake, W; Baranchuk, A; Pinter, A | 1 |
| Brieger, D | 1 |
| Finsterer, J; Stöllberger, C; Valentin, A | 1 |
| MacIsaac, A; Xu, B | 1 |
| Greene, SL; Koutsogiannis, Z; Wong, A | 1 |
| Ardissino, D; Cervellin, G; Lippi, G; Quintavalla, R | 1 |
| Berkowitz, SD; Castillejos, CF; Goldhaber, SZ; Kubitza, D; Levi, M; Levy, JH; Moore, KT; Patel, MR; Raghoebar, M; Weitz, JI | 1 |
| Brouns, R; De Keyser, J; De Smedt, A; Jochmans, K; Nieboer, K; van Hooff, RJ; Yperzeele, L | 1 |
| den Exter, PL; Huisman, MV; Klok, FA; Kooiman, J; van der Hoeven, JJ; van der Hulle, T | 1 |
| Cotté, FE; Durand-Zaleski, I; Gaudin, AF; Kachaner, I; Kongnakorn, T; Lanitis, T | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Passman, R; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA | 1 |
| Blin, P; Gulmez, SE; Moore, N | 1 |
| John, A; Michel, MS | 1 |
| Foley, J; Kirchhof, P; Lip, GY | 1 |
| Amann, U; Enders, D; Garbe, E; Jobski, K; Schink, T; Suzart, K; Wallander, MA | 1 |
| Beyer-Westendorf, J; Ebertz, F; Förster, K; Gelbricht, V; Hänsel, U; Köhler, C; Michalski, F; Pannach, S; Sahin, K; Thieme, C; Tittl, L; Weiss, N; Werth, S | 1 |
| Avorn, J; Brennan, TA; Brill, G; Choudhry, NK; Desai, NR; Krumme, AA; Matlin, OS; Pezalla, EJ; Schneeweiss, S; Shrank, WH; Spettell, CM | 1 |
| Dempfle, CE | 1 |
| Prandoni, P; Taher, A; Temraz, S | 1 |
| Beer, JH; Holy, EW | 1 |
| Hürlimann, D; Noll, G; Noll, S | 1 |
| Ossei-Gerning, N; Shivu, GN | 1 |
| Fiene, M; Greinacher, A; Grotevendt, A; Sümnig, A; Thiele, T; Westphal, A | 1 |
| Evans, RS; Fontaine, GV; Lloyd, JF; Mathews, KD; Stevens, SM; Woller, SC | 1 |
| Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J | 1 |
| Cohen, M; Iyer, D | 1 |
| Freedman, JE; Gersh, BJ | 1 |
| Becker, RC; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Paolini, JF; Patel, MR; Piccini, JP; Singer, DE; Wojdyla, DM | 1 |
| Albertson, TE; Cantrell, FL; Clark, RF; Minns, AB; Smollin, C; Stevenson, JW; Tomaszewski, C | 1 |
| Gross, PL; Weitz, JI; Yeh, CH | 1 |
| Coleman, CI; Damaraju, CV; Nelson, WW; Schein, JR; Smith, DM; Song, X; Thomson, E | 1 |
| Du, S; Harenberg, J; Krämer, R; Krämer, S; Lip, GY; Schulze, A; Wehling, M; Weiss, C; Zolfaghari, S | 1 |
| Hess, T; Konturek, P | 1 |
| Lévy, S | 1 |
| Baker, WL; Chamberlin, KW | 1 |
| Curnow, J; Joseph, J; McLintock, C; McRae, S; Nandurkar, H; Tran, H; Wood, P; Young, L | 1 |
| Dan, GA; Kaski, JC; Martínez-Rubio, A | 1 |
| Kakkos, SK; Kirkilesis, GI; Tsolakis, IA | 1 |
| Angeli, F; Lip, GY; Reboldi, G; Verdecchia, P | 1 |
| Büller, HR; Coppens, M; Middeldorp, S; Schulman, S; van Es, N | 1 |
| Ariyawansa, J; Haskell, L; Moore, KT; Natarajan, J; Turner, KC; Vaidyanathan, S | 1 |
| Baghaei, F; Berndtsson, M; Fagerberg Blixter, I; Faxälv, L; Gustafsson, KM; Hillarp, A; Lindahl, TL; Strandberg, K | 1 |
| Ammar, S; Buiatti, A; Deisenhofer, I; Dillier, R; Hessling, G; Hofmann, M; Kaess, B; Kathan, S; Kolb, C; Lennerz, C; Pavaci, H; Reents, T; Semmler, V | 1 |
| Lip, GY; Shantsila, E | 1 |
| Büller, HR; Cohen, AT; De Sanctis, Y; Haskell, L; Hu, D; Hull, R; Mebazaa, A; Merli, G; Schellong, SW; Spiro, TE; Spyropoulos, AC; Tapson, VF | 1 |
| Ng, HJ; Teo, EC; Than, H | 1 |
| Fernández Guerrero, JC; Garcelán Trigo, JA; Lozano Cabezas, C; Padilla Pérez, M; Salas Bravo, D; Torres Llergo, J; Vazquez Ruiz de Castroviejo, E | 1 |
| Chatelain, C; Devalet, B; Dogné, JM; Douxfils, J; Larock, AS; Mullier, F; Sennesael, AL; Spinewine, A | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Omote, Y; Sato, K; Yamashita, T; Yunoki, T | 1 |
| Watson, HG | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Mukherjee, D; Sardar, P | 1 |
| Aryal, MR; Bhandari, Y; Donato, A; Jalota, L; Karmacharya, P; Mainali, NR; Pandit, A; Pathak, R; Pradhan, R; Ukaigwe, A | 1 |
| Cappato, R; Davies, DW; Fields, LE; Hess, S; Hohnloser, SH; Ma, C; Marchlinski, FE; Naccarelli, GV; Natale, A; Wilber, DJ; Xiang, J | 1 |
| Fukamizu, S; Hiraoka, M; Kitamura, T; Sakurada, H | 1 |
| Berthold, C; Boecher-Schwarz, H; Dooms, G; Gunness, VR; Hana, A; Hertel, F; Koy, J; Matgé, G; Standhardt, H | 1 |
| Askonen, K; Halinen, M; Huikuri, H; Koistinen, J; Parikka, H; Puurunen, M; Raatikainen, P; Virtanen, V | 1 |
| Gotthardt, DN; Schemmer, P; Stremmel, W; Wannhoff, A; Weiss, KH | 1 |
| Asakura, H; Hayashi, T; Kadohira, Y; Morishita, E; Nakagawa, N | 1 |
| Piazza, G | 1 |
| Gerona, RR; Lo, JC | 1 |
| Gómez-Outes, A; Lecumberri, R; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Makris, M | 1 |
| Linkins, LA; Moffat, K | 1 |
| Duarte, J; López-Farré, AJ; Martín-Palacios, N; Modrego, J; Moñux, G; Rodriguez-Sierra, P; Saiz, AM; Segura, A; Serrano, J; Zamorano-León, JJ | 1 |
| Barinov, VE; Boiarintsev, VV; Lobastov, KV; Schastlivtsev, IV | 1 |
| Rodgers, GM; Win, K | 1 |
| Baumann, M; Ceschi, A; Hasler, K; Hofer, KE; Korte, W; Kupferschmidt, H; Lehmann, T; Rohde, G | 1 |
| Ay, C; Hayde, M; Königsbrügge, O; Langer, M; Pabinger, I | 1 |
| Alotaibi, G; Alsaleh, K; Mcmurtry, MS; Wu, C | 1 |
| Chatterjee, S; Halperin, JL; Herzog, E; Mukherjee, D; Nairooz, R; Sardar, P | 1 |
| Bamber, L; Bookhart, BK; Haskell, L; Mody, SH; Schein, J; Wang, M | 1 |
| Fleet, JL; Garg, AX; Lazo-Langner, A; McArthur, E | 1 |
| Geisbüsch, C; Herweh, C; Nagel, S; Richter, D; Ringleb, PA | 1 |
| Brar, N; Shivamurthy, P; Therrien, ML | 1 |
| Amin, A; Graham, J; Jing, Y; Lin, J; Lingohr-Smith, M; Trocio, J | 1 |
| Baba, Y; Hagii, J; Hitomi, H; Iwata, M; Kamada, T; Matsumoto, S; Metoki, N; Okumura, K; Osanai, T; Saito, S; Sasaki, S; Seino, S; Shiroto, H; Takahashi, K; Tomita, H; Uchizawa, T; Yasujima, M | 1 |
| Amarenco, P; Camm, AJ; Haas, S; Hess, S; Kirchhof, P; Turpie, AG; van Eickels, M | 1 |
| Barucci, R; Fattirolli, F; Fracchia, S; Mannarino, G; Orso, F; Pratesi, A | 1 |
| Mitchell, AR; Page, PL; Thomas, R | 1 |
| Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P | 1 |
| Kamphuisen, PW | 1 |
| Imam, F; Iqbal, M; Khalid Anwer, M; Khalil, NY | 1 |
| Aryal, MR; Badal, M; Chaudhary, A; Donato, AA; Mege, J | 1 |
| Engel, G; Kong, MH; Mead, RH; Patrawala, RA; Winkle, RA | 1 |
| Black, DF; McBane, RD; Moder, KG; Schaefer, JK; Williams, LN; Wysokinski, WE | 1 |
| Bonati, LH; Engelter, ST; Gensicke, H; Lyrer, P; Peters, N; Seiffge, DJ; Traenka, C; Tsakiris, DA | 1 |
| Amin, A; Lawrence, JH; Makenbaeva, D; Stokes, M; Wiederkehr, D; Wu, N | 1 |
| Aylward, PE; Camuglia, AC; Hammett, CJ; Waddell-Smith, KE | 1 |
| Boonen, K; Brunsveld, L; Emmen, JM; Schellings, MW; Schmitz, EM; van de Kerkhof, D; van den Heuvel, DJ; van der Graaf, F; van Dongen, JL | 1 |
| Guo, X; Li, L; Tang, B; Xu, G; Zhang, Y; Zhou, X | 1 |
| Steurer, J | 1 |
| Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH | 1 |
| Baumgartner, H; Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR | 1 |
| Fukae, J; Higashi, T; Inoue, T; Iwaasa, M; Kimura, S; Ogata, T; Okawa, M; Tsuboi, Y | 1 |
| Hunt, BJ; Sciascia, S | 1 |
| Heim, M; Krähenbühl, S; Liakoni, E; Rätz Bravo, AE; Terracciano, L | 1 |
| Moorman, ML; Nash, JE; Stabi, KL | 1 |
| Levy, JH | 1 |
| Meddahi, S; Samama, CM; Samama, MM | 1 |
| Dupree, LH; Reddy, P | 1 |
| Bihan, K; Ferreol, L; Funck-Brentano, C; Hulot, JS; Korostelev, M; Tissot, N; Zahr, N | 1 |
| Brueckmann, M; Clemens, A; Konstantinides, S; Lip, GY; Noack, H; Strack, A | 1 |
| Rudakova, AV; Tatarskiĭ, BA | 1 |
| Dobesh, PP; Trujillo, T | 1 |
| Adelmann, D; Frantal, S; Koch, S; Kozek-Langenecker, S; Quehenberger, P; Schaden, E; Scharbert, G; Wiegele, M; Wohlgemuth, RK | 1 |
| Camm, AJ; Cappato, R; Ezekowitz, MD; Hemmrich, M; Hohnloser, SH; Kirchhof, P; Klein, AL; Lanius, V; Le Heuzey, JY; Ma, CS; Meng, IL; Scanavacca, M; Talajic, M; van Eickels, M; Vardas, PE; Wildgoose, P | 1 |
| Bachmeyer, C; Elalamy, I | 1 |
| Carroll, VS; Frei, J | 1 |
| Lane, DA; Lip, GY; Senoo, K | 1 |
| Dale, BJ; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Johnston, M; Weitz, JI | 1 |
| Conway, SE; Mitchell, AP | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Hacke, W; Halperin, JL; Hankey, GJ; Hellkamp, AS; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Steinberg, BA | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Crowther, MA; Cuker, A; Garcia, DA; Siegal, DM | 1 |
| Blann, AD; Lip, GY | 1 |
| Augustin, A; Auzary, C; Cheze, S; Darnige, L; de Boysson, H; Geffray, L; Jeanjean, C; Joalland, F; Johnson, A | 1 |
| Akdemir, HU; Akdemir, N; Başara, G; Çalışkan, F; Nurata, H; Yavuz, Y | 1 |
| Bailleul, E; Chatelain, B; Coucke, W; Demulder, A; Devreese, K; Douxfils, J; Jochmans, K; Mullier, F; Soumali, MR; Van Blerk, M; Van de Walle, P; Vernelen, K; Wijns, W | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Li, L; Li, Y; Liu, K; Liu, X; Yuan, J; Yuan, Y | 1 |
| Demulder, A; Safouris, A; Triantafyllou, N; Tsivgoulis, G | 1 |
| Hantson, P; Hermans, C; Lambert, C | 1 |
| Giugliano, RP; Plitt, A | 1 |
| Barnes, GD; Eagle, KA; Froehlich, JB | 1 |
| Madhusudhana, S; Qasem, A; Strasser, KM | 1 |
| Howell, G; Pluym, M | 1 |
| Lamichhane, D | 1 |
| Husein, H; Samo, S; Sherid, M; Sifuentes, H; Spurr, C; Sridhar, S; Sulaiman, S; Thiruvaiyaru, D; Tupper, R | 1 |
| Aupetit, JF; Chaudesaygues, E; Grasse, M; Marchand, L; Villar, E | 1 |
| Kadauke, S; Khor, B; Van Cott, EM | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Dobesh, PP; Fanikos, J | 1 |
| Kovács, T | 1 |
| Buder, R; Dieplinger, B; Lenz, K; Piringer, P; Rauch, M; Voglmayr, M | 1 |
| Ko, Y; Kong, MC; Lee, LH; Ng, HJ; Wang, Y; Xie, F | 1 |
| de Boer, A; Hasrat, F; Maitland-van der Zee, AH; Redekop, WK; Verhoef, TI | 1 |
| Frolov, DV; Linchenko, DV; Poliantsev, AA; Shchelokova, IuV | 1 |
| Ezekowitz, MD; Kent, AP | 1 |
| Berman, B; Bray, N; Katz, H; Popov, E | 1 |
| Berghold, A; Kemperdick, B; Mergenthal, K; Petersen, JJ; Rauck, S; Roehl, I; Schulz-Rothe, S; Siebenhofer, A; Ulrich, LR | 1 |
| Choi, YJ; Hong, KS; Kwon, SU | 1 |
| Cui, J; Li, Z; Liu, C; Wu, B | 1 |
| Barratt, JD; Caughey, GE; Kalisch Ellett, LM; McDonald, CJ | 1 |
| Mima, Y; Nagata, S; Okada, Y; Sangatsuda, Y; Wakugawa, Y; Yasaka, M | 1 |
| Baber, U; Mastoris, I; Mehran, R | 1 |
| Beyer-Westendorf, J | 2 |
| Duart, M; Kauffman, C; Kusumoto, F; Ray, JC; Snipelisky, D; Ung, R | 1 |
| Bell, AD; Douketis, J; Eikelboom, J; Liew, A | 2 |
| Auckenthaler, T; Innerhofer, P; Oswald, E; Streif, W; Tauber, H; Ulmer, H; Velik-Salchner, C | 1 |
| Ahmad, H; Arbab-Zadeh, A; Borer, JS; Garg, A; Garg, J; Krishnamoorthy, P; Lavie, CJ; Lichstein, E; Mukherjee, D; Sharma, A | 1 |
| Adcock, D; Francart, SJ; Gosselin, RC; Grant, RP; Hawes, EM; Moll, S | 1 |
| Adcock Funk, DM; Francart, SJ; Friedman, KD; Gosselin, RC; Hawes, EM; Moll, S; Taylor, JM | 1 |
| Chatterjee, S; Ghosh, J; Giri, JS; Lavie, CJ; Lip, GY; Mukherjee, D; Sardar, P | 1 |
| Linkins, LA; Warkentin, TE | 1 |
| da Silva, RM | 1 |
| Esmon, N; Grant, R; Marlar, RA; Mauer, K; Rathbun, S; Tafur, A | 1 |
| Greco, C | 1 |
| Bamber, L; Bauersachs, R; Cano, SJ; Erkens, P; Lensing, AW; Prins, MH; Wang, MY | 1 |
| Kartasheva, ED; Shevchenko, IuL; Stoĭko, IuM; Zamiatin, MN | 1 |
| Davis, EM; Schardt, GL; Schmidt, DP; Uhlmeyer, EM | 1 |
| Allouche, E; Amara, W; Dompnier, A; Fromentin, S; Georger, F; Nguyen, C; Saoudi, N; Taieb, J | 1 |
| Cairns, JA; Weitz, JI | 1 |
| Peacock, WF | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Armbruster, HL; Berger, RD; Calkins, H; Habibi, M; Khurram, IM; Lindsley, JP; Marine, JE; Moranville, MP; Spragg, DD | 1 |
| Broncel, M; Ciastkowska, A; Duraj, I; Gorzelak-Pabiś, P; Szlagowska, L | 1 |
| Peerlinck, K; Vanassche, T; Vandenbriele, C; Verhamme, P | 1 |
| Barrett, P; Chalasani, N; Masuoka, H; Vuppalanchi, R | 1 |
| Blann, AD | 1 |
| Dublanchet, N; Dutheil, F; Lebreton, A; Milhaud, G; Moustafa, F; Schmidt, J | 1 |
| Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wettermark, B | 1 |
| Arepally, GM; Ortel, TL | 1 |
| Bozhkova, SA; Drozdova, PV; Novokshonova, AA | 1 |
| Bruckner, T; Hess, A; Katus, HA; Kieser, M; Mereles, D; Pohlmeier, M; Scholz, E; Schweizer, PA; Thomas, D; Zitron, E; Zylla, MM | 1 |
| Chan, KE; Edelman, ER; Maddux, FW; Thadhani, RI; Wenger, JB | 1 |
| Merli, GJ; Weitz, HH | 1 |
| Bultas, J; Karetová, D | 1 |
| Caffrey, MK | 1 |
| Crighton, A; Gibson, J; Scott, A | 1 |
| Garg, P; Ripley, DP | 1 |
| Ansell, JE; Cabral, KP | 1 |
| Iaroslavskaia, EI; Khor'kova, NIu; Rychkov, AIu | 1 |
| Cohen, AT; Lensing, AW; Müller, K; Pap, ÁF; Prandoni, P; Prins, MH; Tewes, MC | 1 |
| Bakchoul, T; Ganzel, C; Greinacher, A; Rowe, JM; Tvito, A | 1 |
| Loh, JB; Ng, HJ; Sum, CL; Than, H | 1 |
| Levasseur-Franklin, KE; Liotta, EM; Naidech, AM | 1 |
| Ambrosoli, A; Cimminiello, C; Compagnone, C; Fanelli, A; Imberti, D; Ottani, F; Tripodi, A | 1 |
| Bultas, J | 1 |
| Konkle, BA; Siegal, DM | 1 |
| Erkens, PM; Fermann, GJ; Lensing, AW; Pap, ÁF; Prins, MH; Wells, PS | 1 |
| Angaran, P; Bell, AD; Berall, M; Bucci, C; Demchuk, AM; Essebag, V; Goldin, L; Goodman, SG; Green, MS; Gregoire, JC; Gross, PL; Heilbron, B; Lin, PJ; Patel, AD; Ramanathan, K; Skanes, A; Tan, MK; Wheeler, BH | 1 |
| Becker, RC; Krishnamoorthy, A; Lopes, RD; Sherwood, MW | 1 |
| Oberhofer, E | 1 |
| Calıskan, A; Demirtas, S; Guclu, O; Kaplan, I; Karahan, O; Tezcan, O; Yavuz, C; Yazıcı, S | 1 |
| Berkowitz, SD; Breithardt, G; Califf, RM; Fox, KA; Halperin, JL; Hankey, GJ; Lokhnygina, Y; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE; Stevens, SR; Washam, JB | 1 |
| Powell, JR | 1 |
| Friedman, RJ; Messerschmidt, C | 1 |
| Fukae, S; Izumida, S; Kawano, H; Kohno, Y; Koide, Y; Maemura, K; Takeno, M; Tsuneto, A | 1 |
| Hogg, K; Weitz, JI; Yeh, CH | 1 |
| Bailleul, E; Borrey, D; Caluwé, R; De Bacquer, D; De Vriese, AS; Emmerechts, J; Van Vlem, B; Vandecasteele, SJ | 1 |
| Cappato, R; Cohen, A; Hammerstingl, C; Kirsch, B; Lip, GY; Marin, F; Meng, IL; Morandi, E; van Eickels, M | 1 |
| Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P | 1 |
| Hashi, S; Penge, J; Simister, R | 1 |
| Bodó, I; Iványi, JL; Plander, M; Szendrei, T | 1 |
| Lane, DA; Wood, K | 1 |
| Abraham, NS; Alexander, GC; Crown, W; Haas, LR; Heien, H; Shah, ND; Singh, S | 1 |
| Alexander, GC; Chang, HY; Singh, S; Tang, W; Zhou, M | 1 |
| Arentz, T; Jadidi, A; Lehrmann, H; Park, CI; Pruvot, E; Weber, R; Zimmermann, M | 1 |
| Dias, JD; Doorneweerd, DD; Norem, K; Omert, LA; Popovsky, MA; Thurer, RL | 1 |
| Gehrie, E; Tormey, C | 1 |
| Hilpert, U | 1 |
| Ay, C; Belik, S; Griesmacher, A; Königsbrügge, O; Pabinger, I; Quehenberger, P; Seger, C; Weigel, G | 1 |
| Arnheim, K | 1 |
| Abouassi, S; Abouchakra, L; Badaoui, G; Khabbaz, Z | 1 |
| Arpey, CJ; Baum, CL; Brewer, JD; Chang, TW; Hochwalt, PC; Hocker, TL; Otley, CC; Roenigk, RK | 1 |
| Kreher, S; Riess, H; Sinn, M | 1 |
| van Eickels, M | 1 |
| Chatelain, B; Devalet, B; Dogné, JM; Douxfils, J; Mani, H; Minet, V; Mullier, F | 1 |
| Botto, GL; Colonna, P; Troccoli, R | 1 |
| Bächli, E; Walti, C | 1 |
| Bode, C; Kelm, M; Zeus, T | 1 |
| Boone, S | 1 |
| Feng, W; Lin, Y; Lu, H; Xi, AM; Yan, CZ; Zhang, Y | 1 |
| Bartle, B; Bond, AM; McFee Winans, AR; Rudd, KM | 1 |
| Lasek-Bal, A; Piekarski, M; Puz, P; Urbanek, T | 1 |
| Undas, A | 1 |
| Ciurzyński, M; Paczyńska, M; Pruszczyk, P; Sobieraj, P | 1 |
| Chen, B; Huang, CC; Kuo, FC; Lin, PC; Wang, JW; Yen, SH | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Bansal, VB; Donovan, A; Gollish, JD; Gomez, D; Murnaghan, JJ; Razmjou, H | 1 |
| Yavelov, IS | 2 |
| Crowther, MA; Cuker, A | 1 |
| Hu, Y; Huang, S; Tang, L | 1 |
| Arya, R; Patel, JP; Roberts, LN; Speed, V | 1 |
| Becker, RC; Berkowitz, SD; Breithardt, G; Califf, RM; Carnicelli, AP; Fox, KAA; Halperin, JL; Hankey, GJ; Hellkamp, AS; Mahaffey, KW; Nessel, CC; Patel, MR; Piccini, JP; Singer, DE | 1 |
| Ding, HY; Jiao, Z; Liu, XQ; Ma, CL; Yan, MM; Zhang, YF; Zhong, MK | 1 |
| Abdar Esfahani, M; Davoudian, A; Esmaeili, T; Omidfar, D; Rezaee, M; Rezaee, S | 1 |
409 review(s) available for thiophenes and rivaroxaban
| Article | Year |
|---|---|
Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Injections, Intravenous; Injections, Subcutaneous; Morpholines; Naphthalenes; Oligosaccharides; Polysaccharides; Propionates; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2006 |
Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Drugs, Investigational; Factor Xa; Factor Xa Inhibitors; Glycine; Humans; Morpholines; Piperazines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2007 |
Rivaroxaban.
Topics: Animals; Anticoagulants; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Thiophenes | 2007 |
Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
Topics: Administration, Oral; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Humans; Molecular Structure; Morpholines; Patents as Topic; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2007 |
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Bleeding Time; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Orthopedics; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
Beyond unfractionated heparin and warfarin: current and future advances.
Topics: Angina, Unstable; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Brain Ischemia; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Forecasting; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudins; Humans; Morpholines; Myocardial Infarction; Peptide Fragments; Polysaccharides; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Thrombosis; Warfarin | 2007 |
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Topics: Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Azetidines; Benzylamines; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2008 |
New anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Morpholines; Oligosaccharides; Postphlebitic Syndrome; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Glycine; Humans; Infusions, Parenteral; Morpholines; Oligosaccharides; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Venous Thromboembolism | 2008 |
Rivaroxaban, an oral direct factor Xa inhibitor.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Aged, 80 and over; Animals; Anticoagulants; Atrial Fibrillation; Binding Sites; Clinical Trials as Topic; Comorbidity; Drug Evaluation, Preclinical; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Rats; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2008 |
[Hematology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fibrinolytic Agents; Hematologic Diseases; Hematologic Neoplasms; Hemoglobinuria, Paroxysmal; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
Rivaroxaban: an oral direct inhibitor of factor Xa.
Topics: Aging; Antithrombin III; Clinical Trials as Topic; Drug Interactions; Fibrinolytic Agents; Hepatic Insufficiency; Humans; Morpholines; Obesity; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
The top 4 advances in antithrombotic care in the last year.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Brave new world: the current and future use of novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban: future in anticoagulation practice?
Topics: Anticoagulants; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
[Rivaroxaban. The first factor Xa inhibitor].
Topics: Animals; Factor Xa Inhibitors; Heart Diseases; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis | 2008 |
New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban.
Topics: Administration, Oral; Animals; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Patient Satisfaction; Quality of Life; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.
Topics: Animals; Antithrombin III; Benzimidazoles; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2009 |
[Anaesthesia and thromboembolic disease].
Topics: Acenocoumarol; Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; Clinical Protocols; Dabigatran; Early Ambulation; Fibrinolytic Agents; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Risk Factors; Rivaroxaban; Safety; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
[Rivaroxaban: clinical pharmacology].
Topics: Administration, Oral; Aged; Anticoagulants; Biological Availability; Clinical Trials as Topic; Contraindications; Cytochrome P-450 CYP3A; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Morpholines; Orthopedic Procedures; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Venous Thrombosis | 2008 |
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Middle Aged; Morpholines; Polysaccharides; Postoperative Complications; Preanesthetic Medication; Pulmonary Embolism; Risk Factors; Rivaroxaban; Stockings, Compression; Thiophenes; Thromboembolism; Thrombophlebitis; Vitamin K | 2008 |
[Rivaroxaban (Xarelto): efficacy and safety].
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hematoma, Epidural, Spinal; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Rivaroxaban: mode of action].
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Molecular Structure; Morpholines; Postoperative Complications; Preanesthetic Medication; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2008 |
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
Topics: Anticoagulants; Antithrombin III; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2009 |
Laboratory monitoring of anticoagulation: where do we stand?
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Incidence; International Normalized Ratio; Monitoring, Physiologic; Morpholines; Polysaccharides; Prothrombin Time; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K | 2009 |
Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.
Topics: Administration, Oral; Benzimidazoles; Blood Coagulation; Dabigatran; Fibrinolytic Agents; Hemorrhage; History, 20th Century; History, 21st Century; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2008 |
Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.
Topics: Administration, Oral; Animals; Antithrombin III; Arthroplasty; Clinical Trials as Topic; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thrombolytic Therapy | 2009 |
[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
Topics: Anticoagulants; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Prothrombin; Pyridines; Risk Assessment; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2009 |
New anticoagulants for prevention and treatment of venous thromboembolism.
Topics: Animals; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Humans; Morpholines; Oligosaccharides; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
A logical approach to surgical thromboprophylaxis.
Topics: Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Premedication; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New anticoagulants and regional anesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Benzimidazoles; Dabigatran; Hematoma, Epidural, Spinal; Humans; Morpholines; Nerve Block; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2009 |
Rivaroxaban in orthopedic surgery--a change of paradigm?
Topics: Anticoagulants; Humans; Morpholines; Orthopedic Procedures; Premedication; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Topics: Animals; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New antithrombotic drugs: potential for use in oncology.
Topics: Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Male; Morpholines; Neoplasms; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Severity of Illness Index; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
New anticoagulants for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K | 2009 |
Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.
Topics: Adult; Anticoagulants; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
[New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Disorders; Dabigatran; Factor Xa Inhibitors; Humans; International Normalized Ratio; Intraoperative Complications; Morpholines; Partial Thromboplastin Time; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2009 |
Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
New oral anticoagulants: a practical guide for clinicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Evidence-Based Medicine; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Thromboprophylaxis after multiple trauma: what treatment and for how long?
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Device Removal; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Multiple Trauma; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Vena Cava Filters | 2009 |
Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2010 |
[Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism; Traumatology; Treatment Outcome | 2010 |
Rivaroxaban: a new oral factor Xa inhibitor.
Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2010 |
Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban).
Topics: Animals; Antithrombins; Binding Sites; Drug Discovery; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Structure-Activity Relationship; Thiophenes | 2010 |
[A new deal with new anticoagulants?].
Topics: Anticoagulants; Antithrombins; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Rivaroxaban; Thiophenes | 2010 |
Old versus new anticoagulants: focus on pharmacology.
Topics: Animals; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2010 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
New oral anticoagulants in development: potential for improved safety profiles.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation; Dabigatran; Drug Evaluation; Factor Xa; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2010 |
Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery.
Topics: Animals; Clinical Trials, Phase III as Topic; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
Topics: Anticoagulants; Aspirin; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2010 |
Potential of new anticoagulants in patients with cancer.
Topics: Anticoagulants; Benzimidazoles; Biotin; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2010 |
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2010 |
Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Drug Approval; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; United States; Venous Thrombosis | 2011 |
New oral anticoagulant drugs in cardiovascular disease.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Pyridines; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Drug and dietary interactions of the new and emerging oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2010 |
Clot prevention--common questions about medications.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; International Normalized Ratio; Morpholines; Pharmacogenetics; Pyridines; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2010 |
[Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data].
Topics: Animals; Anticoagulants; Disease Models, Animal; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Humans; Intracranial Thrombosis; Macaca fascicularis; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
[New oral anticoagulants: better than vitamin K antagonists?].
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Vitamin K | 2010 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Morpholines; Multicenter Studies as Topic; Odds Ratio; Primary Prevention; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Assays for measuring rivaroxaban: their suitability and limitations.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Calibration; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2010 |
New anticoagulants for the prevention of thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drugs, Investigational; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2010 |
Managing bleeding complications in patients treated with the old and the new anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor VIIa; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Polysaccharides; Protamines; Recombinant Proteins; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2011 |
New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.
Topics: Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Oligosaccharides; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
[Novel anticoagulants for stroke prevention in atrial fibrillation].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2010 |
[Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].
Topics: Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thrombin | 2010 |
[Rivaroxaban and factor Xa inhibitors in clinical practice].
Topics: Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis | 2010 |
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Evaluation, Preclinical; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Structure-Activity Relationship; Thiophenes | 2011 |
[New study findings in cardiology. The best is the enemy of the good].
Topics: Angioplasty, Balloon, Coronary; Angiotensin II Type 2 Receptor Blockers; Anticoagulants; Atrial Fibrillation; Cardiology; Coronary Disease; Drug-Eluting Stents; Heart Diseases; Humans; Morpholines; Myocardial Infarction; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2010 |
New anticoagulant agents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cyclic N-Oxides; Fondaparinux; Hirudins; Humans; Morpholines; Peptide Fragments; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes | 2011 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.
Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K | 2011 |
Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Topics: Amidines; Coronary Artery Disease; Cyclic N-Oxides; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Naphthalenes; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2011 |
The need for novel anticoagulation therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Cyclic N-Oxides; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Morpholines; Naphthalenes; Polysaccharides; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Investigational factor Xa inhibitors for thrombosis and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drugs, Investigational; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Venous Thromboembolism | 2011 |
A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Middle Aged; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Young Adult | 2011 |
New anticoagulants: pharmacology and clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prothrombin; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.
Topics: Adolescent; Anticoagulants; Arginine; Benzimidazoles; beta-Alanine; Child; Child, Preschool; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fondaparinux; Hirudins; Humans; Infant; Infant, Newborn; Morpholines; Peptide Fragments; Pipecolic Acids; Polysaccharides; Recombinant Proteins; Risk Factors; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Safety and efficacy of rivaroxaban for thromboprophylaxis following lower limb surgery: an update.
Topics: Anticoagulants; Clinical Trials, Phase III as Topic; Humans; Lower Extremity; Morpholines; Orthopedics; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Approval; Factor X; Humans; Morpholines; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2011 |
The discovery and development of rivaroxaban.
Topics: Adult; Animals; Clinical Trials as Topic; Drug Design; Drug Discovery; Fibrinolytic Agents; Humans; Models, Biological; Models, Molecular; Molecular Targeted Therapy; Morpholines; Rivaroxaban; Thiophenes; Validation Studies as Topic; Venous Thromboembolism | 2011 |
Preventing postsurgical venous thromboembolism: pharmacological approaches.
Topics: Aged; Anticoagulants; Antithrombins; Arthroscopy; Bariatric Surgery; Benzimidazoles; Blood Coagulation Disorders, Inherited; Dabigatran; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Kidney; Knee; Laparoscopy; Morpholines; Neoplasms; Orthopedic Procedures; Polysaccharides; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism | 2011 |
New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outpatients; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism; Warfarin | 2011 |
Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Characteristics of novel anticoagulants and potential economic implications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Cost Savings; Dabigatran; Health Care Costs; Humans; Medication Adherence; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Vitamin K | 2011 |
Rivaroxaban in the contemporary treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Biological Availability; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes | 2011 |
[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Approval; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Forecasting; France; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Thrombophilia; Venous Thromboembolism | 2011 |
Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Evidence-Based Medicine; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost Savings; Health Care Costs; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New anticoagulants: how to deal with treatment failure and bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Treatment Failure | 2011 |
Therapeutic potential of rivaroxaban in the prevention of venous thromboembolism following hip and knee replacement surgery: a review of clinical trial data.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
[The new Anticoagulants - Relevant Facts for the GP].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Factor Xa Inhibitors; General Practice; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Anticoagulating obese patients in the modern era.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Double-Blind Method; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Heparin; Humans; Morpholines; Multicenter Studies as Topic; Obesity; Polysaccharides; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombophilia; Venous Thrombosis; Warfarin | 2011 |
Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Female; Half-Life; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Rivaroxaban for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Rivaroxaban (Xarelto)--a new oral anticoagulant.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
[Thromboembolic prophylaxis 2011: is warfarin on the wane?].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Neurosurgical Procedures; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stockings, Compression; Surgical Procedures, Operative; Thiophenes; Urologic Surgical Procedures; Venous Thrombosis | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
[Atrial fibrillation: what the GP needs to know].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; General Practice; Humans; International Normalized Ratio; Medication Adherence; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2011 |
[New anticoagulants. Characteristics, monitoring and management of bleeding].
Topics: Administration, Oral; Antithrombins; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; Blood Coagulation Tests; Critical Care; Dabigatran; Drug Approval; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2011 |
Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2012 |
A new era of antithrombotic therapy in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[Current status and future of anti-Xa inhibitors].
Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2011 |
Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombosis; United States; Vitamin K | 2012 |
A new generation of oral direct anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2012 |
A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Drugs, Investigational; Factor X; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2012 |
The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
Topics: Aged; Anticoagulants; Blood Coagulation; Drug Administration Schedule; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Topics: Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Improving prevention and treatment of venous thromboembolism: clinical trial results.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The efficacy and safety of pharmacological prophylaxis of venous thromboembolism following elective knee or hip replacement: systematic review and network meta-analysis.
Topics: Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2012 |
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drugs, Investigational; Heparin; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Long-term benefits of preventing venous thromboembolic events.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Follow-Up Studies; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Novel oral anticoagulants in the treatment of acute coronary syndromes: is there any room for new anticoagulants?
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Clinical Trials as Topic; Drug Discovery; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2012 |
Novel oral anticoagulants--key messages for the angiologist.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism | 2012 |
Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Myocardial Infarction; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thrombosis | 2012 |
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.
Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.
Topics: Acute Coronary Syndrome; Anesthesia, Conduction; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New antithrombotic drugs].
Topics: Adenosine; Anticoagulants; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2012 |
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin | 2012 |
Treatment of venous thromboembolism with dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Factor Xa Inhibitors; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
New oral anticoagulants: will they replace warfarin?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Hypersensitivity; Drug Interactions; Factor Xa Inhibitors; Gastritis; Hemorrhage; Humans; Liver; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
[Clinical management of the new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Drugs, Investigational; Hemorrhage; Humans; Morpholines; Multicenter Studies as Topic; Patient Care Planning; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Vitamin K | 2012 |
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New drugs 2012, part 2.
Topics: Abatacept; Adenosine; Aminoglycosides; Bradykinin; Deferiprone; Drug Approval; Fidaxomicin; Growth Hormone-Releasing Hormone; Humans; Immunoconjugates; Morpholines; Nitriles; Pyridones; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Rilpivirine; Rivaroxaban; Thiophenes; Ticagrelor | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Newer oral anticoagulant agents: a new era in medicine.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Warfarin | 2012 |
The management of antithrombotic medication in skin surgery.
Topics: Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Platelet Aggregation Inhibitors; Polysaccharides; Risk Assessment; Rivaroxaban; Thienopyridines; Thiophenes; Vitamin K; Warfarin | 2012 |
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Heart Valve Diseases; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Vitamin K; Warfarin | 2012 |
New oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Substitution; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2012 |
Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Comparative Effectiveness Research; Dabigatran; Drug Monitoring; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Outcome and Process Assessment, Health Care; Pharmacovigilance; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
New oral anticoagulants in the ED setting: a review.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Chi-Square Distribution; Dabigatran; Embolism; Female; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Odds Ratio; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Preventive Health Services; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Female; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Benzoates; Clinical Trials as Topic; Coumarins; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Warfarin | 2012 |
Clinical considerations of anticoagulation therapy for patients with atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiology; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Approval; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Oral anticoagulation in atrial fibrillation: balancing the risk of stroke with the risk of bleed.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Health Status Indicators; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The novel oral anticoagulants: an update for the interventional radiologist.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Radiography, Interventional; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Stroke prevention in atrial fibrillation: concepts and controversies.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Dronedarone; Drug Design; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
[The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Drug interactions with rivaroxaban following total joint replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Transient; Medical Records; Morpholines; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism | 2012 |
New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
The promise of novel direct oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Warfarin | 2012 |
Advances in the management of venous thromboembolism.
Topics: Anticoagulants; Antithrombins; Clinical Trials as Topic; Diagnostic Imaging; Disease Management; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Radiography; Risk; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2012 |
Novel oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2013 |
Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Humans; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes | 2012 |
[New oral anticoagulants for atrial fibrillation: a neurologist's view].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pregnancy; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2012 |
What did we learn from new oral anticoagulant treatment?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2012 |
Antithrombotic treatment of atrial fibrillation: new insights.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Laboratory tests and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Morpholines; Predictive Value of Tests; Pyrazoles; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes | 2012 |
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial.
Topics: Anticoagulants; Atrial Fibrillation; Gastrointestinal Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Anticoagulant treatment: the end of the old agents?
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2012 |
The laboratory and the new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Hemostasis; Humans; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban: a novel anticoagulant.
Topics: Anticoagulants; Biological Availability; Blood Coagulation; Cardiovascular Diseases; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Outcome Assessment, Health Care; Pharmacovigilance; Rivaroxaban; Thiophenes | 2010 |
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2012 |
The new oral anticoagulants and the future of haemostasis laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemostasis; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2012 |
[Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Food-Drug Interactions; Hemostasis; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Switzerland; Thiophenes; Thromboembolism | 2012 |
[Clinical pharmacological aspects of new oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2012 |
Performance of new anticoagulants for thromboprophylaxis in patients undergoing hip and knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Societies, Medical; Thiazoles; Thiophenes; Venous Thromboembolism | 2012 |
[Stroke risk--atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cross-Sectional Studies; Dabigatran; Humans; International Normalized Ratio; Minimally Invasive Surgical Procedures; Morpholines; Population Dynamics; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2012 |
Potential role of rivaroxaban in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Dose-Response Relationship, Drug; Hemorrhage; Humans; Intracranial Hemorrhages; Morpholines; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
Comparing new anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2012 |
The novel anticoagulants: the surgeons' prospective.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Acute management of bleeding in patients on novel oral anticoagulants.
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Plasma; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Renal Dialysis; Renal Insufficiency; Risk Factors; Rivaroxaban; Thiophenes | 2013 |
Perioperative management of patients on chronic antithrombotic therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Middle Aged; Morpholines; Perioperative Care; Risk; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis; Vitamin K | 2012 |
New oral anticoagulants: which one should my patient use?
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hematology; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Warfarin | 2012 |
[New anticoagulants--are we prepared?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
New oral anticoagulants in atrial fibrillation: a reappraisal of trial results looking at absolute figures.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
[Rivaroxaban in prevention of stroke in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Administration Schedule; Humans; International Normalized Ratio; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
New oral therapies for the prevention and treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Implications of new anticoagulants in primary practice.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2013 |
A review of oral anticoagulants in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Rivaroxaban: an oral factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Emergencies; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Topics: Absorption; Anticoagulants; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Liver Diseases; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Tissue Distribution; Venous Thromboembolism | 2013 |
The novel oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Medication Adherence; Morpholines; Renal Insufficiency; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thromboembolism; Vitamin K; Warfarin | 2013 |
Clinical management of rivaroxaban-treated patients.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Consensus; Drug Interactions; Drug Substitution; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Medication Adherence; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
Managing new oral anticoagulants in the perioperative and intensive care unit setting.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Critical Care; Dabigatran; Hemorrhage; Humans; Intensive Care Units; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[From heparin to apixaban: anticoagulants cut both ways?].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; International Normalized Ratio; Liver Failure; Metabolic Clearance Rate; Morpholines; Perioperative Care; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Vitamin K | 2014 |
Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Approval; Europe; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Venous Thromboembolism; Warfarin | 2013 |
Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
Topics: Age Factors; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Comorbidity; Dabigatran; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyridines; Risk Factors; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Topics: Administration, Oral; Aging; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
[Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[New approaches in the treatment of deep vein thrombosis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2012 |
[New evidence in the secondary prevention of thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Biomarkers; Dabigatran; Fibrin Fibrinogen Degradation Products; Humans; Morpholines; Prognosis; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2012 |
[The role of internal medicine in preventing stroke in atrial fibrillation].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Humans; Internal Medicine; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
[Contribution of the new oral anticoagulants to the treatment of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
[Recommendations on use of direct oral anticoagulants in the perioperative period].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Perioperative Care; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Withholding Treatment | 2012 |
[Advances in the secondary prevention of cardioembolic stroke].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Endovascular Procedures; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Spain; Stroke; Thiophenes | 2012 |
[The new oral anticoagulants in special populations].
Topics: Administration, Oral; Age Factors; Anticoagulants; Benzimidazoles; Contraindications; Dabigatran; Embolism; Humans; Morpholines; Obesity; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thrombosis | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Rivaroxaban for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Drug Approval; Drug Interactions; Europe; Humans; Morpholines; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration | 2013 |
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2013 |
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Topics: Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Progression; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Liver Cirrhosis; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2013 |
The laboratory and the direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Novel anticoagulants and laboratory testing.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Risk versus benefit of non-vitamin K dependent anticoagulants compared to warfarin for the management of atrial fibrillation in the elderly.
Topics: Aged; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2013 |
[Improvements in oral anticoagulant therapy for atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Reversal of oral anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Workload | 2013 |
[Factor Xa inhibitor (rivaroxaban and drugs under investigation)].
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
[Oral Rivaroxaban (Xarelto)].
Topics: Anticoagulants; Drug Interactions; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
The new oral anticoagulants in clinical practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Meta-analysis of rivaroxaban and bleeding risk.
Topics: Cause of Death; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
Use of new oral anticoagulants in antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Breast Feeding; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Monitoring; Female; Humans; Infant, Newborn; Maternal Exposure; Morpholines; Pregnancy; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes | 2013 |
Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Disease Management; Embolism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hypertension; Intracranial Embolism; Male; Morpholines; Patient Selection; Pyrazoles; Pyridones; Renal Insufficiency, Chronic; Risk; Risk Factors; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Thrombophilia; Warfarin | 2013 |
Venous thromboembolism management: where do novel anticoagulants fit?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor X; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Insufficiency; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Drug Interactions; Embolism; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Endoscopy; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Dabigatran, ROCKET atrial fibrillation, and beyond: basic science, mechanisms of agents, monitoring, and reversal.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cerebral Hemorrhage; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prodrugs; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thrombin; Thromboembolism; Vitamin K; Warfarin | 2013 |
Rivaroxaban: practical considerations for ensuring safety and efficacy.
Topics: Administration, Oral; Anticoagulants; Body Weight; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Novel oral anticoagulants in gastroenterology practice.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Gastrointestinal Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Monitoring; Drug Overdose; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes | 2013 |
Stroke prevention in patients with atrial fibrillation: focus on new oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2013 |
New anticoagulants as thromboprophylaxis after total hip or knee replacement.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Outcome Assessment, Health Care; Patient Safety; Premedication; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.
Topics: Administration, Oral; Anticoagulants; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Managing bleeding in anticoagulated patients in the emergency care setting.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Hemorrhage; Hemostasis; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Polymorphism, Genetic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chronic Disease; Dabigatran; Drug Monitoring; Heart Failure; Hemorrhage; Humans; Morpholines; Outcome Assessment, Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; Warfarin | 2014 |
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban for the treatment of pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparinux; Fractures, Bone; Heparin; Humans; Mass Screening; Morpholines; Multiple Trauma; Pelvis; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Vena Cava Filters; Venous Thromboembolism | 2013 |
Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis | 2013 |
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2013 |
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Hemorrhage; Hemostatic Techniques; Humans; Morpholines; Perioperative Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
The changing face of oral anticoagulants.
Topics: Anticoagulants; Antithrombin Proteins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prodrugs; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2013 |
The perioperative management of new direct oral anticoagulants: a question without answers.
Topics: Administration, Oral; Aged; Anesthesiology; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Hemostasis; Heparin, Low-Molecular-Weight; Humans; Male; Morpholines; Patient Safety; Perioperative Period; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Emerging antithrombotic drugs for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Fibrinolytic Agents; Humans; Lactones; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy.
Topics: Adult; Aged; Arthroscopy; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Knee Joint; Male; Middle Aged; Morpholines; Polypharmacy; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Risk Factors; Rivaroxaban; Therapeutic Equipoise; Thiophenes; Thrombophilia; Venous Thrombosis | 2014 |
New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
What are the new therapeutic alternatives to warfarin in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pakistan; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Overdose; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
[New clinical perspectives in the management of oral direct anticoagulant agents].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Emergencies; Factor Xa Inhibitors; Hemorrhage; Humans; Kidney Diseases; Morpholines; Orthopedic Procedures; Postoperative Complications; Premedication; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiophenes; Thrombophilia; Vitamin K | 2014 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Review of the American College of Chest Physicians 2012 Guidelines for Anticoagulation Therapy and Prevention of Thrombosis.
Topics: Drug Synergism; Fibrinolytic Agents; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thrombosis; United States; Vitamin K | 2013 |
Disadvantages of VKA and requirements for novel anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Dosage Calculations; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Vitamin K; Warfarin | 2013 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2013 |
Novel oral anticoagulants in secondary prevention of stroke.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Guidelines as Topic; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Heparin, Low-Molecular-Weight; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Bleeding and antidotes in new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Administration Schedule; Hemorrhage; Hemostatics; Humans; Morpholines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2013 |
New oral anticoagulants in elderly patients.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K; Warfarin | 2013 |
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Administration Schedule; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Emergency Medical Services; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Morpholines; Perioperative Care; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thrombin | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
Topics: Anticoagulants; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Advances in venous thromboembolism].
Topics: Anticoagulants; Hemorrhage; Heparin; Humans; Magnetic Resonance Angiography; Morpholines; Pulmonary Artery; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Tomography, X-Ray Computed; Venous Thromboembolism | 2013 |
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.
Topics: Algorithms; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Dosage Calculations; Humans; Morpholines; Pharmacogenetics; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New anticoagulants for thromboprophylaxis after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Fibrinolytic Agents; Forecasting; Humans; Morpholines; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Novel thrombin and factor Xa inhibitors: challenges to reversal of their anticoagulation effects.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhagic Disorders; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
[Prevention of stroke in patients with atrial fibrillation: a role of modern anticoagulants].
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Advantages and limitations of the new anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Fondaparinux; Humans; Male; Morpholines; Obesity; Polysaccharides; Postthrombotic Syndrome; Pulmonary Embolism; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Sex Factors; Thiophenes; Thrombophilia; Ultrasonography; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2014 |
Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials.
Topics: Anticoagulants; Chi-Square Distribution; Humans; Morpholines; Myocardial Infarction; Odds Ratio; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors | 2013 |
Novel oral anticoagulants: a focused review for stroke physicians.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Child; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
[Gastrointestinal bleeding in cardiological patients].
Topics: Algorithms; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Gastrointestinal Hemorrhage; Heart Diseases; Humans; Metabolic Clearance Rate; Morpholines; Phenprocoumon; Platelet Aggregation Inhibitors; Platelet Transfusion; Rivaroxaban; Thiophenes; Vitamin K | 2013 |
[Practical issues with the use of rivaroxaban].
Topics: Anticoagulants; Cerebral Infarction; Humans; Morpholines; Risk Factors; Rivaroxaban; Surgical Procedures, Operative; Thiophenes | 2013 |
Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Adult; Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation Tests; Clinical Trials, Phase III as Topic; Contraindications; Dabigatran; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Hematoma, Epidural, Spinal; Humans; Morpholines; Platelet Aggregation Inhibitors; Postoperative Complications; Postoperative Hemorrhage; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
Topics: Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Benzimidazoles; Cytochrome P-450 Enzyme System; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Outpatient management of oral anticoagulation in atrial fibrillation.
Topics: Ambulatory Care; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
[Evidence of novel oral anticoagulants (NOAC)].
Topics: Administration, Ophthalmic; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Infarction; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban.
Topics: Acute Coronary Syndrome; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials as Topic; Dabigatran; Factor VIIa; Female; Half-Life; Hemophilia A; Hemorrhage; Hemostatics; Humans; Male; Morpholines; Rivaroxaban; RNA Interference; Thiophenes | 2013 |
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
New oral anticoagulants and regional anaesthesia.
Topics: Administration, Oral; Anesthesia, Conduction; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
{blacktriangledown} Apixaban and {blacktriangledown} rivaroxaban for stroke prevention in AF.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
[New anticoagulants in patients with atrial fibrillation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Infarction; Dabigatran; Humans; Intracranial Embolism; Ischemic Attack, Transient; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
New oral anticoagulants in practice: pharmacological and practical considerations.
Topics: Administration, Oral; Aging; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Complementary Therapies; Dabigatran; Drug Interactions; Drug Monitoring; Humans; International Normalized Ratio; Kidney Diseases; Liver Diseases; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2014 |
New antithrombotics for secondary prevention of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Coronary Thrombosis; Dabigatran; Hemorrhage; Humans; Imines; Lactones; Morpholines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Thrombin | 2014 |
New oral anticoagulant agents - general features and outcomes in subsets of patients.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2014 |
[General characteristics of the new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Investigational; Humans; Iatrogenic Disease; Intracranial Hemorrhages; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Novel oral anticoagulants and atrial fibrillation in the elderly].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Drugs, Investigational; Half-Life; Humans; Intracranial Embolism; Metabolic Clearance Rate; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Current state of anticoagulants to treat deep venous thrombosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Patient Selection; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thrombosis | 2014 |
Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Long-Term Care; Morpholines; Perioperative Care; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2014 |
Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Treatment; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Ticlopidine | 2014 |
Rivaroxaban: a review of its use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Ticagrelor | 2014 |
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Practical aspects of new oral anticoagulant use in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison.
Topics: Acute Coronary Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2014 |
[Prevention of embolic heart complications in atrial fibrillation: possibilities of using rivaroxaban].
Topics: Anticoagulants; Atrial Fibrillation; Controlled Clinical Trials as Topic; Embolism; Humans; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Administration Schedule; Drug Interactions; Drug Substitution; Hemorrhage; Humans; Morpholines; Patient Selection; Perioperative Care; Practice Guidelines as Topic; Preventive Health Services; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
[Pharmacologic and clinical characteristics of direct inhibitors of factor Xa: rivaroxaban, apixaban, edoxaban and betrixaban].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzamides; Blood Coagulation; Embolism; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia; Thrombosis | 2014 |
Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Azepines; Azetidines; Benzamides; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Vitamin K | 2014 |
The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Drug Costs; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
The newer direct oral anticoagulants: a practical guide.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Hemostatic Techniques; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thromboembolism; Thrombophilia | 2014 |
Anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Rivaroxaban in acute coronary syndromes--is it prime time?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cataract Extraction; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgery, Plastic; Thiophenes | 2014 |
Anticoagulation: a GP primer on the new oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; General Practice; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Neoplasms; Randomized Controlled Trials as Topic; Recurrence; Risk; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2014 |
Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Primary Prevention; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct oral anticoagulants in the prevention of venous thromboembolism: evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Half-Life; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome | 2014 |
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome | 2014 |
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.
Topics: Acute Coronary Syndrome; Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes | 2014 |
Evolving use of new oral anticoagulants for treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
[Gastrointestinal bleeding under treatment with new oral anticoagulants].
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Embolism; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2014 |
Newer clinically available antithrombotics and their antidotes.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism; Vitamin K | 2014 |
Oral direct inhibitors of coagulation.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Medication Adherence; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2014 |
NOAC and intracerebral bleeding--presentation of four cases and review of the literature.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Female; Humans; Hypertension; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Update on current care guideline: atrial fibrillation].
Topics: Administration, Oral; Anti-Arrhythmia Agents; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Incidence; Morpholines; Practice Guidelines as Topic; Prevalence; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Drug Approval; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes | 2014 |
Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Dabigatran, rivaroxaban and apixaban for extended venous thromboembolism treatment: network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Chi-Square Distribution; Dabigatran; Hemorrhage; Humans; Morpholines; Odds Ratio; Pyrazoles; Pyridones; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Thromboembolism | 2014 |
[Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by new oral anticoagulants, to be cautiously used].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2013 |
Atrial fibrillation - new frontiers in anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation.
Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2014 |
The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Drug Therapy, Combination; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Secondary Prevention; Thiophenes | 2014 |
Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Wounds and Injuries | 2014 |
Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Pharmacology and laboratory testing of the oral Xa inhibitors.
Topics: Administration, Oral; Benzamides; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications.
Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hip Joint; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism | 2014 |
Oral anticoagulants: the move beyond warfarin.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2014 |
Oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes | 2014 |
Rivaroxaban for treatment of venous thromboembolism in older adults.
Topics: Aged; Aged, 80 and over; Aging; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Pulmonary Embolism; Recurrence; Renal Insufficiency; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Target-specific oral anticoagulants: practice issues for the clinician.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Humans; Kidney Function Tests; Morpholines; Perioperative Period; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Switching between oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin | 2014 |
Management of hemorrhage with the target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Transfusion; Charcoal; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Update on secondary prevention of ischaemic stroke.
Topics: Anticoagulants; Blood Coagulation; Brain Ischemia; Foramen Ovale, Patent; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Ventricular Dysfunction, Left | 2014 |
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
A systematic review and adjusted indirect comparison of oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Balancing ischaemia and bleeding risks with novel oral anticoagulants.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
[Bleeding complications under oral anticoagulation].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Family Practice; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Role of oral factor Xa inhibitors after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Topics: Administration, Oral; Antithrombins; Azepines; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Novel oral anticoagulants in non-valvular atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Chemistry, Pharmaceutical; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Strategies for urgent reversal of target-specific oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Charcoal; Dabigatran; Factor VIIa; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2015 |
Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombosis; Treatment Outcome; Vitamin K | 2014 |
[More with atrial fibrillation, anticoagulants since the coming of NOAK ].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Drug Prescriptions; Drug Utilization; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
The role of factor Xa inhibitors in venous thromboembolism treatment.
Topics: Animals; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban.
Topics: Animals; Antidotes; Antithrombins; Benzimidazoles; beta-Alanine; Coagulants; Dabigatran; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Models, Animal; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Periprocedural management of rivaroxaban-treated patients.
Topics: Administration, Oral; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Perioperative Period; Postoperative Complications; Risk; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism | 2015 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Ticlopidine; Warfarin | 2014 |
The periprocedural management of novel oral anticoagulants in patients with nonvalvular atrial fibrillation: rationale and a summary of the available evidence from phase 3 clinical trials.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2015 |
Clinical experience with novel oral anticoagulants for thromboprophylaxis after elective hip and knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Elective Surgical Procedures; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
Overview of the new oral anticoagulants: opportunities and challenges.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Novel oral anticoagulants: efficacy, laboratory measurement, and approaches to emergent reversal.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Laboratories; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin | 2015 |
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations.
Topics: Anticoagulants; Blood Coagulation; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Contraindications; Dabigatran; Drug Interactions; Humans; International Normalized Ratio; Male; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2015 |
[Prophylaxis of thromboembolism in atrial fibrillation: new oral anticoagulants and left atrial appendage closure].
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Combined Modality Therapy; Contraindications; Dabigatran; Hemorrhage; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism; Vitamin K | 2015 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
[Practical Aspects of the Use of Oral Anticoagulant Rivaroxaban for the Prevention of Adverse Outcomes After Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes | 2016 |
145 trial(s) available for thiophenes and rivaroxaban
| Article | Year |
|---|---|
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Rivaroxaban; Single-Blind Method; Thiophenes | 2005 |
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Hemorrhage; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2005 |
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Topics: Administration, Oral; Adult; Antithrombin III; Area Under Curve; Half-Life; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Single-Blind Method; Thiophenes | 2005 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2006 |
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.
Topics: Adult; Aluminum Hydroxide; Antacids; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; Drug Combinations; Drug Interactions; Factor Xa Inhibitors; Fasting; Food-Drug Interactions; Histamine H2 Antagonists; Humans; Intestinal Absorption; Magnesium Hydroxide; Male; Morpholines; Prothrombin Time; Ranitidine; Rivaroxaban; Thiophenes | 2006 |
Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban--an oral, direct factor Xa inhibitor--are not affected by aspirin.
Topics: Administration, Oral; Adolescent; Adult; Antithrombin III; Aspirin; Bleeding Time; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Male; Middle Aged; Molecular Structure; Morpholines; Platelet Aggregation; Rivaroxaban; Thiophenes | 2006 |
Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cross-Over Studies; Drug Interactions; Humans; Male; Middle Aged; Morpholines; Naproxen; Rivaroxaban; Thiophenes | 2007 |
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postmenopause; Postoperative Complications; Rivaroxaban; Safety; Sample Size; Survival Analysis; Thiophenes | 2006 |
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
Topics: Adult; Anticoagulants; Antithrombin III; Body Weight; Female; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes | 2007 |
Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Phlebography; Postoperative Complications; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2007 |
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Morpholines; Orthopedic Procedures; Phlebography; Postoperative Complications; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Ultrasonography; Venous Thrombosis | 2007 |
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Topics: Administration, Oral; Adult; Anticoagulants; Factor Xa Inhibitors; Heparin; Humans; Morpholines; Patient Selection; Pulmonary Embolism; Rivaroxaban; Safety; Thiophenes; Thrombosis | 2007 |
Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Linear Models; Male; Middle Aged; Models, Statistical; Morpholines; Partial Thromboplastin Time; Population; Prothrombin Time; Rivaroxaban; Thiophenes | 2007 |
Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
Topics: Administration, Oral; Adult; Anticoagulants; Blood Coagulation; Blood Platelets; Cross-Over Studies; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Thromboplastin; Time Factors | 2007 |
Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation.
Topics: Administration, Oral; Aged; Algorithms; Antithrombin III; Aza Compounds; Blood Coagulation; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Moxifloxacin; Prospective Studies; Quinolines; Rivaroxaban; Sex Factors; Thiophenes; Time Factors | 2008 |
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Nonlinear Dynamics; Prothrombin Time; Rivaroxaban; Sex Factors; Thiophenes; Time Factors; Tissue Distribution; Venous Thromboembolism | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antithrombin III; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Ultrasonography; Venous Thrombosis | 2008 |
Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Topics: Aged; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Single-Blind Method; Thiophenes | 2008 |
Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Factor Xa; Female; Humans; Male; Middle Aged; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Topics: Administration, Oral; Adult; Animals; Area Under Curve; Bile; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Dogs; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Feces; Female; Humans; Injections, Intravenous; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Middle Aged; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Species Specificity; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry; Thiophenes | 2009 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Phlebography; Risk Reduction Behavior; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Treatment Outcome; Venous Thrombosis | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Myocardial Infarction; Proportional Hazards Models; Pyridines; Recurrence; Risk Reduction Behavior; Rivaroxaban; Safety; Statistics, Nonparametric; Stroke; Thiophenes; Treatment Outcome | 2009 |
Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.
Topics: Adolescent; Adult; Antithrombin III; Asian People; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Single-Blind Method; Thiophenes; Young Adult | 2009 |
Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Asian People; Blood Coagulation; China; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Single-Blind Method; Thiophenes | 2010 |
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Embolism; Factor Xa Inhibitors; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Medical Records; Morpholines; Research Design; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Vitamin K; Warfarin | 2010 |
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Canada; Cost-Benefit Analysis; Enoxaparin; Follow-Up Studies; Humans; Morpholines; Postoperative Complications; Quality of Life; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Venous Thromboembolism | 2010 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Biomarkers; Chronic Disease; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged; Morpholines; Peptide Fragments; Peptide Hydrolases; Prothrombin; Rivaroxaban; Thiophenes; Thrombophilia | 2011 |
The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dalteparin; Factor Xa; Female; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Thrombin; Treatment Outcome; Venous Thromboembolism | 2010 |
Rivaroxaban and false positive lupus anticoagulant testing.
Topics: Anticoagulants; Antiphospholipid Syndrome; Blood Coagulation; Blood Coagulation Tests; False Positive Reactions; Humans; Lupus Coagulation Inhibitor; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamin K; Warfarin | 2010 |
Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alanine Transaminase; Alkaline Phosphatase; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Bilirubin; Chemical and Drug Induced Liver Injury; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Liver Function Tests; Male; Middle Aged; Morpholines; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heart Failure; Humans; Infections; Male; Middle Aged; Morpholines; Pulmonary Embolism; Respiratory Insufficiency; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-c
Topics: Acute Coronary Syndrome; Adolescent; Adult; Anticoagulants; Coronary Angiography; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Prospective Studies; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Treatment Outcome; Young Adult | 2011 |
Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).
Topics: Administration, Oral; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Morpholines; Risk; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2011 |
Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Omeprazole; Proton Pump Inhibitors; Rivaroxaban; Thiophenes; Young Adult | 2011 |
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2011 |
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Weight; Computer Simulation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis; Young Adult | 2011 |
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Topics: Adult; Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Double-Blind Method; Endopeptidases; Factor Xa Inhibitors; Humans; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Young Adult | 2011 |
Rivaroxaban in patients with a recent acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Incidence; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Secondary Prevention; Thiophenes | 2012 |
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Drug Interactions; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[Effect of rivaroxaban on risk of bleeding after total knee arthroplasty].
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Young Adult | 2011 |
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Young Adult | 2012 |
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Humans; Intention to Treat Analysis; Ischemic Attack, Transient; Morpholines; Multicenter Studies as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
Topics: Administration, Oral; Aged; Anticoagulants; Drug Therapy, Combination; Enoxaparin; Female; Follow-Up Studies; Hemorrhage; Humans; International Normalized Ratio; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Pulmonary Embolism; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K | 2012 |
Effects on platelet function of a direct acting antagonist of coagulation factor Xa.
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Artery Disease; Crotalid Venoms; Factor Xa; Factor Xa Inhibitors; Female; Humans; Lectins, C-Type; Male; Middle Aged; Morpholines; Plant Proteins; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rivaroxaban; Thiophenes | 2012 |
Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: A case-control study in 70 patients.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Bone Cements; Case-Control Studies; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Postoperative Hemorrhage; Prospective Studies; Prostheses and Implants; Rivaroxaban; Single-Blind Method; Thiophenes; Thrombosis; Tranexamic Acid; Treatment Outcome | 2012 |
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Area Under Curve; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cross-Over Studies; Dabigatran; Factor VIIa; Humans; Kinetics; Male; Middle Aged; Morpholines; Prothrombin; Recombinant Proteins; Risk; Rivaroxaban; Thiophenes; Thrombin | 2012 |
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Area Under Curve; Atrial Fibrillation; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Partial Thromboplastin Time; Patient Simulation; Prothrombin Time; Rivaroxaban; Thiophenes | 2013 |
Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Hospitals, University; Humans; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2012 |
Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Biomarkers; Blood Proteins; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Proteomics; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Warfarin | 2012 |
How safe is thromboprophylaxis in abdominoplasty?
Topics: Abdominoplasty; Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Hematoma; Humans; Middle Aged; Morpholines; Postoperative Care; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2012 |
Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
Topics: Adult; Anti-Arrhythmia Agents; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Headache; Heptanoic Acids; Humans; Male; Middle Aged; Morpholines; Pyrroles; Rivaroxaban; Self Administration; Thiophenes; Young Adult | 2012 |
Acute coronary syndrome and rivaroxaban: not so fast...
Topics: Acute Coronary Syndrome; Anticoagulants; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes | 2012 |
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K ant
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa; Female; Follow-Up Studies; Humans; Incidence; Male; Morpholines; Predictive Value of Tests; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Japan; Kidney; Male; Middle Aged; Morpholines; Renal Insufficiency; Reproducibility of Results; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
[Evaluation of efficacy and safety of rivaroxaban in the prevention of postoperative venous thromboembolism in adult patients with primary bone tumor undergoing knee operation].
Topics: Adult; Anticoagulants; Bone Neoplasms; Female; Humans; Knee; Male; Middle Aged; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2012 |
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Area Under Curve; Case-Control Studies; Factor Xa Inhibitors; Female; Hepatic Insufficiency; Humans; Least-Squares Analysis; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Polyamines; Prothrombin Time; Rivaroxaban; Sevelamer; Thiophenes | 2013 |
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Erythromycin; Humans; Ketoconazole; Metabolic Clearance Rate; Midazolam; Middle Aged; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Young Adult | 2013 |
Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Hematoma; Humans; Incidence; Male; Middle Aged; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients.
Topics: Asian People; Atrial Fibrillation; Dose-Response Relationship, Drug; Humans; Models, Biological; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Sex Factors; Thiophenes; Young Adult | 2013 |
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention o
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Morpholines; Outcome Assessment, Health Care; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Time Factors; Warfarin; Withholding Treatment | 2013 |
The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Biological Availability; Chemistry, Pharmaceutical; Cross-Over Studies; Dose-Response Relationship, Drug; Fasting; Food-Drug Interactions; Half-Life; Humans; Infusions, Intravenous; Intestinal Absorption; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Statistical; Morpholines; Postprandial Period; Rivaroxaban; Thiophenes; Young Adult | 2013 |
Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thro
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Prospective Studies; Rivaroxaban; Thiophenes; Thrombolytic Therapy; Treatment Outcome | 2013 |
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Multicenter Studies as Topic; Multivariate Analysis; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Topics: Aged; Anticoagulants; Asia; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Europe; Female; Healthcare Disparities; Humans; International Normalized Ratio; Linear Models; Male; Morpholines; Multivariate Analysis; North America; Predictive Value of Tests; Residence Characteristics; Rivaroxaban; South Africa; South America; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2013 |
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stents; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Patient Safety; Postoperative Complications; Risk; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2013 |
Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
Topics: Acute Coronary Syndrome; Adult; Aged; Anticoagulants; Dose-Response Relationship, Drug; Endpoint Determination; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Heart Failure; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2013 |
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Topics: Acute Coronary Syndrome; Anticoagulants; Coronary Thrombosis; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Myocardial Infarction; Randomized Controlled Trials as Topic; Reproducibility of Results; Rivaroxaban; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Protocols; Continuity of Patient Care; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Proportional Hazards Models; Research Design; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Open-label, randomized study of the effect of rivaroxaban with or without acetylsalicylic acid on thrombus formation in a perfusion chamber.
Topics: Adolescent; Adult; Animals; Anticoagulants; Aspirin; Cross-Over Studies; Female; Humans; In Vitro Techniques; Male; Middle Aged; Morpholines; Platelet Aggregation; Rivaroxaban; Swine; Thiophenes; Thrombosis; Venous Thromboembolism; Young Adult | 2013 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Patient Satisfaction; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
Topics: Acute Coronary Syndrome; Aged; Antibodies, Antiphospholipid; Factor Xa Inhibitors; Female; Humans; Immunoglobulin M; Male; Middle Aged; Morpholines; Myocardial Infarction; Phosphorylcholine; Rivaroxaban; Stroke; Thiophenes | 2014 |
Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Data Interpretation, Statistical; Databases, Bibliographic; Double-Blind Method; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
Topics: Adolescent; Adult; Anticoagulants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Models, Biological; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; China; Double-Blind Method; Embolism; Female; Hemorrhage; Humans; Male; Morpholines; Primary Prevention; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF trial.
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Female; Humans; Japan; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism | 2013 |
A head-to-head comparison of periprocedural coagulability under anticoagulation with rivaroxaban versus dabigatran in patients undergoing ablation of atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Double-Blind Method; Embolism; Female; Humans; Kaplan-Meier Estimate; Male; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyridines; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Treatment Outcome; Warfarin | 2014 |
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Data Interpretation, Statistical; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Propensity Score; Risk; Rivaroxaban; Standard of Care; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Humans; Male; Morpholines; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Pressure; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Patient Safety; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Vitamin K; Warfarin | 2014 |
Determination of direct oral anticoagulants from human serum samples.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pregnancy; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin | 2014 |
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Cross-Sectional Studies; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Point-of-Care Systems; Prothrombin Time; Reference Values; Rivaroxaban; Thiophenes; Venous Thromboembolism; Whole Blood Coagulation Time | 2014 |
Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Factor Xa Inhibitors; Female; Fractures, Bone; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Length of Stay; Lower Extremity; Male; Middle Aged; Morpholines; Postoperative Complications; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis; Vitamin K | 2014 |
Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time.
Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Morpholines; Prospective Studies; Prothrombin Time; Rivaroxaban; Thiophenes | 2014 |
D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Morpholines; Multivariate Analysis; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial.
Topics: Aged; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Japan; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
Topics: Adolescent; Adult; Anticoagulants; Blood Coagulation; Factor VIIa; Factor Xa; Healthy Volunteers; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Warfarin; Young Adult | 2014 |
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stro
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Topics: Adult; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Point-of-Care Systems; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antifibrinolytic Agents; Atrial Fibrillation; Blood Transfusion; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Plasma; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Morpholines; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Thiophenes | 2014 |
[Effect of autologous drained blood reinfusion on hidden blood loss and limb swelling following rivaroxaban anticoagulation for primary total hip arthroplasty].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Transfusion, Autologous; Edema; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in at
Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Morpholines; Prospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
[Case-control study on effect of rivaroxaban on the risk of hidden bleeding after total hip arthroplasty].
Topics: Arthroplasty, Replacement, Hip; Case-Control Studies; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Rivaroxaban; Thiophenes; Time Factors | 2014 |
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Monitoring; Embolism; Europe; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; North America; Point-of-Care Systems; Predictive Value of Tests; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial.
Topics: Aged; Anticoagulants; Asia, Eastern; Asian People; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban onc
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Echocardiography, Transesophageal; Electric Countershock; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Vitamin K | 2014 |
[Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement].
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Tests; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Male; Middle Aged; Morpholines; Peptide Fragments; Prothrombin; Rivaroxaban; Thiophenes | 2014 |
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; Blood Coagulation Factors; Body Mass Index; Drug Administration Schedule; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Healthy Volunteers; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Time Factors; Treatment Outcome; Young Adult | 2014 |
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Factor Xa Inhibitors; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Registries; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K | 2014 |
Major bleeding with dabigatran and rivaroxaban in patients with atrial fibrillation: a real-world setting.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Medical Records Systems, Computerized; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2014 |
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Renal Insufficiency; Rivaroxaban; Thiophenes | 2014 |
Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Hospitalization; Humans; Incidence; Male; Middle Aged; Morpholines; Multivariate Analysis; Predictive Value of Tests; Primary Prevention; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Venous Thromboembolism | 2014 |
Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morpholines; Patient Safety; Postoperative Care; Preoperative Care; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Statistics, Nonparametric; Survival Rate; Thiophenes; Treatment Outcome; Venous Thrombosis; Vitamin K; Warfarin | 2014 |
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
Topics: Africa; Atrial Fibrillation; Clinical Protocols; Europe; Factor Xa Inhibitors; Humans; Latin America; Middle East; Morpholines; Prospective Studies; Research Design; Risk Assessment; Risk Factors; Rivaroxaban; Sample Size; Stroke; Thiophenes; Time Factors; Treatment Outcome | 2014 |
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
Topics: Aged; Anticoagulants; Aortic Valve Insufficiency; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mitral Valve Insufficiency; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.
Topics: Administration, Oral; Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K | 2014 |
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Morpholines; Prospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Rationale and design of Triple AXEL: trial for early anticoagulation in acute ischemic stroke patients with nonvalvular atrial fibrillation.
Topics: Adult; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Research Design; Rivaroxaban; Stroke; Thiophenes | 2015 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
Topics: Administration, Oral; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Patient Satisfaction; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2015 |
[Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
Topics: Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2014 |
Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Safety; Thiophenes; Venous Thromboembolism; Vitamin K | 2015 |
Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Emergency Service, Hospital; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Prognosis; Pulmonary Embolism; Risk; Rivaroxaban; Severity of Illness Index; Thiophenes | 2015 |
Dose-finding study of rivaroxaban in hemodialysis patients.
Topics: Administration, Oral; Area Under Curve; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Half-Life; Hemorrhage; Humans; Kidney Failure, Chronic; Male; Morpholines; Renal Dialysis; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia | 2015 |
Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial flutter and a retrospective observational registry prov
Topics: Administration, Oral; Atrial Appendage; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Drug Administration Schedule; Echocardiography, Transesophageal; Electric Countershock; Factor Xa Inhibitors; Female; Heart Diseases; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2015 |
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention
Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K | 2015 |
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Morpholines; Prothrombin Time; Rivaroxaban; Stroke; Thiophenes | 2015 |
[CONKO-011: Evaluation of patient satisfaction with the treatment of acute venous thromboembolism with rivaroxaban or low molecular weight heparin in cancer patients. A randomized phase III study].
Topics: Acute Disease; Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Morpholines; Patient Satisfaction; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2015 |
[Rivaroxaban - Largest Study Program with novel oral anticoagulants].
Topics: Administration, Oral; Anticoagulants; Europe; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2015 |
The Efficacy of Combined Use of Rivaroxaban and Tranexamic Acid on Blood Conservation in Minimally Invasive Total Knee Arthroplasty a Double-Blind Randomized, Controlled Trial.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Transfusion; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hematoma; Humans; Male; Middle Aged; Morpholines; Postoperative Hemorrhage; Postoperative Period; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Tranexamic Acid; Venous Thrombosis | 2017 |
A Phase IV Study of Thromboembolic and Bleeding Events Following Hip and Knee Arthroplasty Using Oral Factor Xa Inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2017 |
[Rivaroxaban in prevention of stroke in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2019 |
567 other study(ies) available for thiophenes and rivaroxaban
| Article | Year |
|---|---|
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor.
Topics: Animals; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Morpholines; Rabbits; Rats; Rivaroxaban; Serine Proteinase Inhibitors; Species Specificity; Thiophenes; Thromboplastin; Venous Thrombosis | 2005 |
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Biological Availability; Crystallography, X-Ray; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Half-Life; Humans; In Vitro Techniques; Male; Models, Molecular; Morpholines; Prothrombin Time; Rats; Rats, Wistar; Rivaroxaban; Stereoisomerism; Structure-Activity Relationship; Thiophenes | 2005 |
Pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--in rats and dogs.
Topics: Administration, Oral; Animals; Anticoagulants; Dogs; Enzyme Inhibitors; Factor Xa Inhibitors; Female; Male; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Thiophenes | 2005 |
New oral anticoagulants show promise.
Topics: Anticoagulants; Clinical Trials as Topic; Factor Xa Inhibitors; Fondaparinux; Glycine; Humans; Morpholines; Piperazines; Polysaccharides; Rivaroxaban; Thiophenes; Thromboembolism | 2006 |
The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Factor Xa; Humans; Morpholines; Postoperative Period; Rivaroxaban; Thiophenes | 2006 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Infusions, Intravenous; Injections, Intravenous; Jugular Veins; Ligation; Morpholines; Nadroparin; Polysaccharides; Rabbits; Random Allocation; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2007 |
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
Topics: Administration, Oral; Antithrombin III; Blood Platelets; Factor Xa Inhibitors; Humans; In Vitro Techniques; Inhibitory Concentration 50; Kinetics; Morpholines; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time; Thromboplastin; Time Factors | 2007 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
A replacement for warfarin: the search continues.
Topics: Administration, Oral; Anticoagulants; Clinical Trials, Phase II as Topic; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K; Warfarin | 2007 |
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Topics: Administration, Oral; Blood Coagulation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2007 |
[New anticoagulants].
Topics: Anticoagulants; Atrial Fibrillation; Education, Medical, Continuing; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Treatment Outcome | 2008 |
Potent anticoagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Research Design; Rivaroxaban; Thiophenes; Venous Thrombosis | 2008 |
New anticoagulants--the path from discovery to clinical practice.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2008 |
Selective factor Xa inhibition for thromboprophylaxis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
Topics: Analysis of Variance; Anticoagulants; Antithrombin III; Arginine; Autoantibodies; Enoxaparin; Flow Cytometry; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pipecolic Acids; Platelet Activation; Platelet Aggregation; Platelet Factor 4; Polysaccharides; Rivaroxaban; Sulfonamides; Thiophenes; Thrombocytopenia | 2008 |
Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Calibration; Chromatography, High Pressure Liquid; Factor Xa Inhibitors; Humans; Morpholines; Reproducibility of Results; Rivaroxaban; Sensitivity and Specificity; Serine Proteinase Inhibitors; Tandem Mass Spectrometry; Thiophenes | 2008 |
[Prophylaxis of venous thromboembolism].
Topics: Anticoagulants; Factor Xa; Humans; Inpatients; Laparoscopy; Morpholines; Reoperation; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
More effective, simpler-to-use clot-buster is on the way. Clot-prevention drug could save lives after joint replacement.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2008 |
[Always more amputations in Germany?].
Topics: Aged; Amputation, Surgical; Anticoagulants; Arterial Occlusive Diseases; Benzimidazoles; Dabigatran; Fibrinolytic Agents; Germany; Humans; Morpholines; Peripheral Vascular Diseases; Pyridines; Rivaroxaban; Thiophenes; Thrombosis | 2008 |
Orally administered factor xa inhibitor, rivaroxaban: a novel thromboembolic prophylaxis agent.
Topics: Administration, Oral; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Body Weight; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Antidotes; Arthroplasty, Replacement; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
Rivaroxaban for thromboprophylaxis.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2008 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
[Thromboembolic disease in orthopedic surgery].
Topics: Anesthesia, Conduction; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Early Ambulation; Enoxaparin; Fibrinolytic Agents; Hip Fractures; Humans; Intraoperative Care; Morpholines; Orthopedics; Postoperative Care; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism | 2008 |
[Rivaroxaban: a decisive step forward in the management of postoperative thromboembolic disease?].
Topics: Fibrinolytic Agents; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thromboembolism | 2008 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; Kidney Failure, Chronic; Morpholines; Obesity; Postoperative Complications; Preanesthetic Medication; Rivaroxaban; Thiophenes; Thromboembolism; Thrombophilia; Venous Thrombosis | 2008 |
In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans.
Topics: Animals; Biotransformation; Cells, Cultured; Chromatography, High Pressure Liquid; Dogs; Factor Xa Inhibitors; Female; Hepatocytes; Humans; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Microsomes, Liver; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Species Specificity; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry; Thiophenes | 2009 |
The novel anticoagulants: entering a new era.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombolytic Therapy; Vitamin K | 2009 |
In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
The direct factor Xa inhibitor rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Drug Interactions; Factor Xa Inhibitors; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
[New anticoagulants].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thromboembolism; Thrombosis | 2009 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
The importance of VTE prevention after orthopaedic surgery.
Topics: Anticoagulants; Cost of Illness; Enoxaparin; Evidence-Based Medicine; Humans; Length of Stay; Morpholines; Orthopedic Procedures; Risk Reduction Behavior; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[The new oral anticoagulant in the Netherlands].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; Dabigatran; Drug Interactions; Elective Surgical Procedures; Humans; Morpholines; Netherlands; Patient Selection; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.
Topics: Animals; Benzimidazoles; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Morpholines; Pyrazoles; Pyridines; Pyridones; Rabbits; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2009 |
Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Design; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Rivaroxaban in acute coronary syndromes: too soon to know?
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome | 2009 |
Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Elective Surgical Procedures; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Factor Xa inhibitors--new anticoagulants for secondary haemostasis.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Glycine; Hemostasis; Humans; Morpholines; Piperazines; Pyrazoles; Pyridones; Pyrrolidines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Patients with oral anticoagulation--bridging anticoagulation in the perioperative phase].
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Humans; Intraoperative Period; Morpholines; Rivaroxaban; Thiophenes | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Research Design; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Aftercare; Anticoagulants; Arthroplasty, Replacement, Knee; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Patient Selection; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Enoxaparin; Europe; Humans; Morpholines; North America; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rivaroxaban; Safety; Thiophenes; Venous Thrombosis | 2009 |
Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Double-Blind Method; Drug Approval; Europe; Factor X; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2009 |
Will oral rivaroxaban improve clinically relevant outcomes and thromboprophylaxis management in the orthopedic patient?
Topics: Humans; Morpholines; Orthopedics; Postoperative Complications; Premedication; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2009 |
Underestimation of the effect of bleeding in clinical trials.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Data Interpretation, Statistical; Hemorrhage; Humans; Morpholines; Research Design; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult | 2009 |
New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Economics, Pharmaceutical; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Rivaroxaban (Xarelto): new anticoagulant inhibitor of factor Xa].
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2009 |
Rivaroxaban, the first oral, direct factor Xa inhibitor.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
[Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Benzimidazoles; Blood Loss, Surgical; Cesarean Section; Contraindications; Dabigatran; Europe; Evidence-Based Medicine; Female; Fetus; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Morpholines; Polysaccharides; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Puerperal Disorders; Pyridines; Rivaroxaban; Societies, Medical; Thiophenes; Thrombophilia; United States; Uterine Hemorrhage; Venous Thromboembolism; Warfarin | 2009 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Blood Coagulation Disorders; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2010 |
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Blood Coagulation; Blood Coagulation Tests; Calibration; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Humans; Morpholines; Partial Thromboplastin Time; Polysaccharides; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Time Factors | 2010 |
[Prophylaxis of venous thromboembolism in orthopaedic surgery--trivial option, huge potential].
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Coagulation Tests; Combined Modality Therapy; Drug Approval; Drug Interactions; Early Ambulation; Enoxaparin; Factor Xa Inhibitors; Humans; Intermittent Pneumatic Compression Devices; Morpholines; Orthopedic Procedures; Postoperative Care; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Stockings, Compression; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
DVT: a new era in anticoagulant therapy.
Topics: Animals; Anticoagulants; Benzimidazoles; Dabigatran; Disease Models, Animal; Factor Xa Inhibitors; Humans; Mice; Mice, Knockout; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thrombosis | 2010 |
Facts and artefacts of coagulation assays for factor Xa inhibitors.
Topics: Administration, Oral; Artifacts; Blood Coagulation; Blood Coagulation Tests; Calibration; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Time Factors | 2010 |
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulation Tests; Dogs; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Morpholines; Pyrazoles; Pyridones; Pyrimidinones; Rabbits; Rats; Rats, Sprague-Dawley; Rivaroxaban; Sulfones; Thiophenes; Thrombin; Venous Thrombosis | 2010 |
Anticoagulation by factor Xa inhibitors.
Topics: Anticoagulants; Blood Coagulation; Computer Simulation; Factor V; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Humans; Morpholines; Polysaccharides; Recombinant Proteins; Rivaroxaban; Software; Thiophenes; Thrombin; Time Factors; Treatment Outcome | 2010 |
[New oral anticoagulants: prospects].
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyridines; Rivaroxaban; Thiophenes | 2010 |
Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
Topics: Fibrinolytic Agents; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
Is there adequate provision of venous thromboembolism prophylaxis following hip arthroplasty? An audit and international survey.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Patient Satisfaction; Postoperative Care; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin | 2010 |
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma.
Topics: Blood Coagulation; Clinical Trials, Phase II as Topic; Colorimetry; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Orthopedic Procedures; Predictive Value of Tests; Rivaroxaban; Thiophenes; Thrombosis | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.
Topics: Blood Coagulation; Calibration; Drug Monitoring; Factor Xa Inhibitors; Feasibility Studies; Fibrinolytic Agents; Humans; Morpholines; Prothrombin Time; Reference Standards; Rivaroxaban; Tetrazolium Salts; Thiophenes; Thromboplastin | 2011 |
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays.
Topics: Activated Protein C Resistance; Administration, Oral; Adult; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrinogen; Humans; Male; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes | 2011 |
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Humans; International Normalized Ratio; Isoxazoles; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
[Prophylaxis of thrombembolic diseases with rivaroxaban].
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Fibrinolytic Agents; Hemorrhage; Humans; International Normalized Ratio; Metabolic Clearance Rate; Morpholines; Partial Thromboplastin Time; Postoperative Complications; Protein Binding; Prothrombin Time; Rivaroxaban; Thiophenes; Thromboembolism | 2010 |
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
Topics: Administration, Oral; Adult; Aged; Area Under Curve; Cohort Studies; Creatinine; Factor Xa Inhibitors; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Morpholines; Renal Insufficiency; Rivaroxaban; Thiophenes | 2010 |
Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drugs, Investigational; Factor Xa Inhibitors; Humans; Lower Extremity; Morpholines; Orthopedic Procedures; Pyridines; Rivaroxaban; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Engineered thrombin aims to take on heparin.
Topics: Anticoagulants; Drug Industry; Factor Xa; Factor Xa Inhibitors; Heparin; Humans; Morpholines; Protein Engineering; Rivaroxaban; Thiophenes; Thrombin | 2010 |
Therapeutic potential of oral factor Xa inhibitors.
Topics: Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
Factor Xa and thrombin as targets for new oral anticoagulants.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K | 2011 |
Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hip Prosthesis; Humans; Knee Prosthesis; Male; Middle Aged; Morpholines; Postoperative Care; Postoperative Complications; Prosthesis-Related Infections; Reoperation; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Tinzaparin | 2011 |
Rivaroxaban for thromboembolism prophylaxis after orthopaedic surgery.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Fibrinolytic Agents; Humans; Morpholines; Postoperative Care; Postoperative Complications; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2010 |
New alternative to warfarin may help reduce stroke risk in patients with AF.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Drug Approval; Humans; Morpholines; Randomized Controlled Trials as Topic; Risk; Rivaroxaban; Stroke; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2011 |
[Rivaroxaban at least as effective as marcumar in stroke prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Humans; International Normalized Ratio; Morpholines; Multicenter Studies as Topic; Phenprocoumon; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes | 2010 |
Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?
Topics: Anticoagulants; Antithrombins; Biomarkers, Pharmacological; Factor Xa; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Prothrombin Time; Reference Standards; Rivaroxaban; Thiophenes | 2011 |
What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2011 |
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Drug Interactions; Hemorrhage; Humans; Kidney Diseases; Morpholines; Pyridines; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Coagulation; Dabigatran; Humans; Male; Middle Aged; Morpholines; Pyridines; Rivaroxaban; Thiophenes | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Recurrence; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT.
Topics: Aged; American Heart Association; Cardiac Resynchronization Therapy; Clinical Trials as Topic; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Morpholines; Natriuretic Peptide, Brain; Peptide Fragments; Rivaroxaban; Telemedicine; Thiophenes; United States | 2011 |
In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Humans; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Morpholines; Protein Transport; Rivaroxaban; Swine; Thiophenes | 2011 |
Evaluation of the efficacy and safety of rivaroxaban using a computer model for blood coagulation.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Circulation; Blood Coagulation; Computer Simulation; Enoxaparin; Humans; Models, Biological; Morpholines; Naphthalenes; Partial Thromboplastin Time; Propionates; Rivaroxaban; Thiophenes; Translational Research, Biomedical; Treatment Outcome; Warfarin | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Health Care Costs; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.
Topics: Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biomarkers; Chronic Disease; Creatinine; Dabigatran; Fibrinolytic Agents; Glomerular Filtration Rate; Humans; Incidence; Kidney; Kidney Diseases; Morpholines; Netherlands; Patient Selection; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes | 2011 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Drug Costs; Drugs, Investigational; Factor Xa Inhibitors; Humans; Hungary; Morpholines; Oligosaccharides; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism | 2011 |
Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time.
Topics: Aged; Anticoagulants; Antithrombins; Blood Coagulation; Blood Coagulation Tests; Clinical Protocols; Drug Interactions; Factor Xa Inhibitors; Female; Fibrinogen; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Postoperative Complications; Rivaroxaban; Thiophenes; Time Factors; Venous Thromboembolism | 2011 |
[Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].
Topics: Anticoagulants; Antithrombin Proteins; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Humans; Intracranial Embolism; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Endopeptidases; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Hydrolases; Predictive Value of Tests; Prothrombin; Rivaroxaban; Thiophenes; Time Factors | 2011 |
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Morpholines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2011 |
Evaluation of plaque stability of advanced atherosclerotic lesions in apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban.
Topics: Animals; Anticoagulants; Apolipoproteins E; Atherosclerosis; Factor Xa Inhibitors; Female; Humans; Lipids; Mice; Mice, Knockout; Morpholines; Plaque, Atherosclerotic; Random Allocation; Rivaroxaban; Thiophenes | 2011 |
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study.
Topics: Anticoagulants; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Models, Biological; Morpholines; Perfusion; Rivaroxaban; Thiophenes; Thrombosis | 2011 |
Effect of rivaroxaban, in contrast to heparin, is similar in neonatal and adult plasma.
Topics: Adult; Anticoagulants; Blood Coagulation; Factor Xa; Fetal Blood; Heparin; Humans; Infant, Newborn; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time | 2011 |
Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells.
Topics: Anticoagulants; Antithrombins; Aorta; Blood Coagulation; Cells, Cultured; DNA; Factor Xa; Factor Xa Inhibitors; Gene Expression Regulation; Hirudins; Humans; Inflammation Mediators; Morpholines; Myocytes, Smooth Muscle; Naphthalenes; Propionates; Rivaroxaban; Thiophenes; Thrombin | 2011 |
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability.
Topics: Anticoagulants; Chromogenic Compounds; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2011 |
[Is the era from the end of warfarin?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Vitamin K | 2011 |
Oral direct factor Xa inhibitor gets FDA's OK.
Topics: Administration, Oral; Anticoagulants; Drug Approval; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Venous Thrombosis | 2011 |
New options in anticoagulation for atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Intention to Treat Analysis; Intracranial Hemorrhages; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2011 |
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
Topics: Adult; Anticoagulants; Artifacts; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Humans; Male; Morpholines; Reproducibility of Results; Rivaroxaban; Sensitivity and Specificity; Switzerland; Thiophenes | 2012 |
New antithrombotic drugs and European approval processes.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Europe; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
New anticoagulants: moving on from scientific results to clinical implementation.
Topics: Acute Coronary Syndrome; Anticoagulants; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diet; Drug Interactions; Factor VIIa; Factor Xa Inhibitors; Humans; Kidney; Life Style; Monitoring, Physiologic; Morpholines; Recombinant Proteins; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2011 |
A new era for anticoagulation in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2011 |
Spontaneous spinal epidural haematoma during Factor Xa inhibitor treatment (Rivaroxaban).
Topics: Anticoagulants; Factor Xa Inhibitors; Female; Hematoma, Epidural, Spinal; Humans; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
The future of anticoagulant therapy.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Dabigatran; Drug Approval; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2012 |
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays.
Topics: Administration, Oral; Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Factor VIII; Factor Xa Inhibitors; Humans; Morpholines; Netherlands; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Rivaroxaban; Thiophenes; Time Factors; Venous Thrombosis | 2011 |
["Xa-tra-xa": opportunities and open questions about new anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Heparin; Humans; Models, Economic; Morpholines; Rivaroxaban; Sweden; Thiophenes; Venous Thromboembolism | 2011 |
Reversal of new oral anticoagulants.
Topics: Anticoagulants; Antidotes; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Factors; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2011 |
Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
Topics: Anticoagulants; Blood Coagulation; Calibration; Coagulants; Humans; Indicators and Reagents; International Normalized Ratio; Morpholines; Plasma; Prothrombin Time; Recombinant Proteins; Regression Analysis; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thromboplastin | 2011 |
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Carotid Artery Injuries; Coronary Occlusion; Coronary Thrombosis; Disease Models, Animal; Electrolytes; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fibrinolytic Agents; Injections, Intravenous; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes | 2011 |
Evaluating rivaroxaban for nonvalvular atrial fibrillation--regulatory considerations.
Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Government Regulation; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration | 2011 |
Novel oral anticoagulants: new challenges for anesthesiologists in bleeding patients.
Topics: Animals; Anticoagulants; Factor VIIa; Male; Morpholines; Prothrombin; Recombinant Proteins; Rivaroxaban; Thiophenes | 2012 |
Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban.
Topics: Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Dose-Response Relationship, Drug; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Time Factors | 2012 |
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Enoxaparin; Health Services; Humans; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2011 |
The new oral anticoagulants.
Topics: Anticoagulants; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2011 |
The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin.
Topics: Aged; Alkaline Phosphatase; Anticoagulants; Bone Morphogenetic Protein 2; Cell Survival; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Enoxaparin; Factor Xa Inhibitors; Female; Gene Expression; Humans; Morpholines; Osteoblasts; Osteocalcin; Rivaroxaban; RNA, Messenger; Thiophenes | 2011 |
Rivaroxaban: direct factor Xa inhibition to treat acute deep vein thrombosis.
Topics: Acute Disease; Anticoagulants; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2011 |
Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Topics: Anesthesia; Animals; Anticoagulants; Bleeding Time; Blood Coagulation Tests; Blood Pressure; Body Temperature; Dose-Response Relationship, Drug; Factor VIIa; Hemorrhage; Liver; Male; Monitoring, Physiologic; Morpholines; Prothrombin; Rabbits; Recombinant Proteins; Respiration, Artificial; Rivaroxaban; Spleen; Thiophenes; Thrombelastography; Thrombin; Thrombosis | 2012 |
FDA advisory decision highlights some problems inherent in pragmatic trials.
Topics: Advisory Committees; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Approval; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; United States Food and Drug Administration; Warfarin | 2011 |
Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.
Topics: Antibodies; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Cells; Cells, Cultured; Dabigatran; Drug Evaluation, Preclinical; Drug Interactions; HEK293 Cells; Heparin; Humans; Morpholines; Platelet Factor 4; Rivaroxaban; Sulfates; Thiophenes; Thrombocytopenia; Transfection | 2012 |
Lack of an antagonist to reverse the action of dabigatran.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Hemorrhage; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Xarelto: a new drug for new joints. Hip and knee recipients can avoid postsurgical clots without undergoing painful injections.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Embolism; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Thrombosis | 2011 |
A new era in secondary prevention after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2012 |
Test of the month: The chromogenic antifactor Xa assay.
Topics: Antibodies; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Chromogenic Compounds; Drug Monitoring; Factor Xa; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Immunoassay; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes | 2012 |
Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2012 |
[Anticoagulation in atrial fibrillation: a new era has begun].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Drugs in traffic: the road to approval.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Abiraterone Acetate; Adenine; Androstadienes; Antibodies, Monoclonal, Humanized; Anticarcinogenic Agents; Benzhydryl Compounds; Bevacizumab; Drug Approval; Drug Industry; Glucosides; Hydroxyprogesterones; Indans; Morpholines; Natriuretic Peptide, Brain; Organophosphonates; Protein C; Recombinant Proteins; Rivaroxaban; Tenofovir; Thiophenes | 2011 |
Rivaroxaban (Xarelto) for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Approval; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration | 2011 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Approval; Humans; Kidney; Liver; Morpholines; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; United States; United States Food and Drug Administration | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis; Warfarin | 2011 |
Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Dabigatran; Decision Making, Computer-Assisted; Denmark; Humans; Intracranial Hemorrhages; Morpholines; Population Groups; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Topics: Anticoagulants; Blood Chemical Analysis; Calibration; Chromogenic Compounds; Europe; Factor Xa Inhibitors; Feasibility Studies; Humans; Morpholines; North America; Observer Variation; Reproducibility of Results; Rivaroxaban; Sensitivity and Specificity; Thiophenes | 2012 |
Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Enoxaparin; Humans; Middle Aged; Models, Economic; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Oral thromboprophylaxis in pelvic trauma: a standardized protocol.
Topics: Adult; Aged; Anticoagulants; Drug Administration Schedule; Female; Fractures, Bone; Glasgow Coma Scale; Humans; Injury Severity Score; Lower Extremity; Male; Middle Aged; Morpholines; Pelvic Bones; Pulmonary Embolism; Radionuclide Imaging; Rivaroxaban; Thiophenes; Time Factors; Ultrasonography; Venous Thrombosis; Young Adult | 2012 |
Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice.
Topics: Adult; Aged; Drug Interactions; Evaluation Studies as Topic; Forecasting; Humans; Middle Aged; Models, Biological; Morpholines; Physiological Phenomena; Rivaroxaban; Thiophenes; Young Adult | 2012 |
Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.
Topics: Animals; Anticoagulants; Apolipoproteins E; Blood Coagulation; Disease Models, Animal; Factor Xa Inhibitors; Fibrinolytic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Rivaroxaban; Thiophenes; Thrombosis | 2012 |
[Secondary prevention of myocardial infarct. A new anticoagulant improves survival prospects].
Topics: Anticoagulants; Controlled Clinical Trials as Topic; Coronary Thrombosis; Dose-Response Relationship, Drug; Humans; Morpholines; Myocardial Infarction; Risk Assessment; Rivaroxaban; Secondary Prevention; Survival Rate; Thiophenes | 2011 |
[New anticoagulants].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fondaparinux; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
What's the "go to" anticoagulant for stroke prevention in atrial fibrillation?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2012 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Darexaban has high sensitivity in the prothrombin time clotting test.
Topics: Azepines; Benzamides; Blood Coagulation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glucuronides; Humans; Morpholines; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes | 2012 |
New directions in anticoagulation.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Disorders; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51, TRACER and PALLAS.
Topics: Acute Coronary Syndrome; American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dronedarone; Fibrinolytic Agents; Humans; Lactones; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; United States; Venous Thromboembolism | 2012 |
Rivaroxaban and recurrent stroke prevention in AF.
Topics: Anticoagulants; Atrial Fibrillation; Humans; Ischemic Attack, Transient; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Coagulopathies and thrombosis: usual and unusual causes and associations, part VI.
Topics: Acute Coronary Syndrome; Altitude; Blood Coagulation Disorders; Coffee; Factor Xa Inhibitors; Heparin; Humans; Lipoproteins; Lymphatic Diseases; Morpholines; Myocardial Infarction; Platelet Aggregation Inhibitors; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis; Troponin; Venous Thrombosis; von Willebrand Diseases | 2012 |
Determination of rivaroxaban in human plasma samples.
Topics: Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes; Venous Thrombosis | 2012 |
Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?
Topics: Anticoagulants; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Rivaroxaban: a new oral anticoagulant.
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes | 2012 |
New antithrombotic drugs: a revolution in stroke management.
Topics: Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Approval; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Monitoring, Physiologic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
[Update on current care guidelines: atrial fibrillation].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Dronedarone; Finland; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Control; Dabigatran; Endpoint Determination; Health Expenditures; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; United States; Warfarin | 2012 |
Rivaroxaban to prevent pulmonary embolism after hip or knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2012 |
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Humans; Morpholines; Ontario; Postoperative Complications; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[Anticoagulant therapeutics: In order not to jeopardize a potential therapeutical progress].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2012 |
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Topics: Anticoagulants; Antithrombins; Calibration; Chromatography, High Pressure Liquid; Diagnostic Errors; Drug Monitoring; Factor Xa; Humans; Morpholines; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2012 |
[Anticoagulants and dual antiplatelet therapy combined, a challenge to our intelligence].
Topics: Acute Coronary Syndrome; Anticoagulants; Drug Therapy, Combination; Humans; Morpholines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Rivaroxaban; Thiophenes | 2012 |
Rivaroxaban for thromboprophylaxis after hip or knee replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Interactions; Humans; Morpholines; Postoperative Complications; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Prevention of venous thromboembolism in total knee and hip replacement.
Topics: Aged; Anesthesia, Conduction; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Female; Hip Prosthesis; Humans; Morpholines; Obesity; Postoperative Complications; Postoperative Hemorrhage; Practice Guidelines as Topic; Premedication; Prosthesis Failure; Recurrence; Reoperation; Risk; Risk Factors; Rivaroxaban; Stockings, Compression; Thiophenes; Venous Thromboembolism | 2012 |
[Therapy of pulmonary embolism. Rivaroxaban is superior to standard therapy].
Topics: Anticoagulants; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thrombosis | 2012 |
Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE.
Topics: Acute Disease; Anticoagulants; Evidence-Based Medicine; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2012 |
[Expanded arsenal in atrial fibrillation: bye-bye marcumar?].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Drug Substitution; Factor Xa Inhibitors; Germany; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Thiophenes; Thromboembolism | 2012 |
Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Markov Chains; Medicare; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism | 2012 |
Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Biological Availability; Blood Coagulation Tests; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Half-Life; Humans; Morpholines; Narcotics; Oral Hemorrhage; Oral Surgical Procedures; Postoperative Hemorrhage; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Oral anticoagulants for atrial fibrillation: Which one to choose?
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Drug Costs; Drug Substitution; Humans; Morpholines; Pyridines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Rivaroxaban, an oral, direct factor Xa inhibitor: a new option for thromboprophylaxis.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Topics: Anticoagulants; Hemorrhage; Hip Joint; Humans; Knee Joint; Morpholines; Orthopedic Procedures; Registries; Research Design; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2012 |
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Decision Support Techniques; Drug Costs; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes | 2012 |
A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Databases, Factual; Decision Trees; Enoxaparin; Germany; Humans; Morpholines; Multicenter Studies as Topic; National Health Programs; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
[Rivaroxaban in the prevention and treatment of thromboembolic disorders].
Topics: Evidence-Based Medicine; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2012 |
Indirect comparison studies--are they useful? Insights from the novel oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Evidence-Based Medicine; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Time Factors; Treatment Outcome; Warfarin | 2012 |
The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2.
Topics: Alkaline Phosphatase; Anticoagulants; Calcification, Physiologic; Cell Line; Creatine Kinase; DNA; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Humans; Morpholines; Osteoblasts; Rivaroxaban; Thiophenes | 2012 |
New oral anticoagulant in atrial fibrillation: are they comparable?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin | 2012 |
[The ROCKET AF study].
Topics: Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty.
Topics: Age Distribution; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cerebral Hemorrhage; Cohort Studies; Confidence Intervals; Databases, Factual; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Incidence; Male; Middle Aged; Morpholines; Odds Ratio; Postoperative Complications; Retrospective Studies; Risk Assessment; Rivaroxaban; Sex Distribution; Surgical Wound Infection; Survival Analysis; Thiophenes; Treatment Outcome; Venous Thrombosis; Wound Healing | 2012 |
Head-to-head or indirect comparisons of the novel oral anticoagulants in atrial fibrillation: what's next?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Humans; Male; Morpholines; Multicenter Studies as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Thrombophilia | 2012 |
J-ROCKET AF trial increased expectation of lower-dose rivaroxaban made for Japan.
Topics: Anticoagulants; Atrial Fibrillation; Embolism; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Concerns about storage and application of dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Capsules; Dabigatran; Drug Packaging; Drug Stability; Drug Storage; Humans; Humidity; Morpholines; Rivaroxaban; Sunlight; Temperature; Thiophenes | 2013 |
New anticoagulants.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Drug Administration Schedule; Female; Fondaparinux; Germany; Humans; Kaplan-Meier Estimate; Logistic Models; Longevity; Male; Middle Aged; Morpholines; Orthopedic Procedures; Polysaccharides; Postoperative Hemorrhage; Proportional Hazards Models; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2012 |
The in vitro anticoagulant effect of rivaroxaban in children.
Topics: Adolescent; Adult; Age Factors; Anticoagulants; Child; Child, Preschool; Factor Xa Inhibitors; Female; Humans; Infant; Infant, Newborn; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Young Adult | 2012 |
Pneumococcal vaccines; use of rivaroxaban for DVT and PE.
Topics: Anticoagulants; Humans; Morpholines; Pneumococcal Vaccines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis | 2012 |
Danger ahead: watch out for indirect comparisons!
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2012 |
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Embolism; Humans; Markov Chains; Models, Economic; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Establishing safe and effective antithrombotic therapy use in children.....finally.
Topics: Anticoagulants; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2012 |
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Calibration; Chromogenic Compounds; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Observer Variation; Predictive Value of Tests; Prothrombin Time; Reference Standards; Reproducibility of Results; Rivaroxaban; Thiophenes | 2012 |
Absence of both MDR1 (ABCB1) and breast cancer resistance protein (ABCG2) transporters significantly alters rivaroxaban disposition and central nervous system entry.
Topics: Administration, Oral; Animals; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Membrane Permeability; Central Nervous System; Humans; Male; Metabolic Clearance Rate; Mice; Mice, Knockout; Morpholines; Rivaroxaban; Substrate Specificity; Thiophenes; Tissue Distribution | 2013 |
Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Humans; Morpholines; Risk Assessment; Rivaroxaban; Thiophenes | 2012 |
Rivaroxaban in atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2012 |
[The ATLAS ACS 2-TIMI 51 study].
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Double-Blind Method; Factor Xa Inhibitors; Humans; Morpholines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2012 |
Rivaroxaban delivery and reversal at a venous flow rate.
Topics: Administration, Oral; Anticoagulants; Blood Flow Velocity; Dose-Response Relationship, Drug; Factor V; Factor Va; Factor Xa; Humans; Models, Biological; Morpholines; Regional Blood Flow; Risk Factors; Rivaroxaban; Thiophenes; Thromboplastin; Venous Thrombosis | 2012 |
Rivaroxaban and other novel anticoagulants for stroke prevention in atrial fibrillation: time to embrace the future.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Forecasting; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2013 |
Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Disease Models, Animal; Factor Xa Inhibitors; Femoral Artery; Lipids; Male; Morpholines; Plaque, Atherosclerotic; Prothrombin Time; Rabbits; Rivaroxaban; Thiophenes; Thrombosis | 2012 |
Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Blood Viscosity; Data Interpretation, Statistical; Factor Xa Inhibitors; Humans; In Vitro Techniques; Male; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; ROC Curve; Thiophenes; Thrombelastography | 2012 |
Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; United States; Warfarin | 2013 |
EINSTEIN-PE study results, with South African expert comment.
Topics: Anticoagulants; Clinical Trials as Topic; Humans; Morpholines; Rivaroxaban; South Africa; Thiophenes | 2012 |
Effects of rivaroxaban, acetylsalicylic acid and clopidogrel as monotherapy and in combination in a porcine model of stent thrombosis.
Topics: Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Morpholines; Platelet Aggregation; Rivaroxaban; Stents; Swine; Swine, Miniature; Thiophenes; Thrombosis; Ticlopidine | 2012 |
Periprocedural anticoagulant management.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Restenosis; Dabigatran; Heart Valve Prosthesis; Hemorrhage; Humans; Morpholines; Neoplasms; Perioperative Care; Risk Assessment; Rivaroxaban; Stents; Thiophenes; Venous Thromboembolism; Warfarin | 2012 |
The new oral anticoagulants: a challenge for hospital formularies.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Formularies, Hospital as Topic; Humans; Morpholines; Pennsylvania; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Topics: Anticoagulants; Blood Chemical Analysis; Blood Coagulation Tests; Blood Donors; Calibration; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombin | 2012 |
Increase in referrals.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Creatinine; Dabigatran; Dental Service, Hospital; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Referral and Consultation; Rivaroxaban; Thiophenes; Tooth Extraction | 2012 |
[Role of new oral anticoagulants in interventional cardiology].
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Cardiac Surgical Procedures; Cardiology; Dabigatran; Humans; Morpholines; Percutaneous Coronary Intervention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome | 2012 |
Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy.
Topics: Adolescent; Anticoagulants; Capillaries; Chronic Disease; Factor Xa Inhibitors; Female; Humans; Infarction; Livedo Reticularis; Morpholines; Rivaroxaban; Skin; Thiophenes; Young Adult | 2013 |
Rivaroxaban in acute coronary syndromes and atrial fibrillation: rivaroxaban shown to reduce cardiovascular deaths in STEMI patients.
Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Electrocardiography; Expert Testimony; Humans; Morpholines; Myocardial Infarction; Practice Guidelines as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2012 |
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Topics: Anticoagulants; Arthroplasty, Replacement, Ankle; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic; Enoxaparin; Hemarthrosis; Hemorrhage; Humans; Morpholines; Postoperative Complications; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
[Risk of bleeding and haemorrhagic complication with rivaroxaban--periprocedural management of haemostasis].
Topics: Anticoagulants; Contraindications; Hemostasis; Humans; Morpholines; Postoperative Hemorrhage; Rivaroxaban; Thiophenes | 2012 |
[Introduction].
Topics: Acenocoumarol; Anticoagulants; Benzamides; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Thrombosis; Warfarin | 2012 |
[New advances in anticoagulation: is it time to forget about heparin and vitamin K antagonists? Yes].
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Warfarin | 2012 |
[Questions--answers on the use of rivaroxaban for the treatment of venous thromboembolic disease].
Topics: Age Factors; Anticoagulants; Drug Interactions; Factor Xa; France; Hemorrhage; Humans; Morpholines; Pulmonary Embolism; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Vitamins | 2012 |
[Rivaroxaban versus warfarin: results of the ROCKET study].
Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Humans; Morpholines; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Renal Insufficiency; Rivaroxaban; Secondary Prevention; Severity of Illness Index; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2012 |
Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials, Phase III as Topic; Comparative Effectiveness Research; Dabigatran; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Morpholines; Pharmacovigilance; Primary Prevention; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2012 |
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Chromatography, High Pressure Liquid; Chromogenic Compounds; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Factor Xa; Factor Xa Inhibitors; False Positive Reactions; Humans; Morpholines; Nephelometry and Turbidimetry; Predictive Value of Tests; Reproducibility of Results; Rivaroxaban; Tablets; Tandem Mass Spectrometry; Thiophenes; Thrombophilia; Thrombosis; Time Factors; Treatment Outcome | 2013 |
New oral anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Canada; Contraindications; Dabigatran; Drug Dosage Calculations; Drug Interactions; Humans; Morpholines; Postoperative Complications; Pyridines; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2013 |
Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.
Topics: Anticoagulants; Biological Assay; Blood Coagulation; Factor Xa Inhibitors; Fondaparinux; Humans; Kinetics; Morpholines; Partial Thromboplastin Time; Polysaccharides; Rivaroxaban; Thiophenes; Thromboplastin; Time Factors | 2013 |
Optimal initial anticoagulant therapy in pulmonary thromboembolism: randomized trial suggested.
Topics: Anticoagulants; Drug Administration Schedule; Humans; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes | 2013 |
Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban.
Topics: Adult; Anticoagulants; Edema; Enoxaparin; Humans; Iliac Vein; Incidental Findings; Male; Morpholines; Rivaroxaban; Thiophenes; Tomography, X-Ray Computed; Travel; Vena Cava, Inferior; Venous Thrombosis; Warfarin; Young Adult | 2012 |
A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Drug Hypersensitivity; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2013 |
[New anticoagulants: better knowledge, better prescriptions].
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2012 |
Simplifying venous thromboembolism management: a new and safer era.
Topics: Anticoagulants; Clinical Trials as Topic; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; South Africa; Thiophenes; Thrombectomy; Venous Thromboembolism | 2012 |
[Management of intracranial hemorrhage during anticoagulant therapy with warfarin or novel anticoagulants].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cerebral Hemorrhage; Dabigatran; Humans; Intracranial Embolism; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Fibrinolytic Agents; Germany; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Kaplan-Meier Estimate; Length of Stay; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome; Venous Thrombosis | 2013 |
Margins.
Topics: Anticoagulants; HIV Reverse Transcriptase; Humans; Morpholines; Nitriles; Pyrimidines; Rilpivirine; Rivaroxaban; Thiophenes | 2012 |
Rivaroxaban and atrial fibrillation: continue to use warfarin or in some cases, dabigatran.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Factor Xa Inhibitors; Humans; Kidney; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2012 |
[Impact of ivaroxaban on hidden blood loss and blood transfusion rate after primary total knee arthroplasty].
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Transfusion; Female; Hemoglobins; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Knee; Postoperative Complications; Postoperative Hemorrhage; Range of Motion, Articular; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2012 |
Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Chemistry Tests; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Point-of-Care Systems; Pregnancy; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
Repeated bleeding complications during therapy with vitamin K antagonists in a patient with the VKORC1*2A and the CYP2C9*3/*3 alleles: genetic testing to support switching to new oral anticoagulants.
Topics: Administration, Oral; Adult; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Exons; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Haplotypes; Hemorrhage; Humans; Hypertension; Mixed Function Oxygenases; Morpholines; Mutation; Poland; Rivaroxaban; Thiophenes; Vitamin K; Vitamin K Epoxide Reductases; Warfarin | 2013 |
Normal prothrombin time in the presence of therapeutic levels of rivaroxaban.
Topics: Aged; Anticoagulants; Humans; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Transitions of care in anticoagulation management for patients with atrial fibrillation.
Topics: Administration, Oral; Aftercare; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Continuity of Patient Care; Dabigatran; Drug Monitoring; Drug Substitution; Emergencies; Hemorrhage; Humans; Morpholines; Patient Education as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2012 |
Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Topics: Anticoagulants; Blood; Blood Coagulation; Blood Platelets; Erythrocytes; Factor XIII; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Humans; Morpholines; Permeability; Plasma; Risk Factors; Rivaroxaban; Thiophenes; Thrombin; Thrombolytic Therapy; Thromboplastin; Thrombosis; Time Factors | 2013 |
"R" for "renal" and for "risk": refining risk stratification for stroke in atrial fibrillation.
Topics: Atrial Fibrillation; Embolism; Factor Xa; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2.
Topics: Alkaline Phosphatase; Anticoagulants; Cell Line; Cell Proliferation; Creatine Kinase; DNA; Enzyme Activation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Factor Xa; Factor Xa Inhibitors; Female; Genistein; Ginsenosides; Humans; Isoflavones; Morpholines; Nitriles; Osteoblasts; Osteogenesis; Parathyroid Hormone; Rivaroxaban; RNA, Messenger; Sapogenins; Thiophenes; Vitamin D | 2013 |
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Primary Prevention; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban.
Topics: Animals; Anticoagulants; Blood Coagulation Factors; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Factor VIIa; Hematoma; Hemostatic Techniques; Male; Mice; Mice, Inbred C57BL; Models, Animal; Morpholines; Plasma; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Resolution of giant left atrial appendage thrombus with rivaroxaban.
Topics: Anticoagulants; Atrial Appendage; Echocardiography, Three-Dimensional; Echocardiography, Transesophageal; Heart Diseases; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Reconsideration of anticoagulant therapy in Japanese patients with atrial fibrillation and moderate renal impairment.
Topics: Anticoagulants; Asian People; Atrial Fibrillation; Female; Humans; Male; Morpholines; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes | 2013 |
Laboratory assessment of novel oral anticoagulants: method suitability and variability between coagulation laboratories.
Topics: Administration, Oral; Analysis of Variance; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Humans; International Normalized Ratio; Laboratories; Morpholines; Partial Thromboplastin Time; Reproducibility of Results; Rivaroxaban; Thiophenes | 2013 |
Discontinuation of rivaroxaban: filling in the gaps.
Topics: Atrial Fibrillation; Blood Coagulation; Female; Humans; Male; Morpholines; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
Which test to use to measure the anticoagulant effect of rivaroxaban: the anti-factor Xa assay.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.
Topics: Anticoagulants; Humans; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban prophylaxis too risky for medical inpatients.
Topics: Aged; Anticoagulants; Case-Control Studies; Female; Humans; Inpatients; Length of Stay; Male; Morpholines; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemoprevention; Elective Surgical Procedures; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Hip; Osteoarthritis, Knee; Outcome and Process Assessment, Health Care; Postoperative Complications; Rivaroxaban; Thiophenes; United Kingdom; Venous Thromboembolism; Wound Healing | 2013 |
Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.
Topics: Adult; Anticoagulants; Bariatric Surgery; Female; Humans; International Normalized Ratio; Morpholines; Obesity, Morbid; Rivaroxaban; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
[New anticoagulants--should we have a little bit of cold water in the blood?].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2013 |
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Topics: Animals; Anticoagulants; Antidotes; Benzamides; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fondaparinux; Hemorrhage; Hemostasis; Male; Mice; Mice, Inbred C57BL; Morpholines; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rabbits; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Rivaroxaban; Thiophenes | 2013 |
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombin; Thrombin Time | 2013 |
Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Comorbidity; Dabigatran; Hemorrhage; Humans; Morpholines; Platelet Aggregation Inhibitors; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Warfarin replacements: good for patients, challenging for laboratories.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Humans; Laboratories; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban modulates electrical and mechanical characteristics of left atrium.
Topics: Action Potentials; Animals; Atrial Fibrillation; Calcium; Heart Atria; Humans; Ion Transport; Male; Microelectrodes; Morpholines; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Pulmonary Veins; Rabbits; Rivaroxaban; Thiophenes | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Venous thromboembolism: prophylactic and therapeutic practice guideline.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chemoprevention; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Monitoring; Drug Substitution; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Morpholines; Preoperative Care; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Vena Cava Filters; Venous Thromboembolism | 2013 |
Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Humans; Markov Chains; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2013 |
The use of rivaroxaban for chemical thromboprophylaxis following total knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Case-Control Studies; Female; Follow-Up Studies; Humans; Middle Aged; Morpholines; Postoperative Complications; Primary Prevention; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Rivaroxaban; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2013 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
April editorial.
Topics: Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
Topics: Anticoagulants; Area Under Curve; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Calibration; Fibrinolytic Agents; Humans; Morpholines; Plasma; Prothrombin; Prothrombin Time; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Time Factors; Vitamin K | 2013 |
Successful treatment of a patient with chronic thromboembolic pulmonary hypertension with rivaroxaban.
Topics: Adult; Anticoagulants; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
[Stroke prevention in atrial fibrillation : old and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K | 2013 |
Laboratory testing for the new oral anticoagulants: a review of current practice.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Factor X; Humans; Morpholines; Rivaroxaban; Surveys and Questionnaires; Thiophenes | 2013 |
Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
Topics: Animals; Anticoagulants; Bleeding Time; Blood Coagulation; Blood Coagulation Factors; Factor VIIa; Humans; Male; Morpholines; Primates; Prothrombin Time; Rats; Rats, Wistar; Recombinant Proteins; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[Rivaroxaban: Xarelto--recommendations for pharmacists].
Topics: Anticoagulants; Humans; Morpholines; Pharmacists; Rivaroxaban; Thiophenes; Venous Thrombosis; Vitamin K | 2013 |
New approaches to reversing oral anticoagulant therapy. Introduction.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Plasma; Primary Prevention; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1 | 2013 |
Pharmacologic interventions for reversing the effects of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Blood Loss, Surgical; Dabigatran; Drug Therapy, Combination; Emergencies; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Plasma; Pyrazoles; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Thromboembolism; Treatment Outcome; Vitamin K 1; Warfarin | 2013 |
Cerebral hemorrhage under rivaroxaban.
Topics: Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Female; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Anticoagulant guidelines.
Topics: Anticoagulants; Benzimidazoles; Coumarins; Dabigatran; Dental Care for Chronically Ill; Hemostatic Techniques; Humans; Interprofessional Relations; Morpholines; Oral Hemorrhage; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyridines; Rivaroxaban; Thiophenes | 2013 |
Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model.
Topics: Acenocoumarol; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Humans; Microscopy, Electron, Transmission; Morpholines; Rivaroxaban; Thiophenes; Vitamin K; Warfarin | 2013 |
Conventional and new oral anticoagulants in the treatment of chest disease and its complications.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Practice Guidelines as Topic; Prognosis; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Vitamin K | 2013 |
TB-402 for the prevention of venous thromboembolism in orthopaedic surgery: something new and promising, or not?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Hip; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Venous thromboembolism. Currently it is worthwhile to use anticoagulants longer].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Long-Term Care; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Secondary Prevention; Thiophenes; Venous Thromboembolism | 2013 |
Procoagulants for management of bleeding with the new oral anticoagulants.
Topics: Animals; Anticoagulants; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[New oral anticoagulants and digestive hemorrhages].
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
The direct factor Xa inhibitor Rivaroxaban reduces platelet activation in congestive heart failure.
Topics: Animals; Anticoagulants; Factor Xa Inhibitors; Heart Failure; Humans; Male; Morpholines; Platelet Activation; Platelet Aggregation; Rats; Rats, Wistar; Rivaroxaban; Thiophenes | 2013 |
[Comparison of effects of two anticoagulants on hidden blood loss after total hip arthroplasty].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Blood Volume; Enoxaparin; Female; Femur Head Necrosis; Humans; Injections, Subcutaneous; Male; Middle Aged; Morpholines; Postoperative Complications; Postoperative Hemorrhage; Retrospective Studies; Rivaroxaban; Thiophenes; Young Adult | 2013 |
Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid.
Topics: Bile Acids and Salts; Body Fluids; Furosemide; Gastrointestinal Contents; Hydrogen-Ion Concentration; Intestines; Lipids; Micelles; Morpholines; Niflumic Acid; Papaverine; Rivaroxaban; Solubility; Thiophenes | 2013 |
Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2013 |
Contra: "New oral anticoagulants should not be used as 1st choice for secondary stroke prevention in atrial fibrillation".
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Middle Aged; Morpholines; Patient Safety; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Pro: "The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.".
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Diabetes Complications; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Warfarin | 2013 |
Perioperative management of patients who are receiving a novel oral anticoagulant.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Perioperative Care; Postoperative Complications; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
[New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Measurement and reversal of prophylactic and therapeutic peak levels of rivaroxaban: an in vitro study.
Topics: Adult; Blood Coagulation Factors; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombelastography | 2014 |
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
Topics: Calibration; Chromatography, Liquid; Chromogenic Compounds; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2013 |
Successful treatment of acute portal vein thrombosis with rivaroxaban.
Topics: Acute Disease; Anticoagulants; Disease-Free Survival; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Neovascularization, Physiologic; Portal Vein; Recovery of Function; Regional Blood Flow; Rivaroxaban; Thiophenes; Ultrasonography, Doppler, Duplex; Venous Thrombosis | 2013 |
[Comparison of the therapeutic effect of the Warfarin and Rivaroksaban among the patients with not-valuate fibrillation of atrium].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost Savings; Cost-Benefit Analysis; Dabigatran; Drug Costs; Drug Utilization; Female; Humans; Male; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Severity of Illness Index; Stroke; Thiophenes; United States; Warfarin | 2013 |
[New oral anticoagulants in the treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
Investigation of the effects of Enoxaparin, Fondaparinux, and Rivaroxaban used in thromboembolism prophylaxis on fracture healing in rats.
Topics: Animals; Enoxaparin; Femoral Fractures; Fibrinolytic Agents; Fondaparinux; Fracture Healing; Male; Morpholines; Polysaccharides; Rats; Rats, Sprague-Dawley; Rivaroxaban; Thiophenes; Thromboembolism; Tomography, X-Ray Computed | 2013 |
[Questions and answers regarding the use of rivaroxaban in daily practice].
Topics: Administration, Oral; Anticoagulants; General Practice; Humans; Morpholines; Orthopedic Procedures; Rivaroxaban; Switzerland; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2013 |
[Thromboprophylaxis in medical patients: Which modifications with the new oral anticoagulants?].
Topics: Administration, Oral; Anticoagulants; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism | 2013 |
Anticoagulation with a new oral anticoagulant in heart transplant recipients.
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Female; Heart Transplantation; Humans; Middle Aged; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Data Collection; Female; Hemorrhage; Humans; Male; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Thiophenes | 2013 |
Should the newer oral anticoagulants be withheld from patients with valvular AF?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; International Normalized Ratio; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
The promise of pharmacoepidemiology in helping clinicians assess drug risk.
Topics: Administration, Oral; Advertising; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Confounding Factors, Epidemiologic; Dabigatran; Decision Making; Evidence-Based Medicine; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pharmacoepidemiology; Product Surveillance, Postmarketing; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Rivaroxaban; Therapeutic Equivalency; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2013 |
[Differential therapy with the new anticoagulants, 5].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Drug Interactions; Germany; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2013 |
New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2013 |
New oral anticoagulants and risks in ENT.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Otolaryngology; Rivaroxaban; Thiophenes | 2013 |
The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2013 |
Management of disseminated intravascular coagulopathy with direct factor Xa inhibitor rivaroxaban in Klippel-Trénaunay syndrome.
Topics: Adolescent; Anticoagulants; Disseminated Intravascular Coagulation; Factor Xa; Humans; Klippel-Trenaunay-Weber Syndrome; Male; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting.
Topics: Anticoagulants; Atrial Fibrillation; Belgium; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Humans; Markov Chains; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; China; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Models, Economic; Morpholines; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Ticlopidine; Warfarin | 2014 |
A comparison of methods for estimating glomerular filtration rate for a population in Hawai'i with non-valvular atrial fibrillation.
Topics: Aged, 80 and over; Anticoagulants; Arginine; Asian People; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Glomerular Filtration Rate; Hawaii; Humans; Male; Morpholines; Pipecolic Acids; Retrospective Studies; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2013 |
Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Topics: Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dogs; Dose-Response Relationship, Drug; Female; Male; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes | 2013 |
Percutaneous left atrial appendage occlusion with a Watchman device following recurrent stroke on warfarin and rivaroxaban in patient with paroxysmal atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiac Catheterization; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
[Critical haematuria after prostate biopsies with RIVAROXABAN. Case report].
Topics: Anticoagulants; Biopsy; Critical Illness; Hematuria; Humans; Male; Morpholines; Prostate; Rivaroxaban; Thiophenes | 2013 |
Safe-dose thrombolysis plus rivaroxaban for moderate and severe pulmonary embolism: drip, drug, and discharge.
Topics: Administration, Oral; Aged; Drug Administration Schedule; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Morpholines; Patient Discharge; Pulmonary Embolism; Recurrence; Risk Factors; Rivaroxaban; Severity of Illness Index; Thiophenes; Thrombolytic Therapy; Time Factors; Treatment Outcome | 2014 |
Anticoagulation without monitoring.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Hemorrhage; Heparin; Humans; Morpholines; Pharmacovigilance; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2013 |
Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Utilization; Female; Humans; Male; Middle Aged; Morpholines; Practice Patterns, Physicians'; Rivaroxaban; Spain; Thiophenes | 2014 |
Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Drug Costs; Factor Xa Inhibitors; Health Care Costs; Humans; Italy; Markov Chains; Morpholines; Pyrazoles; Pyridones; Quality of Life; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Topics: Anticoagulants; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Morpholines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulant treatment with rivaroxaban in severe protein S deficiency.
Topics: Anticoagulants; Child; Factor Xa Inhibitors; Female; Humans; Morpholines; Protein S Deficiency; Rivaroxaban; Severity of Illness Index; Thiophenes; Treatment Outcome | 2013 |
Phamacokinetics of rivaroxaban in adolescents.
Topics: Adolescent; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Metabolic Clearance Rate; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; Humans; Markov Chains; Middle Aged; Morpholines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Vitamin K | 2014 |
[New direct oral anticoagulants and venous thromboprophylaxis].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Initial experience with rivaroxaban in mechanical valve prosthesis in an animal model.
Topics: Animals; Factor Xa Inhibitors; Heart Valve Prosthesis Implantation; Male; Morpholines; Rivaroxaban; Thiophenes; Thromboembolism; Transplantation, Heterotopic | 2014 |
Stroke and urosepsis after discontinuation of rivaroxaban.
Topics: Aged, 80 and over; Anticoagulants; Humans; Male; Morpholines; Rivaroxaban; Sepsis; Stroke; Thiophenes; Urinary Tract Infections | 2013 |
Dissolution of the left atrial appendage thrombus with rivaroxaban therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thrombosis; Treatment Outcome | 2013 |
Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment.
Topics: Administration, Intravenous; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Contraindications; Endovascular Procedures; Female; Fibrinolytic Agents; Humans; Ischemia; Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation.
Topics: Administration, Oral; Adult; Disseminated Intravascular Coagulation; Factor Xa Inhibitors; Fibrin Fibrinogen Degradation Products; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vascular Malformations | 2014 |
Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Diagnostic Tests, Routine; Drug Monitoring; Factor Xa Inhibitors; False Negative Reactions; Female; Fondaparinux; Heparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Prothrombin; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombophilia | 2013 |
Correlating prothrombin time with plasma rivaroxaban level.
Topics: Blood Coagulation; Calibration; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Patient Compliance; Prothrombin Time; Rivaroxaban; Sensitivity and Specificity; Thiophenes | 2013 |
Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Costs and Cost Analysis; Dabigatran; Female; Germany; Humans; Male; Models, Econometric; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes | 2014 |
Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Models, Statistical; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; United States; Warfarin | 2013 |
[Prevention and therapy of thromboembolism: rivaroxaban - better outcome - risk profile as standard therapy].
Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Drug Substitution; Factor Xa Inhibitors; Humans; Morpholines; Phenprocoumon; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; Dabigatran; Emergency Service, Hospital; Humans; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thrombosis | 2013 |
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Topics: Aged; Anticoagulants; Atrial Fibrillation; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Investigation of the antiangiogenic behaviors of rivaroxaban and low molecular weight heparins.
Topics: Angiogenesis Inhibitors; Animals; Anticoagulants; Chick Embryo; Chorioallantoic Membrane; Enoxaparin; Heparin, Low-Molecular-Weight; Morpholines; Neovascularization, Physiologic; Rivaroxaban; Thiophenes; Tinzaparin | 2014 |
Inaccuracy of point-of-care international normalized ratio in rivaroxaban-treated patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Humans; International Normalized Ratio; Male; Morpholines; Point-of-Care Systems; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis | 2013 |
Atrial fibrillation and prior MI: searching for balance in ischaemic and bleeding events in patients treated with factor-specific anticoagulants.
Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[How to properly use warfarin and new anticoagulants].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Humans; International Normalized Ratio; Morpholines; Practice Guidelines as Topic; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2013 |
Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban.
Topics: Accidental Falls; Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Coma; Female; Glasgow Coma Scale; Hematoma, Subdural; Humans; Morpholines; Rivaroxaban; Thiophenes; Ultrasonography, Doppler, Transcranial | 2014 |
Lysis of thrombus located in the left atrial appendage. Is it the right time for a Xa factor inhibitor?
Topics: Aged; Anticoagulants; Atrial Appendage; Factor Xa Inhibitors; Female; Heart Diseases; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Tomography, X-Ray Computed; Vitamin K | 2013 |
New oral anticoagulants: their role and future.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
Topics: Animals; Factor Xa Inhibitors; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Male; Morpholines; Rivaroxaban; Swine; Thiophenes; Thromboembolism; Transplantation, Heterotopic | 2014 |
[Experience with rivaroxaban and dabigatran].
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Morpholines; Protein C Deficiency; Rivaroxaban; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Topics: Animals; Anticoagulants; Blood-Brain Barrier; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Morpholines; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Time Factors | 2014 |
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus.
Topics: Animals; Anticoagulants; Blood Coagulation; Cell Adhesion; Diabetes Mellitus, Type 2; Factor Xa Inhibitors; Female; Leukocytes; Mice; Microvessels; Morpholines; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Automation, Laboratory; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Equipment and Supplies; Factor VII; Hemorrhage; Humans; Morpholines; Postoperative Complications; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombin; Thrombin Time; Venous Thrombosis; Withholding Treatment | 2014 |
[Pulmonary embolism due to interaction between rivaroxaban and carbamazepine].
Topics: Anticoagulants; Anticonvulsants; Arthroplasty, Replacement, Knee; Carbamazepine; Drug Interactions; Epilepsy; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2013 |
How I treat target-specific oral anticoagulant-associated bleeding.
Topics: Administration, Oral; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Dabigatran; Drug Monitoring; Factor VIIa; Hemorrhage; Hemostatics; Humans; Morpholines; Pyrazoles; Pyridones; Recombinant Proteins; Renal Dialysis; Rivaroxaban; Thiophenes | 2014 |
Treatment of acute portal vein thrombosis by nontraditional anticoagulation.
Topics: Acute Disease; Anticoagulants; Drug Administration Schedule; Humans; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Rivaroxaban; Thiophenes; Tomography, X-Ray Computed; Venous Thrombosis | 2014 |
Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests.
Topics: Anticoagulants; Arginine; Artifacts; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Fondaparinux; Humans; Morpholines; Pipecolic Acids; Platelet Function Tests; Point-of-Care Systems; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombelastography; Whole Blood Coagulation Time | 2014 |
Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Perioperative Period; Postoperative Complications; Prospective Studies; Registries; Rivaroxaban; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
The in-vitro anticoagulant effect of rivaroxaban in neonates.
Topics: Age Factors; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Female; Humans; Infant, Newborn; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
New oral anticoagulants for acute venous thromboembolism.
Topics: Acute Disease; Anticoagulants; Benzimidazoles; Dabigatran; Drug Approval; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke.
Topics: Aged; Anticoagulants; Blood Coagulation; Factor XI; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombelastography; Thrombolytic Therapy | 2014 |
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Bone Marrow Transplantation; Dabigatran; Disease Models, Animal; Factor Xa; Factor Xa Inhibitors; Female; Immunoenzyme Techniques; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Receptor, PAR-1; Receptor, PAR-2; Rivaroxaban; Thiophenes; Thrombin; Vascular Diseases | 2014 |
Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus.
Topics: Ankle Fractures; Anticoagulants; Darunavir; Drug Interactions; Gastrointestinal Hemorrhage; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Morpholines; Ritonavir; Rivaroxaban; Sulfonamides; Thiophenes | 2014 |
Treatment with novel oral anticoagulants in a real-world cohort of patients undergoing cardiac rhythm device implantations.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiac Pacing, Artificial; Dabigatran; Defibrillators, Implantable; Electric Countershock; Female; Germany; Hematoma; Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Pacemaker, Artificial; Prospective Studies; Prosthesis Design; Prosthesis Implantation; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.
Topics: Aged; Antibiotics, Antitubercular; Anticoagulants; Atrial Fibrillation; Ciprofloxacin; Coronary Artery Bypass; Drug Incompatibility; Female; Humans; Morpholines; Rifampin; Rivaroxaban; Thiophenes | 2014 |
Comparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber model.
Topics: Adenosine Triphosphate; Adult; Anticoagulants; Antithrombins; Aspirin; Benzimidazoles; beta-Alanine; Blood Platelets; Dabigatran; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Female; Fibrin; Humans; Lab-On-A-Chip Devices; Male; Microscopy, Confocal; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Rivaroxaban; Thiophenes; Thrombin; Thromboplastin; Thrombosis | 2014 |
Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.
Topics: Anticoagulants; China; Female; Health Care Costs; Heparin, Low-Molecular-Weight; Hospitalization; Humans; International Normalized Ratio; Logistic Models; Male; Middle Aged; Morpholines; Pulmonary Embolism; Retrospective Studies; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2014 |
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Dabigatran; Female; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Male; Middle Aged; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes; Thrombin | 2014 |
PROS1 mutations associated with protein S deficiency in Polish patients with residual vein obstruction on rivaroxaban therapy.
Topics: Adolescent; Adult; Blood Proteins; Female; Humans; Male; Morpholines; Mutation; Poland; Protein S; Protein S Deficiency; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Humans; Markov Chains; Models, Economic; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2014 |
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Drug Interactions; Factor VIIa; Humans; Morpholines; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin | 2014 |
Design of the rivaroxaban for heparin-induced thrombocytopenia study.
Topics: Anticoagulants; Cohort Studies; Factor Xa Inhibitors; Heparin; Humans; Morpholines; Prospective Studies; Research Design; Rivaroxaban; Thiophenes; Thrombocytopenia | 2014 |
Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Prescriptions; Drug Utilization Review; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Portugal; Practice Patterns, Physicians'; Prospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Venous gangrene and intravascular coagulation and fibrinolysis in a patient treated with rivaroxaban.
Topics: Aged; Anticoagulants; Blood Coagulation; Female; Fibrinolysis; Gangrene; Humans; Lower Extremity; Morpholines; Neoplasms; Rivaroxaban; Thiophenes; Veins; Venous Thrombosis | 2014 |
Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Atrial Flutter; Benzimidazoles; beta-Alanine; Dabigatran; Dose-Response Relationship, Drug; Echocardiography, Transesophageal; Electric Countershock; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Morpholines; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome | 2014 |
Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
Topics: Anticoagulants; Cohort Studies; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Morpholines; Rivaroxaban; Thiophenes; United States; Venous Thromboembolism | 2014 |
Rivaroxaban-induced epidural hematoma and cauda equina syndrome after total knee arthroplasty: a case report.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Female; Hematoma, Epidural, Spinal; Humans; Middle Aged; Morpholines; Polyradiculopathy; Reoperation; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
At least two!
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Anticoagulants; Bevacizumab; Humans; Morpholines; Rivaroxaban; Thiophenes | 2013 |
Rivaroxaban and pulmonary embolism: no better than established anticoagulant therapy.
Topics: Anticoagulants; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2013 |
Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy.
Topics: Aged; Anticoagulants; Brain; Cerebral Hemorrhage; Fatal Outcome; Female; Hematoma, Subdural, Intracranial; Humans; Morpholines; Neuroimaging; Rivaroxaban; Stroke; Thiophenes; Tomography, X-Ray Computed | 2014 |
Spontaneus splenic rupture in a patient treated with rivaroxaban.
Topics: Abdominal Pain; Aged; Anticoagulants; Atrial Fibrillation; Emergency Service, Hospital; Humans; Male; Morpholines; Rivaroxaban; Rupture, Spontaneous; Shock, Hemorrhagic; Splenic Diseases; Stroke; Thiophenes | 2014 |
Protein S deficiency and novel oral anticoagulants: an intriguing case.
Topics: Blood Proteins; Female; Humans; Male; Morpholines; Protein S; Protein S Deficiency; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation.
Topics: Aged; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Pulmonary Veins; Retrospective Studies; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin; Young Adult | 2014 |
Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Drug Monitoring; Female; Humans; Male; Middle Aged; Morpholines; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thromboplastin | 2014 |
Rivaroxaban postmarketing risk of liver injury.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Product Surveillance, Postmarketing; Risk; Rivaroxaban; Thiophenes | 2014 |
[Comparison of rivaroxaban and enoxaparin on blood loss after total knee arthroplasty].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Blood Volume; Enoxaparin; Female; Humans; Male; Middle Aged; Morpholines; Osteoarthritis, Knee; Postoperative Complications; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Chromatography, Liquid; Dabigatran; Humans; Mass Spectrometry; Molecular Structure; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2014 |
Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome.
Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Biological Availability; Blood Coagulation; Dabigatran; Drug Monitoring; Drug Substitution; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Intestinal Absorption; Morpholines; Predictive Value of Tests; Pyridines; Risk Factors; Rivaroxaban; Short Bowel Syndrome; Thiophenes; Treatment Outcome | 2014 |
Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Registries; Rivaroxaban; Thiophenes; Vitamin K | 2014 |
Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Patient Selection; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome; Venous Thromboembolism | 2014 |
Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Support Techniques; Humans; Markov Chains; Models, Statistical; Morpholines; Norway; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Reduced smoke-like echo and resolved thrombus in the left atrium with rivaroxaban therapy in an acute cardioembolic stroke patient.
Topics: Aged; Echocardiography, Transesophageal; Embolism; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombosis; Treatment Outcome | 2014 |
Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Effects of enoxaparin and rivaroxaban on tissue survival in skin degloving injury: an experimental study.
Topics: Animals; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; Inflammation; Male; Morpholines; Necrosis; Rats; Rats, Sprague-Dawley; Rivaroxaban; Skin; Soft Tissue Injuries; Thiophenes; Tissue Survival; Trauma Severity Indices; Treatment Outcome | 2014 |
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Databases, Factual; Female; Hospital Costs; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Morpholines; Propensity Score; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin; Young Adult | 2014 |
Stroke prevention in Asian patients with atrial fibrillation.
Topics: Anticoagulants; Asian People; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Blood Platelets; Enzyme-Linked Immunosorbent Assay; Factor Xa Inhibitors; Humans; Male; Morpholines; Plasma; Platelet Count; Protein C; Prothrombin; Rats; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Thrombomodulin; Thrombophilia; Thromboplastin | 2014 |
Patient-reported compliance with thromboprophylaxis using an oral factor Xa inhibitor (rivaroxaban) following total hip and total knee arthroplasty.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Factor Xa; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Morpholines; Patient Compliance; Prospective Studies; Risk Factors; Rivaroxaban; Surveys and Questionnaires; Thiophenes; Treatment Outcome; Young Adult | 2014 |
A cost-analysis model for anticoagulant treatment in the hospital setting.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Factor Xa Inhibitors; Humans; Inpatients; Length of Stay; Models, Economic; Morpholines; Pulmonary Embolism; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Warfarin | 2014 |
Triple antithrombotic therapy: risky but sometimes necessary.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Ticlopidine; Vitamin K | 2014 |
Perioperative management of patients on new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin | 2014 |
Pseudo-ventricular tachycardia mimicking malignant arrhythmia in a patient with rapid atrial fibrillation.
Topics: Adrenergic beta-1 Receptor Antagonists; Artifacts; Atrial Fibrillation; Bisoprolol; Diagnosis, Differential; Diagnostic Errors; Electrocardiography; Factor Xa Inhibitors; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Tachycardia, Ventricular; Thiophenes; Treatment Outcome; Unnecessary Procedures | 2014 |
Severe bleeding after jugular central venous line insertion in a patient under rivaroxaban.
Topics: Aged; Aged, 80 and over; Anticoagulants; Catheterization, Central Venous; Female; Hemorrhage; Humans; Jugular Veins; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Life-threatening haemorrhagic pericarditis associated with rivaroxaban.
Topics: Aged; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Morpholines; Pericarditis; Rivaroxaban; Thiophenes | 2014 |
Pulmonary haemorrhage from therapeutic rivaroxaban use: chest radiograph consolidation is not always infection!
Topics: Aged; Diagnosis, Differential; Factor Xa Inhibitors; Hemorrhage; Humans; Lung Diseases; Male; Morpholines; Pneumonia; Radiography; Rivaroxaban; Thiophenes | 2014 |
Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.
Topics: Administration, Oral; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Monitoring, Physiologic; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes; Thrombin Time | 2014 |
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
Topics: Aged, 80 and over; Brain Ischemia; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Male; Morpholines; Polypharmacy; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2014 |
Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Factor Xa Inhibitors; Female; France; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
New oral anticoagulants (NOAC) and liver injury.
Topics: Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
[Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Humans; Morpholines; Postoperative Hemorrhage; Premedication; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Urologic Surgical Procedures | 2014 |
Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Databases, Factual; Drug Utilization; Factor Xa Inhibitors; Female; Germany; Hospitals; Humans; Male; Middle Aged; Morpholines; Off-Label Use; Rivaroxaban; Thiophenes; Venous Thromboembolism; Young Adult | 2014 |
Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Drug Utilization Review; Factor Xa Inhibitors; Fees, Pharmaceutical; Female; Humans; Income; Male; Middle Aged; Morpholines; Multivariate Analysis; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Severity of Illness Index; Sex Factors; Stroke; Thiophenes; United States; Vitamin K; Warfarin; Young Adult | 2014 |
Direct oral anticoagulants (DOACs) versus "new" oral anticoagulants (NOACs)?
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Humans; Models, Molecular; Morpholines; Rivaroxaban; Terminology as Topic; Thiophenes; Vitamin K | 2014 |
Direct oral anticoagulants--pharmacology, drug interactions, and side effects.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Drug Monitoring; Half-Life; Hemorrhage; Humans; Kidney; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism | 2014 |
Direct oral anticoagulants in atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Direct oral anticoagulants in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Ischemia; Morpholines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2014 |
Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation.
Topics: Administration, Oral; Aged; Anticoagulants; Blood Coagulation Tests; Diagnosis, Differential; Diagnostic Errors; Emergency Medical Services; Female; Hemophilia A; Humans; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Atrial fibrillation and stroke prevention in aging patients: what's good can be even better.
Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2014 |
An observational case series of dabigatran and rivaroxaban exposures reported to a poison control system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; California; Child; Child, Preschool; Dabigatran; Drug Overdose; Female; Humans; Infant; Male; Middle Aged; Morpholines; Poison Control Centers; Prospective Studies; Retrospective Studies; Rivaroxaban; Thiophenes; Young Adult | 2014 |
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Databases, Factual; Female; Humans; Male; Medication Adherence; Middle Aged; Morpholines; Proportional Hazards Models; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; United States; Warfarin | 2014 |
Measurement of rivaroxaban and apixaban in serum samples of patients.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Biological Assay; Case-Control Studies; Chromogenic Compounds; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Rivaroxaban; Serum; Specimen Handling; Thiophenes; Thromboembolism | 2014 |
New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cytochrome P-450 CYP2C9; Dabigatran; Factor Xa Inhibitors; Genotype; Humans; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2014 |
New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation Tests; Blood Loss, Surgical; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Elective Surgical Procedures; Emergencies; Hematoma, Epidural, Spinal; Hemorrhage; Humans; Kidney Diseases; Liver Diseases; Morpholines; Patient Selection; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thrombophilia | 2014 |
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Meta-Analysis as Topic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Vitamin K; Warfarin | 2014 |
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.
Topics: Administration, Oral; Blood Coagulation; Calibration; Factor Xa; Factor Xa Inhibitors; False Positive Reactions; Healthy Volunteers; Humans; International Normalized Ratio; Lupus Coagulation Inhibitor; Morpholines; Partial Thromboplastin Time; Phospholipids; Protein C; Protein S; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes | 2014 |
Safety of continuous periprocedural rivaroxaban for patients undergoing left atrial catheter ablation procedures.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Chi-Square Distribution; Drug Administration Schedule; Female; Germany; Heart Atria; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Odds Ratio; Phenprocoumon; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Sex Factors; Thiophenes; Thromboembolism; Time Factors; Treatment Outcome | 2014 |
Thrombotic complications in heart failure: an underappreciated challenge.
Topics: Enoxaparin; Female; Heart Failure; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia.
Topics: Aged; Blood Coagulation; Factor Xa Inhibitors; Female; Heparin; Heparin Antagonists; Humans; Kidney Failure, Chronic; Male; Middle Aged; Morpholines; Peripheral Vascular Diseases; Platelet Count; Renal Dialysis; Rivaroxaban; Thiophenes; Thrombocytopenia; Venous Thrombosis | 2015 |
Resolution of left ventricular thrombus by rivaroxaban.
Topics: Aged; Dose-Response Relationship, Drug; Echocardiography; Factor Xa Inhibitors; Follow-Up Studies; Heart Diseases; Heart Ventricles; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombosis | 2014 |
Appropriateness of prescribing dabigatran etexilate and rivaroxaban in patients with nonvalvular atrial fibrillation: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Female; Hemorrhage; Humans; Inappropriate Prescribing; Male; Middle Aged; Morpholines; Prospective Studies; Pyridines; Rivaroxaban; Thiophenes | 2014 |
Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat.
Topics: Animals; Anticoagulants; Blood Coagulation; Brain; Brain Ischemia; Fibrinolytic Agents; Intracranial Hemorrhages; Male; Morpholines; Pyrazoles; Pyridones; Rats; Rats, Wistar; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy; Tissue Plasminogen Activator | 2014 |
Development of delayed cardiac tamponade 55 days after catheter ablation for atrial fibrillation with a new oral anticoagulant.
Topics: Aged; Atrial Fibrillation; Cardiac Tamponade; Catheter Ablation; Echocardiography, Doppler; Follow-Up Studies; Humans; Male; Morpholines; Pericardiocentesis; Pleural Effusion; Postoperative Complications; Rare Diseases; Rivaroxaban; Thiophenes; Time Factors; Treatment Outcome | 2014 |
Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A.
Topics: Aged; Anticoagulants; Cyclosporine; Drug Interactions; Drug Monitoring; Female; Hemorrhage; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Tacrolimus; Thiophenes | 2014 |
Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: a case report.
Topics: Aged; Anticoagulants; Aortic Aneurysm, Thoracic; Aortic Dissection; Disseminated Intravascular Coagulation; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
Thrombophilia testing, recurrent thrombosis, and women's health.
Topics: Adult; Aged; Anticoagulants; Female; Humans; Male; Mass Screening; Morpholines; Mutation; Prothrombin; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Thrombophilia; Treatment Outcome; Venous Thrombosis; Warfarin; Women's Health | 2014 |
Atrial fibrillation choices. Picking an anti-clotting drug.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Food-Drug Interactions; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
A case of rivaroxaban associated intracranial hemorrhage.
Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Fatal Outcome; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Prothrombin complex concentrate for non-vitamin K oral anticoagulant reversal: good enough for now?
Topics: Anticoagulants; Blood Coagulation Factors; Drug Combinations; Factor IX; Factor VII; Factor X; Female; Humans; Male; Morpholines; Prothrombin; Rivaroxaban; Thiophenes | 2014 |
Monitoring the anticoagulant effect after a massive rivaroxaban overdose.
Topics: Adult; Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Blood Coagulation Tests; Drug Monitoring; Drug Overdose; Factor Xa; Humans; International Normalized Ratio; Male; Morpholines; Prothrombin Time; Rivaroxaban; Thiophenes; Thromboembolism; Tranexamic Acid; Treatment Outcome | 2014 |
Effects of factor Xa on the expression of proteins in femoral arteries from type 2 diabetic patients.
Topics: Acetyl Coenzyme A; Aged; Carnitine O-Palmitoyltransferase; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Energy Metabolism; Factor Xa; Female; Femoral Artery; Glycolysis; Humans; Male; Mitochondria; Morpholines; Oxidative Stress; Rivaroxaban; Thiophenes | 2014 |
[Treatment of acute deep vein thrombosis with new oral anticoagulant rivaroxaban: the first experience].
Topics: Acute Disease; Adult; Aged; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Moscow; Prospective Studies; Rivaroxaban; Secondary Prevention; Thiophenes; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome.
Topics: Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2014 |
Treatment of atrial fibrillation.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Massive human rivaroxaban overdose.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Drug Overdose; Factor Xa; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Suicide, Attempted; Tandem Mass Spectrometry; Thiophenes; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Male; Morpholines; Pregnancy; Pregnancy Complications, Cardiovascular; Recurrence; Risk Factors; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Young Adult | 2014 |
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; United States; Venous Thrombosis; Vitamin K; Young Adult | 2014 |
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Hip; Humans; Male; Molecular Weight; Morpholines; Ontario; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2014 |
Novel factor xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients.
Topics: Adolescent; Adult; Aged; Anticoagulants; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Rivaroxaban; Sinus Thrombosis, Intracranial; Thiophenes; Treatment Outcome; Venous Thrombosis; Young Adult | 2014 |
Isolated hemopericardium associated with rivaroxaban: first case report.
Topics: Aged; Atrial Fibrillation; Chest Pain; Factor Xa Inhibitors; Humans; Male; Morpholines; Pericardial Effusion; Rivaroxaban; Thiophenes | 2014 |
Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Fees, Pharmaceutical; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Monte Carlo Method; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Hemorrhage; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Gaining experience with the NOACs.
Topics: Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2014 |
A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.
Topics: Chromatography, High Pressure Liquid; Factor Xa Inhibitors; Humans; Mass Spectrometry; Morpholines; Plasma; Rivaroxaban; Thiophenes | 2015 |
Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.
Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Hemorrhage; Hospitalization; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Anticlotting therapy for atrial fibrillation: should you stay with the devil you know? Preventing stroke with warfarin (Coumadin) can be tricky. New anticlotting drugs can help if you accept certain trade-offs--and take them exactly as directed.
Topics: Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Approval; Female; Fibrinolytic Agents; Humans; Male; Morpholines; Patient Education as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; United States; United States Food and Drug Administration; Warfarin | 2014 |
Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban.
Topics: Administration, Oral; Aged; Algorithms; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Combined Modality Therapy; Dabigatran; Female; Heparin; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Radio Waves; Rivaroxaban; Thiophenes; Thromboembolism; Warfarin | 2014 |
Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Benzimidazoles; beta-Alanine; Cerebral Infarction; Dabigatran; Drug Substitution; Female; Humans; International Normalized Ratio; Lupus Erythematosus, Systemic; Male; Mesenteric Veins; Middle Aged; Morpholines; Portal Vein; Recurrence; Retrospective Studies; Rivaroxaban; Splenic Vein; Stroke; Thiophenes; Thromboembolism; Thrombophilia; Treatment Failure; Venous Thrombosis; Warfarin | 2014 |
Intravenous thrombolysis in stroke patients receiving rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombolytic Therapy | 2014 |
Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Health Expenditures; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagulation Tests; Calibration; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Quality Control; Reference Values; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes | 2014 |
[The clinical analysis of atrial fibrillation of 1 310 in patients in Urumqi of China].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; China; Comorbidity; Diabetes Mellitus; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Hypertension; Incidence; Inpatients; Male; Morpholines; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
[New oral anticoagulants are as safe in elderly patients as conventional drugs].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Treatment Outcome | 2014 |
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin | 2014 |
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
Topics: Aged, 80 and over; Brain Ischemia; Cerebral Revascularization; Factor Xa Inhibitors; Female; Humans; Infarction, Middle Cerebral Artery; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombectomy; Tissue Plasminogen Activator | 2014 |
New oral anticoagulants in the management of venous thromboembolism: a major advance?
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles; Thiophenes; Venous Thromboembolism | 2014 |
Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban.
Topics: Aged; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Female; Fracture Fixation, Internal; Hepatocytes; Humans; Hyperbilirubinemia; Liver; Male; Middle Aged; Morpholines; Necrosis; Primary Prevention; Rivaroxaban; Thiophenes; Tibial Fractures; Venous Thrombosis | 2014 |
Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability.
Topics: Administration, Oral; Adolescent; Anticoagulants; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Morpholines; Nephrotic Syndrome; Pulmonary Embolism; Rivaroxaban; Thiophenes; Thrombophilia; Venous Thromboembolism; Warfarin | 2014 |
Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Calibration; Chromatography, High Pressure Liquid; Cold Temperature; Dabigatran; Drug Monitoring; Drug Stability; Factor Xa Inhibitors; Humans; Limit of Detection; Linear Models; Molecular Structure; Morpholines; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; Time Factors | 2014 |
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Early Detection of Cancer; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Incidence; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thiophenes; Warfarin | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Drug Monitoring; Hemorrhage; Humans; Models, Statistical; Morpholines; Myocardial Infarction; Prognosis; Pyrazoles; Pyridones; Risk Factors; Rivaroxaban; Russia; Stroke; Thiophenes; Warfarin | 2014 |
Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
Topics: Blood Coagulation; Factor Xa Inhibitors; Humans; Morpholines; Point-of-Care Systems; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thrombelastography | 2014 |
Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Factor Xa Inhibitors; Female; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombophlebitis; Treatment Outcome | 2014 |
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.
Topics: Blood Coagulation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thiophenes | 2014 |
Laboratory monitoring of the non-vitamin K oral anticoagulants.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
[Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report].
Topics: Adolescent; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Disseminated Intravascular Coagulation; Factor Xa Inhibitors; Fondaparinux; Humans; Male; Morpholines; Polysaccharides; Rivaroxaban; Thiophenes | 2014 |
Rıvaroxaban-induced severe diffuse ıntracerebral hemorrhage.
Topics: Aged, 80 and over; Cerebral Hemorrhage; Factor Xa Inhibitors; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2015 |
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Belgium; Benzimidazoles; beta-Alanine; Biomarkers; Blood Coagulation; Dabigatran; Dose-Response Relationship, Drug; Equipment Design; Fibrinogen; Health Care Surveys; Humans; Laboratory Proficiency Testing; Morpholines; Observer Variation; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Quality Indicators, Health Care; Reproducibility of Results; Rivaroxaban; Thiophenes; Time Factors | 2015 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
A novel synthesis of the oxazolidinone antithrombotic agent rivaroxaban.
Topics: Factor Xa Inhibitors; Morpholines; Proton Magnetic Resonance Spectroscopy; Rivaroxaban; Thiophenes | 2014 |
Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
Rivaroxaban for arterial thrombosis related to heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Factor Xa Inhibitors; Heparin; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombocytopenia; Thrombosis | 2015 |
Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Female; Fibrinolytic Agents; Humans; Length of Stay; Male; Middle Aged; Morpholines; Retrospective Studies; Rivaroxaban; Socioeconomic Factors; Stroke; Thiophenes; Warfarin | 2014 |
New way to individualize pulmonary embolism initial anticoagulant treatment-using adequate approved doses of rivaroxaban.
Topics: Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Morpholines; Practice Guidelines as Topic; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2014 |
Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban.
Topics: Aged; Aged, 80 and over; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes | 2014 |
[Nephrotic syndrome revealed by pulmonary embolism: about four cases].
Topics: Adult; Aged; Antithrombin III; Delayed Diagnosis; Drug Therapy, Combination; Echocardiography, Doppler; Fatal Outcome; Female; Humans; Kidney Function Tests; Male; Middle Aged; Morpholines; Nephrotic Syndrome; Prednisone; Proteinuria; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thrombosis | 2014 |
Activated protein C resistance testing for factor V Leiden.
Topics: Activated Protein C Resistance; Adult; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Biological Assay; Blood Coagulation Tests; Child; Dabigatran; Factor V; Factor Xa; False Positive Reactions; Female; Hirudins; Humans; Lupus Coagulation Inhibitor; Morpholines; Peptide Fragments; Pipecolic Acids; Pregnancy; Protein C; Recombinant Proteins; Rivaroxaban; Sulfonamides; Thiophenes; Warfarin | 2014 |
Successful treatment of partial portal vein thrombosis (PVT) with low dose rivaroxaban.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Middle Aged; Morpholines; Portal Vein; Radiography; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2014 |
Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Humans; Morpholines; Quality-Adjusted Life Years; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Coumarins; Dabigatran; Humans; Markov Chains; Middle Aged; Morpholines; Netherlands; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiophenes; United Kingdom | 2014 |
[Application of rivaroxabane in patients with proteins C and S deficiency].
Topics: Adult; Anticoagulants; Blood Coagulation; Diosmin; Drug Combinations; Drug Monitoring; Female; Hesperidin; Humans; Male; Morpholines; Protein C Deficiency; Protein S Deficiency; Rivaroxaban; Thiophenes; Time; Treatment Outcome; Venous Thrombosis | 2014 |
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.
Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin | 2014 |
Mesenteric vein thrombosis caused by secondary polycythaemia from AndroGel.
Topics: Abdominal Pain; Diagnosis, Differential; Humans; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Middle Aged; Morpholines; Polycythemia; Rivaroxaban; Testosterone; Thiophenes; Tomography, X-Ray Computed; Venous Thrombosis | 2014 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Family Practice; Female; Germany; Guideline Adherence; Heart Diseases; Heart Valve Prosthesis; Humans; International Normalized Ratio; Male; Mass Screening; Middle Aged; Morpholines; Practice Guidelines as Topic; Process Assessment, Health Care; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Thrombosis; Venous Thromboembolism | 2014 |
Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Evaluation; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2014 |
A cross-country comparison of rivaroxaban spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm.
Topics: Adverse Drug Reaction Reporting Systems; Anticoagulants; Australia; Canada; Female; Humans; Male; Middle Aged; Morpholines; Odds Ratio; Product Surveillance, Postmarketing; Risk Assessment; Rivaroxaban; Thiophenes; United States | 2014 |
Acute thrombocytopenia after initiating anticoagulation with rivaroxaban.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Humans; Intracranial Hemorrhages; Male; Morpholines; Rivaroxaban; Stroke; Thiophenes; Thrombocytopenia; Warfarin | 2014 |
A comparison of bleeding complications between warfarin, dabigatran, and rivaroxaban in patients undergoing cryoballoon ablation.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Comorbidity; Cryosurgery; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Morpholines; Retrospective Studies; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2014 |
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Family Practice; Hemorrhage; Humans; Morpholines; Preoperative Care; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Time Factors; Venous Thromboembolism | 2014 |
Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
Topics: Aged; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Cohort Studies; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Morpholines; Orthopedic Procedures; Prospective Studies; Rivaroxaban; Thiophenes; Thrombelastography; Thrombin; Venous Thromboembolism | 2015 |
Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Calibration; Chromatography, Liquid; Dabigatran; Dose-Response Relationship, Drug; Drug Labeling; Humans; Morpholines; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Reference Standards; Reproducibility of Results; Rivaroxaban; Tandem Mass Spectrometry; Thiophenes; United States | 2015 |
[Safety and efficacy of rivaroxaban for prevention of deep vein thrombosis in patients with preoperative abnormal D-dimer after total knee arthroplasty].
Topics: Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Factor Xa Inhibitors; Fibrin Fibrinogen Degradation Products; Humans; Knee Joint; Length of Stay; Morpholines; Osteoarthritis, Knee; Postoperative Complications; Postoperative Period; Preoperative Care; Prothrombin Time; Range of Motion, Articular; Rivaroxaban; Safety; Thiophenes; Venous Thrombosis | 2014 |
Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
Topics: Blood Coagulation Tests; Factor Xa Inhibitors; Humans; Morpholines; Partial Thromboplastin Time; Prothrombin Time; Rivaroxaban; Thiophenes | 2014 |
Rivaroxaban for treatment of HIT: a riveting first experience.
Topics: Factor Xa Inhibitors; Female; Heparin; Heparin Antagonists; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Thrombocytopenia | 2015 |
Comparison of methods to determine rivaroxaban anti-factor Xa activity.
Topics: Adult; Cohort Studies; Factor Xa Inhibitors; Female; Humans; Male; Mass Spectrometry; Morpholines; Prospective Studies; Rivaroxaban; Thiophenes; Venous Thrombosis | 2015 |
[Rivaroxaban in non valvular atrial fibrillation: subgroups analysis].
Topics: Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes | 2014 |
[Standard and new regimens of anticoagulation for pulmonary thromboembolism].
Topics: Anticoagulants; Blood Coagulation; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Heparin; Heparin, Low-Molecular-Weight; Humans; Morpholines; Outcome Assessment, Health Care; Patient Selection; Pulmonary Embolism; Risk Adjustment; Rivaroxaban; Thiophenes | 2014 |
New oral anticoagulants in patients undergoing atrial flutter radiofrequency catheter ablation: an observational study.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Flutter; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Female; Humans; Male; Middle Aged; Morpholines; Pilot Projects; Retrospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome | 2014 |
Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Hospitalization; Humans; Morpholines; Primary Health Care; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2015 |
Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Warfarin | 2015 |
Severe drug-induced skin and liver injury from rivaroxaban.
Topics: Aged; Biopsy; Chemical and Drug Induced Liver Injury; Drug Eruptions; Factor Xa Inhibitors; Humans; Male; Morpholines; Rivaroxaban; Thiophenes | 2015 |
[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room].
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Emergency Service, Hospital; Female; France; Hemorrhage; History, Ancient; Hospitalization; Humans; Male; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiophenes | 2015 |
[Aspects of the practical application of direct oral anticoagulants in traumatological and orthopedic hospital].
Topics: Administration, Oral; Anticoagulants; Chemoprevention; Costs and Cost Analysis; Humans; Morpholines; Orthopedic Procedures; Orthopedics; Outcome Assessment, Health Care; Postoperative Complications; Retrospective Studies; Rivaroxaban; Russia; Secondary Prevention; Thiophenes; Traumatology; Venous Thromboembolism | 2014 |
Prevalence of intracardiac thrombi under phenprocoumon, direct oral anticoagulants (dabigatran and rivaroxaban), and bridging therapy in patients with atrial fibrillation and flutter.
Topics: Aged; Anticoagulants; Arrhythmias, Cardiac; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Electric Countershock; Female; Humans; Male; Middle Aged; Morpholines; Phenprocoumon; Prevalence; Rivaroxaban; Thiophenes; Thrombosis; Vitamin K | 2015 |
Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Databases, Factual; Dose-Response Relationship, Drug; Drug Utilization; Female; Hemorrhage; Hospitalization; Humans; Kidney; Kidney Failure, Chronic; Male; Matched-Pair Analysis; Middle Aged; Morpholines; Poisson Distribution; Practice Patterns, Physicians'; Renal Dialysis; Retrospective Studies; Risk; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
Web Exclusives. The consult guys--too close for comfort? For how long must I stop this anticoagulant for an epidural?
Topics: Adrenal Cortex Hormones; Aged; Anticoagulants; Drug Administration Schedule; Female; Hemorrhage; Humans; Injections, Epidural; Morpholines; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Warfarin; Withholding Treatment | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Venous Thrombosis | 2014 |
Use of rivaroxaban could trim hospital spending in treating pulmonary embolism.
Topics: Administration, Oral; Cardiology; Congresses as Topic; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Infusions, Intravenous; Length of Stay; Morpholines; Pulmonary Embolism; Rivaroxaban; Societies, Medical; Thiophenes | 2014 |
Novel anticoagulants make life easier for patients with atrial fibrillation. The new drugs have many advantages over Coumadin--but they aren't perfect--and they have no antidotes in case of overdose.
Topics: Anticoagulants; Antidotes; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
The management of dental patients taking new generation oral anticoagulants.
Topics: Anesthetics, Local; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dental Care for Chronically Ill; Drug Interactions; Factor Xa Inhibitors; Hemostatic Techniques; Humans; Morpholines; Oral Surgical Procedures; Postoperative Hemorrhage; Practice Guidelines as Topic; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2014 |
Defining non-valvular atrial fibrillation while selecting anticoagulation therapy.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Heart Valve Diseases; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes | 2015 |
[Rivaroxaban for thrombosis of the left atrium in a patient with atrial flutter].
Topics: Atrial Flutter; Catheter Ablation; Coronary Angiography; Drug Monitoring; Echocardiography, Transesophageal; Electrophysiologic Techniques, Cardiac; Factor Xa Inhibitors; Heart Atria; Heart Failure; Humans; Male; Middle Aged; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Treatment Outcome | 2014 |
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
Topics: Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Dalteparin; Female; Fondaparinux; Hip Fractures; Hirudins; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Morpholines; Peptide Fragments; Platelet Count; Polysaccharides; Recombinant Proteins; Rivaroxaban; Thiophenes; Thrombocytopenia; Venous Thrombosis | 2015 |
Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report.
Topics: Administration, Oral; Blood Coagulation; Drug Monitoring; Factor Xa Inhibitors; Female; Heparin; Humans; International Normalized Ratio; Middle Aged; Morpholines; Predictive Value of Tests; Prothrombin Time; Reproducibility of Results; Rivaroxaban; Thiophenes; Thrombocytopenia; Time Factors; Treatment Outcome; Warfarin | 2015 |
What is the effect of rivaroxaban on routine coagulation tests?
Topics: Blood Coagulation; Blood Coagulation Tests; Female; Humans; International Normalized Ratio; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes | 2014 |
Risk stratification and stroke prevention therapy care gaps in Canadian atrial fibrillation patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation chart audit).
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Canada; Dabigatran; Hemorrhage; Humans; Male; Medical Audit; Morpholines; Predictive Value of Tests; Primary Health Care; Pyrazoles; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2015 |
[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Monitoring; Drug Substitution; Half-Life; Hemorrhage; Humans; Kidney Function Tests; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Warfarin | 2015 |
Investigation of possible prophylactic, renoprotective, and cardioprotective effects of thromboprophylactic drugs against ischemia-reperfusion injury.
Topics: Animals; Anticoagulants; Aryldialkylphosphatase; Aspirin; Cardiotonic Agents; Clopidogrel; Dipeptidases; Drug Evaluation, Preclinical; Enoxaparin; Femoral Artery; Heparin, Low-Molecular-Weight; Hindlimb; Kidney; Male; Malondialdehyde; Morpholines; Myocardium; Nitric Oxide; Oxidative Stress; Rats, Sprague-Dawley; Reperfusion Injury; Rivaroxaban; Thiophenes; Ticlopidine | 2015 |
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Death, Sudden; Diabetes Mellitus; Digoxin; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Intracranial Embolism; Male; Morpholines; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Rivaroxaban; Sex Distribution; Stroke; Thiophenes; Vitamin K; Warfarin | 2015 |
Are new oral anticoagulant dosing recommendations optimal for all patients?
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes | 2015 |
Rivaroxaban therapy resulting in the resolution of right atrial thrombosis resistant to ordinary control with warfarin in a patient with atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Thrombosis; Factor Xa Inhibitors; Heart Atria; Humans; Male; Morpholines; Rivaroxaban; Thiophenes; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Successful intravenous thrombolysis following full dose rivaroxaban 5 hours before ictus.
Topics: Administration, Oral; Atrial Fibrillation; Brain Ischemia; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Morpholines; Rivaroxaban; Severity of Illness Index; Thiophenes; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator | 2015 |
Successful treatment with rivaroxaban of an extended superficial vein thrombosis in a patient with acquired antithrombin deficiency due to Peg-asparaginase treatment.
Topics: Adult; Antithrombin III Deficiency; Asparaginase; Delayed-Action Preparations; Humans; Male; Morpholines; Polyethylene Glycols; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thrombosis | 2015 |
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia | 2015 |
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Medicaid; Middle Aged; Morpholines; Patient Selection; Practice Patterns, Physicians'; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Gastrointestinal Hemorrhage; Humans; Incidence; Male; Middle Aged; Morpholines; Observational Studies as Topic; Retrospective Studies; Risk Factors; Rivaroxaban; Thiophenes; United States; Warfarin | 2015 |
[Periprocedural management of anticoagulation in patients undergoing atrial fibrillation ablation].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Catheter Ablation; Dabigatran; Humans; Morpholines; Practice Guidelines as Topic; Rivaroxaban; Thiophenes; Thromboembolism | 2015 |
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants.
Topics: Adolescent; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Sensitivity and Specificity; Thiophenes; Thrombelastography; Venous Thromboembolism; Young Adult | 2015 |
Rivaroxaban 2.5 mg. No justification for using this anticoagulant after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Drug Dosage Calculations; Drug Therapy, Combination; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Patient Selection; Platelet Aggregation Inhibitors; Recurrence; Risk Assessment; Risk Factors; Rivaroxaban; Secondary Prevention; Thiophenes; Treatment Outcome | 2014 |
[Prevention and emergency measures].
Topics: Administration, Oral; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Emergencies; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2015 |
Rivaroxaban 10mg/d in severe renal failure does not prevent ischemic events in premorbid neurologic disease.
Topics: Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Morpholines; Recurrence; Renal Insufficiency; Rivaroxaban; Stroke; Thiophenes | 2015 |
[New ESC guideline takes NOAK into account].
Topics: Acute Disease; Anticoagulants; Guideline Adherence; Heparin; Humans; Morpholines; Pulmonary Embolism; Risk Assessment; Rivaroxaban; Thiophenes; Vitamin K | 2015 |
Rivaroxaban for treatment of heparin-induced thrombocytopenia after cardiac surgery: A case report.
Topics: Anticoagulants; Coronary Artery Bypass; Factor Xa Inhibitors; Graft Occlusion, Vascular; Heparin; Humans; Male; Middle Aged; Morpholines; Off-Label Use; Platelet Count; Radiography; Rivaroxaban; Saphenous Vein; Thiophenes; Thrombocytopenia; Thrombosis; Treatment Outcome | 2015 |
Complications With New Oral Anticoagulants Dabigatran and Rivaroxaban in Cutaneous Surgery.
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Dermatologic Surgical Procedures; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Minnesota; Mohs Surgery; Morpholines; Retrospective Studies; Risk Factors; Rivaroxaban; Skin Diseases; Thiophenes | 2015 |
[The X-VeRT study].
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Heart Diseases; Hemorrhage; Humans; International Normalized Ratio; Middle Aged; Morpholines; Multicenter Studies as Topic; Myocardial Infarction; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Risk; Rivaroxaban; Stroke; Thiophenes; Thrombophilia; Time Factors; Treatment Outcome; Vitamin K; Warfarin | 2015 |
Cardiac Tamponade Associated with Rivaroxaban.
Topics: Aged, 80 and over; Anticoagulants; Cardiac Tamponade; Factor Xa Inhibitors; Humans; Male; Morpholines; Pericarditis; Rivaroxaban; Thiophenes | 2015 |
[The changes of vascular active substances in pulmonary embolism rats and a comparative study of anticoagulant drugs].
Topics: Animals; Anticoagulants; Disease Models, Animal; Endothelin-1; Heparin, Low-Molecular-Weight; Hypertension, Pulmonary; Lung; Morpholines; Pulmonary Embolism; Rats; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Possible Rivaroxaban Failure during the Postpartum Period: An Alternative Viewpoint.
Topics: Anticoagulants; Factor Xa Inhibitors; Female; Humans; Morpholines; Postpartum Period; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2016 |
Response to the letter concerning the article "Rivaroxaban in secondary cardiogenic stroke prevention: two-year single-centre experience based on follow-up of 209 patients".
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Follow-Up Studies; Humans; Morpholines; Rivaroxaban; Secondary Prevention; Stroke; Thiophenes; Treatment Outcome; Warfarin | 2016 |
Who could benefit most from treatment of acute pulmonary embolism with rivaroxaban? Commentary to the article: "Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy….
Topics: Administration, Oral; Anticoagulants; Factor Xa Inhibitors; Hospitalization; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2016 |
Response to the letter concerning the article "Acute pulmonary embolism treatment with rivaroxaban results in a shorter duration of hospitalisation compared to standard therapy….
Topics: Anticoagulants; Factor Xa Inhibitors; Hospitalization; Humans; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes | 2016 |
Letter to the Editor "Gender related aspects of bleeding with rivaroxaban in venous thromboembolism - Potential for pitfalls": A comment to "Impact of gender on safety and efficacy of rivaroxaban in adolescents & young adults with venous thromboembolism"
Topics: Adult; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Rivaroxaban; Thiophenes; Thrombosis; Venous Thromboembolism | 2016 |
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism.
Topics: Anticoagulants; Humans; Morpholines; Rivaroxaban; Thiophenes; Veins; Venous Thromboembolism | 2017 |
Present status and future orientation of rivaroxaban application in patients with nonvulvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Stroke; Thiophenes; Warfarin | 2017 |
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis - Reply to Jacobs & Ryan comment.
Topics: Anticoagulants; Body Weight; Humans; Rivaroxaban; Thiophenes | 2021 |
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Intention to Treat Analysis; Morpholines; Rivaroxaban; Stroke; Thiophenes; Treatment Outcome | 2021 |
Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation.
Topics: Anticoagulants; Atrial Fibrillation; Bilirubin; China; Factor Xa Inhibitors; Humans; Morpholines; Nucleotides; Prospective Studies; Rivaroxaban; Stroke; Thiophenes | 2022 |
Rivaroxaban population pharmacokinetic and pharmacodynamic modeling in Iranian patients.
Topics: Anticoagulants; Factor Xa Inhibitors; Humans; Iran; Morpholines; Partial Thromboplastin Time; Rivaroxaban; Thiophenes | 2022 |